





OLD AGE HEALTH AND HIV IN A RURAL AREA WITH 
HIGH HIV PREVALENCE AND INCIDENCE: 
 
















































The widespread  roll‐out  of  antiretroviral  therapy  (ART)  has  resulted  in  a  decline  of  HIV‐
related  deaths;  as  a  result  the  HIV  positive  population  is  rapidly  ageing  with  improved 
survival of HIV positive adults on ART.  In sub‐Saharan Africa,  including South Africa, where 
older adults comprise a significant proportion of the total population, health services face the 
complexities  of  an  ageing  population  and  HIV.  The  aim  of  this  PhD  study  is  to  inform 











Data  from  the  HIV  Treatment  and  Care  programme,  linked  to  an  electronic  Hospital 
Information database  (n=8598  adults  aged  ≥16  years)  show  that older  adults had  a  lower 
hospitalisation rate, but higher case fatality rates, than younger adults.  
In the HIV  treatment and Care programme,  including 8846 overall,  in  the  first year of ART, 
mortality was higher  in older than younger adults, but rates  in the two groups were similar 
thereafter. Older adults had a blunted  immunological but superior virological response. All‐
cause mortality risk  increased with a decline  in CD4 cell count and unsuppressed viral  load. 
Further  detailed  data  from  the  ART  Clinical  Cohort  showed  that,  in  both  age  groups,  the 
contribution of multiple co‐morbidity to early mortality was high. 
The  results  presented  here  contribute  towards  evidence  required  to  understand  issues 
surrounding  the health of older adults  in  the context of high HIV prevalence and  incidence 
with widespread availability and access to ART and provide knowledge required for evidence‐




















































































3  Results: Morbidity burden in older adults - associations with HIV/ART status, 
















































6  Results: Association between age and mortality, viral suppression and CD4 












7  Results: Contribution of morbidity and abnormal bio-measures to cause-
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2.7  333  Manuscript Chronic morbidity in adults aged 50 years or older in rural 
South Africa: Validation of self‐report 
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The overall  aim of  this PhD  study  is  to  inform understanding of  the  issues  relating  to older 
adults and HIV infection and its treatment, using various data sources relating to older adults, 
aged 50 years or more, who are  resident  in an established demographic surveillance area  in 
Northern KwaZulu‐Natal, South Africa. The study area is characterised by high HIV prevalence 
and  incidence,  and  since  late 2004  substantial  access  to  antiretroviral  treatment  (ART)  in  a 
public health programme delivered at primary health care level. Associations between chronic 
morbidity, HIV  and ART  status  are explored, using data  from  a  cross‐sectional  study nested 






further quantifies  the contribution of co‐morbidities at  time of ART  initiation  to  subsequent 
morbidity and mortality, using data from an ART Clinical Cohort nested within the public sector 
HIV Treatment and Care Programme as well as  linked data  from the HIV treatment and care 
programme  and  an  electronic patient  information  system  at  the only  local district hospital. 












The  Human  Immunodeficiency  Virus  (HIV)  has  caused  the  world’s  largest  epidemic  and 
Acquired ImmunoDeficiency Syndrome (AIDS), the disease caused by HIV, is one of the world’s 
most serious health challenges (UNAIDS 2012). In low income countries in 2008 HIV/AIDS was 








HIV  (UNAIDS  2012).  HIV  prevalence  in  sub‐Saharan  Africa  is  five  times  higher  than  in  the 
Caribbean and Eastern Europe and Central Asia and 25 times higher than in South, South‐East 
and East Asia. HIV  incidence  is also highest  in  sub‐Saharan Africa accounting  for 71% of  the 
adults and children newly infected worldwide in 2011. From the peak of the epidemic in 1999, 
worldwide, HIV  incidence has been declining with  the number of new HIV cases  reported  in 
2011 (2.5 million cases) being 20% lower than the number reported in 2001 (UNAIDS 2012). In 
25  countries  across  the  world  including  Haiti,  India,  Thailand,  Barbados,  Ethiopia,  Zambia, 
Malawi and Botswana, HIV  incidence  rates declined by 50% between 2001 and 2011. Across 
sub‐Saharan Africa combined HIV incidence declined by 25% between 2001 and 2011 (UNAIDS 
2012), with  the estimated decline greater  than 50%  in  countries  such as Zimbabwe, Ghana, 







Despite  these  declines  in  new HIV  cases, HIV  remains  the  largest  epidemic  in  sub‐Saharan 
Africa.  South Africa has  the  largest number of people  living with HIV  in  the world  (UNAIDS 
2010; UNAIDS 2011; UNAIDS 2013).  In 2013,  South Africa was home  to 5.26 million people 
living with HIV  in  a population of  52 million; up  from  an  estimated  4 million  in 2002,    and 







health care  improvements  (Kinsella and Ferreira 1997).  In 2011, South Africa had 7.6 million 


















after which  they move  from being a “parent”  to a “grandparent”.  In most African traditions, 
this  confers  the  title  “older”  and  adds  respectability  regardless  of  chronological  age  (WHO 




2010; Hasse,  Ledergerber  et  al.  2011;  Scholten, Mugisha  et  al.  2011;  Bendavid,  Ford  et  al. 




The HIV  epidemic  substantially  affects  people  aged  50  years  and  above;  not  only  do  older 
adults play an  important role as caretakers of their adult HIV positive children and orphaned 
grandchildren  but  they  themselves  are  increasingly  likely  to  be  HIV  infected  (WHO  2002; 
Schmid, Williams et al. 2009; Wallrauch, Barnighausen et al. 2010).  The true burden of HIV in 














et al. 2012; Negin, Barnighausen et al. 2012).   Another reason  for the  lack of HIV prevalence 
data  in older adults  is  the  fact  that prior  to widespread availability of antiretroviral  therapy 
(ART),  HIV  and  ageing were  once mutually  exclusive  conditions;  the  HIV  pandemic mostly 














36%  (306  934/872  990)  of  all people  living with HIV  (Centers  for Disease  Control  2011).  In 




(UNAIDS 2010; UNAIDS 2012), data on HIV prevalence  in older  adults  are  limited. Available 
reports do not have  a  consistent  age  cut‐off, with most only  going up  to  age 59  years  and 






across  settings  as  illustrated  in  Figure  1.1.  A  review  that  employed  UNAIDS  prevalence 
estimates derived from 43 Demographic Health Surveys  in sub‐Saharan Africa estimated that 




only  if  they  were  men  and  the  upper  age  limits  ranged  from  54‐64  years;  18  had  HIV 









of  increased HIV prevalence  in older adults  from  two nationally  representative Demographic 
and Health Surveys (in 2003 and 2008/9), from 5.7% to 8.3%  in 50‐54 years old males (Mills, 






























































































































































































































































































































































































































































































































































































































































































































































































and Evaluation, estimated HIV prevalence was   10.4% and 10.2%  in male and  female 50‐54 
year old;  6.2%  and  7.7%  in  55‐59  year old  and  3.5%  and  1.8%  in  ≥60  year old  respectively 
(Shisana, Rehle et al. 2009). The survey was population‐based, covering rural and urban areas 
of South Africa with a total sample size of 23 369  individuals aged two years and above. The 
sample  was  multi‐stage  stratified  by  province,  settlement  geography  (geo‐type)  and 
predominant  race  group  in  each  area.  The  sample  was  further  stratified  into  census 
enumeration areas of 15 households each and  in each household, one person was randomly 
selected in each of <2 years; 2‐14years; 15‐24 years and ≥25 years age groups. The results from 
the  sample of 23 369  individuals was  then weighted by  age,  race  and province  to  give HIV 
prevalence  and  incidence  rates  representative of  the  general  South African population. The 
response rate for HIV testing was 64% (Shisana, Rehle et al. 2009).  
 
A year prior  to  this  survey  in 2007‐2008,  the WHO Study of global AGEing and adult health 
(SAGE), including a South African nationally representative cohort of 3 842 individuals aged 50 








KwaZulu‐Natal,  the  area  where  this  PhD  was  conducted,  had  the  second  highest  HIV 
prevalence  in older adults of 8.8% (Negin, Martiniuk et al. 2012). The SAGE cohort comprised 
of  a  population‐based  sample  representative  of  the  general  population  of  people  aged  50 
years  and  above  in  South  Africa,  which  was  weighted  during  analyses  to  make  the  data 
nationally representative. The response rate  for HIV testing was 75%  (Negin, Martiniuk et al. 
2012). Data from our own population  in rural KwaZulu‐Natal, using a  longitudinal population‐




al. 2010). Data used  in  the  study  included  all  adults  aged 50  years  and  above  and  resident 
within  a  geographically  defined well  established  surveillance  area.  The  authors  report  that 
prevalence estimate calculations were adjusted  for non‐response by sex and age but did not 
explicitly state the response rate (Wallrauch, Barnighausen et al. 2010). Using that same rural 




Much  of  the  increasing  and  substantial HIV  prevalence  among  people  over  50  year  of  age 
reflects  longer  longevity due to  increasing availability and use of ART (Hontelez, de Vlas et al. 





















































































































the WHO Communicable Diseases Unit  from  central, eastern and western Europe  shows an 
increase  in new HIV cases from 2003 to 2007 from 10.4% to 12.9%  in Western Europe, 8.2 to 





One of  the  few  reports on  incidence  in older adults  in Africa, used prevalence  rates  from a 
meta‐analysis of pooled data from five  longitudinal community‐based surveys participating  in 
the Alpha network (Uganda‐  two sites; 1990 to 2005, Tanzania; 1994‐2004, Zimbabwe; 1999‐
2004  and  South  Africa;  2004‐5),  to  infer  incidence  rates.  The  study  showed  a  primary 
prevalence peak in younger adults and a second lower prevalence peak in those aged 50 years 
and  above  and  attributed  the  second  prevalence  peak  to  incident  cases  occurring  in  older 
adults  (Zaba, Todd et al. 2008). The study does not explicitly measure incidence rates by age, 
making  it difficult to determine the exact  incidence  rate  in older adults.  In the 2008/9 South 














years  in  older  adults  aged  50  years  and  above who were  HIV  negative  in  2006  and were 
surveyed again before 2008. The incidence rate was higher in men (0.9 per 100 person years) 
than  in women  (0.4 per 100 person years)  (Wallrauch, Barnighausen et al. 2010). The  study 
consisted of 1 549 older adults contributing 1 575 person years at risk and 8 HIV incident cases 








older adults  is sexual activity. While  in Europe and USA  it  is mainly transmitted through anal 
sex  in Men who  have  Sex with Men  (MSM),  in  Africa  it  is   mainly  through  vaginal  sex  in 
heterosexuals (Manfredi, Calza et al. 2003; Schmid, Williams et al. 2009; Negin and Cumming 
2010; Smith, Delpech et al. 2010). Several biological and behavioural factors predispose older 
adults to HIV  infection;  firstly the thinning of the vaginal wall after menopause  increases the 
risk of sexual transmission and acquisition due to  loss of vaginal mucosal  integrity (Smith and 
Robinson 2002; Drew and Sharrard 2008). Secondly  the association of ageing with  increased 







Behavioural  factors also predispose older adults  to HIV  transmission; studies have suggested 
that risk of transmission and acquisition within the marriage may be high due to low condom 
use  within  the  marriage  relationship  irrespective  of  extramarital  relationships  (Abel  and 
Werner  2003;  Negin  and  Cumming  2010;  Peltzer,  Phaswana‐Mafuya  et  al.  2010;  Schick, 
Herbenick  et  al.  2010).  A  study  based  on  data  from  the  2005  South  African  national  HIV 
prevalence  and  sexual behaviour  survey  consisting of 3 795 older  adults  reported  that 40% 
reported being sexually active  in the past month, 12.3% of whom had not used a condom at 
last sex act (Peltzer, Phaswana‐Mafuya et al. 2010). The survey employed multi‐stage stratified 
sampling  technique  to  ensure  that  the  sample was  representative of  rural  and urban older 
adult populations within South Africa.  In addition, a South Africa national survey with 21 000 
individuals reported substantial numbers of multiple concurrent sexual partnerships with 7.5% 
of males aged 50 years and above reporting to be  in such relationships  in 2002, 9.8%  in 2005 
and 3.7%  in 2008. The percentage of women aged 50 years and above  in multiple concurrent 
relationships was low at 0.6% in 2005 and 0.8% in 2008 (Shisana, Rehle et al. 2009). In  2010 in 
rural South Africa, 152 of 1349 men  (11.3%) and 96 of 2768 women  (3.5%)  reported having 
two  concurrent  sexual  partners,  although  this  study  consisted  of  adults  aged  16  years  and 
above, about 13% were older adults (Miles, Barnighausen et al. 2011). Findings of low condom 
use  and  having more  than  one  concurrent  sexual  partner  in  older  adults  have  also  been 
reported  from Benin, Democratic Republic of Congo and Nigeria  (Shisana, Rehle et al. 2009; 
Negin and Cumming 2010). This behaviour may also translate to high risk in acquiring sexually 
transmitted  infection  (STIs)  more  generally,  which  are  known  to  increase  the  risk  of  HIV 
transmission  in  all  age  groups  (Laga, Manoka  et  al.  1993; Abel  and Werner  2003).  In  sero‐
discordant  couples, where  one  partner  is HIV  positive  and  the  other  not,  low  condom  use 
presents a transmission risk even in the absence of extramarital relationships (Grabar, Weiss et 







et al. 2011; Reynolds, Makumbi et al. 2011).  Lastly, practices of wife  inheritance where  the 
widow  marries  the  deceased’s  relative  are  common  in  many  parts  of  sub‐Saharan  Africa 
(Grabar, Weiss et al. 2006; Nguyen and Holodniy 2008; Schmid, Williams et al. 2009; Shisana, 
Rehle et al. 2009; Negin and Cumming 2010) and may  likely  increase risk of HIV transmission 
and  acquisition.  These  factors  raise  concerns  about  increased  risk  of HIV  infection  in  older 
adults.   
 
In  sub‐Saharan Africa  it  is  generally, mistakenly,  assumed  that older  adults  are not  sexually 
active (Kohli, Klein et al. 2006; Schmid, Williams et al. 2009; Shisana, Rehle et al. 2009; Negin 
and Cumming 2010; Negin, Barnighausen et al. 2012). However,  in a   Ugandan study of 750 
HIV positive  individuals  aged  50  years  and  above,  40%  reported  to  continue  to be  sexually 
active after being diagnosed with HIV (Funk, Odit et al. 2012). Similarly, a 2005 South African 
HIV prevalence  and behaviour  survey  reported 41%  and  36% of older  adults being  sexually 








risk  in  older  adults  by  being  sexually  exposed  to  younger  age  groups with  a much  higher 







The burden of HIV  in older adults consists of two groups:  firstly those who are  infected with 
HIV at ages younger  than 50 years who get onto ART and progress  into  the older adult age 
group  and  secondly  those  who  acquire  HIV  after  the  age  of  50  years.  Although  the 
considerable HIV incidence in older adults cannot be ignored, the burden of HIV in those aged 
50 years and above  is most  likely  largely driven by HIV positive  individuals ageing  (Manfredi, 
Calza et al. 2003; Grabar, Weiss et al. 2006; Nguyen and Holodniy 2008; Hontelez, de Vlas et al. 
2012;  Negin,  Barnighausen  et  al.  2012). With  the  introduction  of  life‐saving  ART  and  the 
expansion  of  ART  programmes,  life  expectancy  is  increasing  (Bor,  Herbst  et  al.  2013) with 
significant  declines  in  mortality  in  both  resource‐rich  and  ‐poor  settings.  Survival  is  now 
expected to exceed 15‐20 years from sero‐conversion (Gebo 2008; Herbst, Cooke et al. 2009; 
Negin,  Barnighausen  et  al.  2012;  Bor,  Herbst  et  al.  2013).  A  recent  publication  based  on 
empirical data  from a  large HIV treatment cohort  linked to surveillance data  in our setting  in 
rural KwaZulu‐Natal reports an  increase in  life expectancy from 49.2 years in 2003 before the 
introduction of ART in South Africa, to 60.5 years in 2011: an 11.3‐year gain (Bor, Herbst et al. 
2013), which  is  in  line with emerging data  from other African countries,  including Botswana, 
Uganda, Kenya  and  Zambia  (Mermin, Were et  al. 2008;  Stover,  Fidzani et  al. 2008; UNAIDS 
2010; UNAIDS 2012; UNPD 2013). Within  the  same  rural KwaZulu‐Natal  setting  in 2009 HIV 
prevalence  peaked  in women  aged  30  to  34  years  old  and men  aged  35  to  39  years  old 
(Mutevedzi and Newell 2011) and  if  these peaks were  to be  sustained  through provision of 
ART, in the next two decades, the peak will be in women aged 50 to 54 and men aged 55 to 59 
years old. Evidence of  this  is already emerging depicted by  the changing age pattern of HIV 
prevalence: whereas  in 2004 HIV prevalence peaked  in the ages 25‐29 for women and 30‐34 
for men (Welz, Hosegood et al. 2007), in 2009 the prevalence peak for both sexes had shifted 5 
























































































































































































































































therapy  in a public sector ART programme  in early 2013, 12% were 50 years or over   at  the 
time  of  ART  initiation  (www.africacentre.ac.za).  Yet  little  is  known  in  these  settings  about 
responses  to ART  in  terms  of morbidity,  virological  and  immunological  outcomes,  and  how 





younger  adults  has  substantially  reduced  mortality  and  increased  life  expectancy  (Hasse, 
Ledergerber et al. 2011; Herbst, Mafojane et al. 2011; Bendavid, Ford et al. 2012; Bor, Herbst 
et  al.  2013;  Zaidi, Grapsa  et  al. 2013)  and HIV  infection has become  a  chronic disease. HIV 
positive individuals aged 50 years and above on ART are likely to be faced with competing risks 













2009). However  these authors acknowledge  that  the exact mechanisms  leading  to  increased 










Before  discussing  the  associations  between  HIV  with  life‐long  ART  and  other  chronic 
morbidities  in older adults and possible complications  thereof,  it  is necessary  to understand 
age‐associated chronic morbidities that occur in the absence of HIV.  Progression through the 




changes may result  in sub‐optimal clearance of  toxins and drugs  from the body especially  in 
advanced  ages  (Davies  and  Shock  1950;  Effros,  Fletcher  et  al.  2008; Nguyen  and Holodniy 
2008). Ageing also alters the  immune system; the number of B cell repertoire decreases and 
there is evidence of decreased B cell function. The ability of polysaccharide antigens to activate 








significantly  reduced  (Nylor,  Li  et  al.  2005).  The  study  excluded  individuals  with  serious 
diseases, such as a chronic inflammatory disease, cancer, a history of chemotherapy, advanced 
atherosclerotic  disease  or  congestive  heart  failure,  poorly  controlled  diabetes mellitus,  or 
chronic obstructive pulmonary disease. Other  studies have  reported  that  cognitive  function, 
gut absorption  rate and bone density are also  lower  in older  than younger adults, with  the 
most  impact  in  those  aged  over  65  (Grabar, Weiss  et  al.  2006;  Gebo  2008;  Nguyen  and 
Holodniy 2008). These physiological changes may increase the risk of chronic morbidity such as 
heart  disease,  arthritis,  diabetes  and  hypertension  (Grabar, Weiss  et  al.  2006;  Gebo  2008; 
Christensen,  Doblhammer  et  al.  2009;  Mayosi,  Flisher  et  al.  2009).  As  such,  the  chronic 
morbidity burden of cardiovascular diseases, cancers, bone disorders, metabolic disorders  is 
usually higher  in those aged 50 years and above than  in younger adults (Kahn, Tollman et al. 




Studies  suggest  that  across  all  age  groups, HIV  increases  the  risk  of  age‐associated  chronic 
conditions such as malignancies, metabolic disorders  inclusive of diabetes and cardiovascular 












authors  hypothesize  that  this  may  be  due  to  underreporting  or  competing  mortality.  A 
commentary  on  this  French  study  suggested  that  the  lack  of  difference  in  cancer  risk was 
because women  included  in  the  French  hospital  study  had  lower  cancer  risk  factors  (lower 
social class, early age at first birth, high parity and  low alcohol  intake). The commentary also 
reported that as of 2004 there were only a limited number of published breast cancer cases in 
HIV positive women  and  suggested  that HIV may have  a protective effect on breast  cancer 
(Pantanowitz and Dezube 2004).      In  the same French hospital study,  the risk of  lung cancer 
was  twice  as  high  in  HIV‐positive  men  and  women  compared  to  the  general  population. 
Similarly,  in  a  study  that  linked  the  Swiss HIV  Cohort  Study  and  the  Swiss  cantonal  cancer 
registries,  high  age  standardised  incidence  ratios  of  Kaposi  sarcoma,  anal  cancer,  cervical 
cancer,  liver cancer,  lip, mouth, pharynx,  lung and skin cancer were  reported  in HIV positive 
people  compared  to  the  general  population.  The  Swiss  study  included  7304  HIV  positive 
individuals  aged  16  years  and  above  contributing  28  836  person‐years  from  1985  to  2003 
(Clifford, Polesel et al. 2005).  In HIV positive patients only,  the  risk of  cancer was  the  same 




Similar  to  cancer  risk  in  HIV  positive  populations  compared  to  the  general  HIV  negative 
population, a review on cardiovascular risk and body  fat abnormalities  in HIV  infected adults 
reported  increased  body‐fat  abnormalities  and  dyslipidemia  in  HIV  positive  adults  possibly 
associated  with  increased  diabetes.  In  HIV  positive  individuals  with  lipoatrophy,  diabetes 






June 2004  in a cohort study  in Boston, USA with 3 851 HIV positive (41% on ART) and   1 044 
589 HIV negative individuals showed that the rate of acute myocardial infarction was twice as 
high in the HIV positive group as in those HIV negative. HIV positive individuals also had higher 
proportions  of  hypertension  (21.2%  versus  15.9%),  diabetes  (11.5%  versus  6.6%)  and 
dyslipidemia (23.3% versus 17.6%) than the HIV negative population (Triant, Lee et al. 2007). 
This Boston study included patients aged 18‐84 years and the median age of participants was 
38  years  for  those  HIV  positive  and  39  years  for  those  HIV  negative.  Although  all  studies 
mentioned  above  did  not  exclusively  look  at  older  adults,  these  results  highlight  that  HIV 





of  disease  from    non‐HIV  chronic morbidities  and  HIV‐associated morbidities  (Andrew  and 
David 2000; Rhee and Greenblatt 2008; Pardi, Nunes et al. 2009; Negin, Wariero et al. 2010). 
Irrespective of age, the distribution of chronic morbidity at population level is mainly driven by 
socioeconomic  disparities  that  influence  lifestyle  risk  factors  such  as  smoking,  exercise, 
alcohol, diet  and  stress  levels  (Bailis,  Segall  et  al.  2003; Bradshaw, Groenewald  et  al.  2003; 
Lorant, Deliege  et  al.  2003; Kahn,  Tollman  et  al.  2006;  Lopez, Mathers  et  al. 2006; Mayosi, 
Flisher et al. 2009; Kyobutung, Egondi et al. 2010). Consequently, the largest morbidity burden 
is  borne  by    poor  communities  in  urban  areas where  these  lifestyle  risk  factors  are  highly 
prevalent  (Bailis, Segall et al. 2003; Bradshaw, Groenewald et al. 2003; Lorant, Deliege et al. 
2003;  Lopez,  Mathers  et  al.  2006;  Mayosi,  Flisher  et  al.  2009).  The  UNAIDS  Global  HIV 





related  morbidity  of  being  higher  in  poor  communities  (UNAIDS  2010);  meaning  that 
populations  prone  to  chronic  morbidities  may  also  face  HIV.    However  for  older  adults, 
irrespective of lifestyle risk factors, the chronic morbidity burden is increased because of age. 
In a nationally  representative South African  survey of 3 795  rural and urban older adults of 
whom 5.8% were HIV positive,   50% and 38% of those positive  reported at  least one or two 
other  illness  respectively,  in addition  to being HIV positive  (Peltzer, Phaswana‐Mafuya et al. 






A  review on  the burden of non‐communicable diseases  in South Africa utilising various data 
sources  inclusive of  the national burden of disease  study,  Statistics  South Africa,  the  South 
African Demographic and Health Surveys, population‐based demographic surveillance systems 
and  other  surveillance  studies  estimated  that  the  chronic  morbidity  burden  from 
cardiovascular diseases, diabetes mellitus,  respiratory diseases and cancers  in all age groups 
contributed 12% of the overall disease burden in a country with high HIV prevalence. Chronic 
morbidity  burden  was  higher  in  older  than  younger  adults.  The  authors  suggested  that 
prevention and treatment of non‐communicable disease may be marginalised  in South Africa 
because of  the overwhelming burden of HIV and  tuberculosis    (Mayosi, Flisher et al. 2009). 
High non‐HIV‐related age‐associated chronic morbidity in areas with high HIV prevalence leads 
to  a population with dual burden of  communicable  and non‐communicable diseases  (Kahn, 







A  study  in  a  socio‐economically poor  community  in Nairobi,  including 2 072  adults  aged 50 
years and above reported poor health coupled with high HIV prevalence (Kyobutungi, Ezeh et 
al.  2009;  Kyobutung,  Egondi  et  al.  2010).  The  study used  the WHO  composite health  score 
measure  to estimate health  status. The proportion of older adults below  the median health 
score of 67.5  increased with age  from 33%  in those aged 50 to 59 years old to 79%  in those 
aged  80  years  and  above  (Kyobutung,  Egondi  et  al.  2010).  Similar  to  the  African  studies 
discussed above, cross‐sectional and longitudinal studies from Europe and the United States of 
America  report  higher  chronic  morbidity  including  diabetes  mellitus,  cardiac  diseases, 
hypertension, chronic kidney and  liver disease, arthritis, depression and some cancers  in HIV 




These  studies  begin  to  confirm  the  dual  burden  of  infectious  and  chronic morbidity  in HIV 














clinic  visits  for  ART  collection.  The  South  African  HIV  treatment  guidelines  stipulate  that 
patients  collect ART monthly  (National Department of Health 2004; National Department of 
Health  2010;  National  Department  of  Health  2013).  This  means  older  adults  who  would 
otherwise not utilise health care services now have frequent access by virtue of being on ART, 
increasing  opportunities  for  diagnosis  and  treatment  of  any  other  co‐existing  morbidity. 
Generally,  the  earlier  a  disease  is  diagnosed,  the more  likely  it  is  that  it  can  be  cured  or 
successfully managed  (Suzman, Harris et al. 1992; WHO 1995; van der Hoeven, Kruger et al. 





impact  on  morbidity  burden  and  mortality  because  health  care  utilisation  increases  the 
chances of diagnosing and  treating disease. For HIV positive  individuals  in HIV care  receiving 
ART,  contacts  with  health  care  facilities  are  increased  compared  to  the  HIV  negative 
population  as  they  have  to  frequently  visit  the  clinic  for ART  collection  and  regular  clinical 
monitoring.  The  South African HIV  treatment  guideline  stipulate  that patients  visit  the ART 
clinic  monthly  for  ART  collection  and  three‐monthly  for  a  nurse  appointment  (National 
Department  of Health  2004; National Department  of Health  2010; National Department  of 
Health  2013).  The  most  recent  guidelines  allow  patients  who  are  stable  on  ART  with 
suppressed viral load to collect ART pills every other month, although in practice monthly visits 













the  three months prior  to  the  interview,  from musculoskeletal,  respiratory, sight and dental 
conditions, 63% of these perceived themselves as healthy and not requiring medical attention. 
Of  those  reporting  illness  on  the  day  of  the  study  interview,  only  26% were  on  treatment 
whilst 73%  reported  that money hindered health  care access. Participants  criticised  the  fact 
that health care  facilities were placed  long distances apart making  it difficult  to  reach  them  
(Waweru,  Kabiru  et  al.  2003).  Similarly,  in  a  household‐based  survey  of  756  households  in 
Nigeria with  at  least one household member  aged  60  years  and  above, over  70%  reported 
having either body pain, poor sight, depression, headaches, decreased mobility and weakness 




rate of 77% resulting  in a sample size of 3 840  individuals aged 50 years and above  in South 
Africa showed that only 1 919 (50%) of the participants had utilised outpatient care in the last 
year and of these only 1% did so for a routine medical check‐up. The majority of participants 






health  services,  especially  those  aged  55  years  and  above.  The  major  reasons  for 
dissatisfaction included long waiting times, staff attitudes, non‐availability of medications,  and 
staff  shortages  (Peltzer  and Phaswana‐Mafuya 2012).  Issues  relating  to  lack of  facilities  and 
financial and geographic barriers  to health care access  (Waweru, Kabiru et al. 2003; Ahmed, 
Tomson et al. 2005; van der Hoeven, Kruger et al. 2012), likely make older adults resort to self‐
treatment.  As  such,  older  adults  participating  in  research  from  South  Africa,  Kenya  and 
Bangladesh,  self‐reported  that  they  preferred  to  seek  no  treatment  or  to  self‐treat  for 
musculoskeletal problems, decreased mobility, general body pain and fever  (Sarkisian, Hays et 
al. 2002; Waweru, Kabiru et al. 2003; van der Hoeven, Kruger et al. 2012).  Low health  care 
utilisation  highlighted  by  these  studies  highlights  a  gap  in  health  care  that  is  probably  not 





may be an  indication of  increased morbidity  risk or  increased  risk of  future mortality. Since 
biomarkers are superior predictors of morbidity and mortality than self‐reported health status 
(Goldman  2007;  Neaton,  Neuhaus  et  al.  2010;  Armah,  McGinnis  et  al.  2012),  they  are 
increasingly  employed  in  monitoring  health,  identifying  individuals  with  particular 
susceptibility  to morbidities and evaluating    therapeutic  interventions  (Harris, Ferrucci et al. 
1999; Penninx, Kritchevsky et al. 2004; Kuller, Tracy et al. 2008; Population Reference Bureau 
2008; Neaton, Neuhaus  et  al.  2010; Neuhaus,  Jacobs  et  al.  2010).  For  example,  cholesterol 
provides  information on metabolic processes and  future risk of coronary heart disease, body 






and  their  elevated  presence  has  been  linked  to  chronic  morbidity  (diabetes,  arthritis, 
cardiovascular  diseases  and  atherosclerosis)  and  increased mortality  (Harris,  Ferrucci  et  al. 
1999; Bruunsgaard, Pedersen et al. 2001; Targher, Zenari et al. 2001; Penninx, Kritchevsky et 
al. 2004; Danesh, Kaptoge et al. 2008; Kuller, Tracy et al. 2008; Armah, McGinnis et al. 2012). 
Interleukin 1  (IL1) and Tumor Necrosis Factor‐alpha  (TNFα) are early mediators of  the acute 
phase response;  Interleukin 1  (IL16)  is an anti‐inflammatory and  immune‐regulatory cytokine 
which  controls  inflammatory  responses  and high  sensitivity C‐reactive protein  (hsCRP)  is  an 
acute phase protein (Harris, Ferrucci et al. 1999; Bruunsgaard, Pedersen et al. 2001; Targher, 
Zenari et al. 2001; Bastard, Maachi et al. 2006). Although  these markers are usually  slightly 







Jacobs et al. 2010; Armah, McGinnis et al. 2012). These  levels are  likely  to be higher during 
advanced  stage  HIV  disease  when  immune  activation  is  greatest.  The  Strategies  for 
Management  of  Antiretroviral  Therapy  (SMART  study),  a  large  randomised  control  trial 














positive  than  in HIV negative  individuals. Differences  in median biomarker  levels were most 





reducing  cytokine  levels  (Neuhaus,  Jacobs  et  al.  2010).    However,  HIV  positive  individuals 
always have elevated  inflammatory markers  (Armah, McGinnis et al. 2012) compared  to HIV 
negative  individuals, even after successful suppression of the HIV viral  load (Neuhaus, Jacobs 
et  al.  2010).  The  perpetually  elevated  cytokine  levels may  increase  the  risk  of  age‐related 
chronic  morbidities  including  cardiovascular  diseases.  Kuller  at  al.  recommended  further 
longitudinal studies assessing mortality and morbidity  levels  in patients on ART but with high 
IL6 levels (Kuller, Tracy et al. 2008)  In a further SMART substudy, different classes of ART drugs 
were  associated  with  different  levels  of  inflammatory  markers.  Patients  receiving  a  non‐
nucleoside  reverse  transcriptase  inhibitor  had  higher median  hsCRP  levels  than  those  on  a 
protease  inhibitor, whilst  for  those  on  nucleoside  reverse  transcriptase  inhibitors,  abacavir 
patients  had  higher  levels  of  IL6  and  hsCRP  than  those  on  any  other  nucleoside  reverse 
transcriptase  inhibitors  (Neuhaus,  Jacobs et al. 2010). Abacavir use has also been associated 
















very few studies  in this area from African populations  in Africa. A small study  in South Africa 
including  80  HIV  positive  patients,  the  majority  (60/80;  75%)  of  whom  were  ART‐  naive, 
reported higher  levels of  IL6  in HIV positive  individuals with AIDS‐associated co‐infections of 
either tuberculosis, bacterial, viral or fungal infections than in 10 HIV negative controls (Cassol, 
Malfeld  et  al.  2010).  The  study  also  showed  a  non‐statistically  significant  trend  towards 
elevated  IL6  levels  in HIV positive  individuals without co‐infections.   HIV positive patients  in 
this study with WHO disease stage III or IV were stratified into three groups: on ART and ART‐
naive  patients  with  (n=20)  and  without  (40)  opportunistic  infections.  For  the  HIV  positive 
group, the median CD4 cell count was 135 for the ART‐naive group and 386 for the HIV positive 
group  and  20  (25%)  had  bacterial,  viral  or  fungal  co‐infection  inclusive  of  TB.  The  20  HIV 
positive patients on ART had  to have had undetectable viral  load  for at  least 6 months. The 
eligibility criteria and the small size of the HIV negative control group limit the generalisability 
of this study’s results. Despite these  limitations, this study provides valuable knowledge  in an 
area  that  is critically  lacking  studies. However,  since  the  study was  in younger adults with a 
mean age of 39 years  in those HIV positive, the majority of whom were ART‐naive, the study 





biomarkers  in older adults.  It  is unclear  if ART reduces cytokine  levels to  levels similar to HIV 
negative older adults.  
 
Further,  in  older  adults  it  remains  unclear  if  elevated  levels  in  the  presence  of  ART  are 
associated with chronic disease. All the above mentioned studies, except for the VACS study, 
(Armah, McGinnis et al. 2012) were  limited by their  inability to adjust for multiple co‐morbid 
conditions  such  as  diabetes  and  cardiovascular  diseases  that  have  been  associated  with 
elevated  inflammatory markers.  The  association  between  elevated biomarkers  in  those HIV 
positive    and  increased  co‐morbidity  burden  are  unknown  (Armah, McGinnis  et  al.  2012). 
Possibly  ART  reduces  inflammatory markers  in  older  adults  to  levels  that  are  not  clinically 
significant and not associated with chronic morbidity, making  these markers  less efficient  in 
identifying  risk  groups  for  disease  in  older HIV  positive  patients  receiving  ART.  Studies  are 
required  in all settings to determine the associations between inflammatory markers and HIV 
status in the presence or absence of ART and associations between biomarkers and morbidity 
by HIV  and ART  status  in older  adults who due  to  age may  already have  elevated  levels of 
inflammatory markers. 
 
Obesity,  irrespective  of  HIV  status  and  age  is  a  global  concern  due  to  its  association with  
chronic  health  problems  such  as  cardiovascular  diseases,  diabetes,  stroke  and  arthritis 
(Cheymol 2000; Bastard, Maachi et al. 2006; Population Reference Bureau 2008).  Similar  to 
ageing,  obesity  is  also  characterised  by  elevation  in  inflammatory markers  (Trayhurn  2005; 







normally higher  in obese  individuals (Trayhurn 2005; Bastard, Maachi et al. 2006) and also  in 
HIV  positive  individuals  especially  during  advanced  stage  HIV  disease  (Hober,  Haque  et  al. 
1989; Kuller, Tracy et al. 2008; Rodger, Fox et al. 2009). High  levels of obesity despite an HIV 
epidemic  in the South African population have previously been reported (Barnighausen, Welz 
et  al. 2008; Malaza, Mossong et  al. 2012), which  raises  important questions  relating  to  the 
association of elevated cytokine  levels  in this population of older adults. Considering the  lack 
of knowledge  in African populations on bio‐marker  levels  that may  identify  increased  risk of 
morbidity,  studies  focusing on how bio‐marker  levels and BMI  relate  to morbidity  in African 





Age  at  both  infection  and  treatment  commencement  is  a  major  determinant  of  disease 
progression and mortality for many diseases, including HIV infection, but the effect of age itself 
on other prognostic factors is not often studied directly (CGAIHS 2000; Collaborative Group on 
AIDS  incubation  and HIV  survival  2000; Babiker, Peto et  al.  2001; Nylor,  Li  et  al.  2005;  The 
Collaboration  of Observational HIV  Epidemiological  Research  Europe  (COHERE)  study  group 
2008). A large study which pooled data from 38 studies in Australia and 14 countries in Europe 
and North America  including 13 000 HIV positive adults aged 15‐54 years, showed before the 
widespread  use  of  ART,  the  risk  of  death  increased  by  50%,  and  of  progression  to  AIDS 










Maryland, United  States with  906 ART‐naive  patients  enrolled  between  February  1989  and 
January 2006 who went on to initiate ART between December 1995 and February 2006, 670 of 
whom were  less  than 40 years of age and 149 50 years and over,  the survival  time  in older 
adults was half that in younger adults (25% of older and 25 % of younger adults died within 36 







Pre‐ART,  in an analysis of pooled data  from  seven  studies  in  five African  countries and one 
study  in Thailand  , the median survival for adults aged 45 years and above was half (6 years) 
that in adults aged 25‐34 years (11 years) (Todd, Glynn et al. 2007). The study included 3 823 
sero‐converters  with  age  at  sero‐conversion  ranging  from  15  to  90  years,  from  three 
community population‐based HIV surveys, two occupational clinics and three HIV clinics with 










adults may  be  due  to modest  immune  response  to  infection  and  disease,  age‐related  co‐
morbidities and decreased liver and kidney function that occurs with ageing.  
 




with  changes  to  the  adaptive  immune  system  seen  in  very  old  individuals  (Deeks  2011). A 
study  on  115  HIV‐infected women  and  43  age‐  and  race‐matched  HIV  uninfected  controls 
reported that even  in the absence of multiple classical risk  factors  for age‐related conditions 
such  as  smoking  and obesity,  long‐term  infection with HIV may directly  increase  the  risk of  
heart diseases (Kaplan, Sinclair et al. 2011). The authors hypothesized that this may be due to 
HIV promoting  a permanent  inflammatory  state,  causing  accelerated  ageing of  the  immune 
system possibly damaging blood vessels  in ways that promote development of heart disease 
(Kaplan, Sinclair et al. 2011). However  if this  is the case then ART which  leads to a decline  in 
inflammatory markers should reverse the accelerated ageing effects posed by HIV infection. A 
review  including an unknown number of manuscripts stratified  into pre‐defined categories of 
peer  reviewed  articles,  systematic  reviews  and  Centres  for Disease  Control  and  Prevention 
data, concluded that premature frailty was a manifestation of HIV‐related accelerated ageing 
(Onen  and Overton  2011).  In  this  review,  three  studies  reported  that  frailty  prevalence  in 
younger HIV infected adults (5% to 20%) was similar to prevalence of age‐driven frailty in older 
adults which has been reported between 3‐32%, possibly indicating the presence of HIV‐driven 
premature  ageing.  Additionally,  introduction  of  ART  was  associated  with  a  decline  in 
prevalence  of  frailty markers. Despite  some  literature  advocating  for  accelerated  ageing  in 






2011). Accelerated ageing  in HIV  is currently topical, but there  is no clear evidence of such a 
condition and the exact mechanisms of how HIV infection leads to chronic conditions of ageing 










2009).  Assessing  age  as  a  continuous  variable,  two  studies  have  suggested  an  association 
between  increasing age and higher mortality on ART (Toure, Kouadio et al. 2008; Lawn, Little 
et  al.  2009).  Two  studies  analysing  age  as  a  categorical  variable  have  reported  significantly 
higher  mortality  for  individuals  aged  greater  than  50  years:  the  ART‐LINC  cohort,  a 





conditions within  the  first  6 months  of ART,  causes  of mortality were not  available  (Tuboi, 
Pacheco  et  al.  2010).  In  the  South  African  Free  State  programme  that  followed‐up  14  267 










On  the other hand, data  from  the  International Epidemiological Databases  to Evaluate AIDS 
(IeDEA),  including ART programmes  from Cote d’Ivoire, Malawi, South Africa and Zimbabwe, 
with 13 249  individuals contributing 1 177 deaths  in 14 695 years of  follow‐up,  reported no 
significant difference in mortality risk at 2 years after initiation of ART between patients aged 
50 years and above   and  those aged 16  to 29 years at ART  initiation  (Brinkhof, Boulle et al. 
2009).  Similarly, other  studies  from  sub‐Saharan Africa  including  from  South Africa,  Zambia 
and Senegal have reported no clear association between age and mortality on ART, even with 
considerable  sample  sizes  (Etard,  Ndiaye  et  al.  2006;  Stringer,  Zulu  et  al.  2006;  Brinkhof, 
Pujades‐Rodriguez  et  al.  2009;  MacPherson,  Moshabela  et  al.  2009).  Comparison  across 
studies  is complicated by the use of different age categories and different follow‐up periods. 




rates  in HIV positive and HIV negative older adults  showed  that  the excess mortality  in HIV 
positive older adults  is not accounted  for by  the  increased mortality  that comes with ageing 
(Collaborative Group on AIDS incubation and HIV survival 2000),  indicating that there may be 
factors  related  to  HIV  infection  and  ART  contributing  to mortality  in  HIV  positives.  Rapid 






et  al.  2007;  Sabin,  Smith  et  al.  2009;  Schmid,  Williams  et  al.  2009),  possible  drug‐drug 





Cause‐specific  mortality  and  morbidity  data  are  largely  lacking  in  sub‐Saharan  Africa  and 
registration  systems  do  not  record  detailed mortality  causes  (Kahn,  Tollman  et  al.  2006), 
making  it difficult  to determine  the  contribution of  co‐morbidities  to  increased mortality  in 
patients  aged 50  years  and  above.  In  a  verbal  autopsy  study  in  rural Kenya, HIV‐associated 
conditions were the cause of death in 27% of people aged 50 years and older and the leading 
cause of death up to the age of 70 years  (Negin, Wariero et al. 2010). Other than this study, 





years,  the most  common  causes  of mortality were  TB  (5%  to  44%), wasting  (5%  to  53%), 
advanced HIV (20% to 37%) and chronic diarrhea (10% to 25%) (Gupta, Nadkarni et al. 2011).  
 
Despite a  reported decline  in HIV mortality  in Africa by a study utilising verbal autopsy data 
within our population‐based demographic surveillance system in  rural KwaZulu‐Natal  (Herbst, 







Negin, Wariero  et  al.  2010).  These  two  studies  did  not  investigate  the  likely  variations  in 
mortality causes between younger and older adults making it difficult to understand how age 
influences  causes  of  mortality.  Studies  that  quantify  the  effect  of  age  on  cause‐specific 
mortality following ART initiation and associated risk factors will provide useful insight into the 
special  needs  to  older  adults  receiving  ART.  Identification  of  risk  factors may  be  useful  to 
identify  and  target  older  adults  at  higher  risk  of  mortality  who  may  benefit  from  more 





(Goulet, Fultz et al. 2007), and even  less so  in Africa  (Nguyen and Holodniy 2008; Negin and 
Cumming 2010; Greig, Carrillo et al. 2012; Negin, Barnighausen et al. 2012). Additionally, little 
is known about the contribution of co‐morbidity to mortality on ART because data on causes of 
mortality are mostly  incomplete  in sub‐Saharan Africa  (Greig, Carrillo et al. 2012). Autopsies 
are rarely done and many deaths  in rural areas go unreported (Herbst, Mafojane et al. 2011; 
Bradshaw, Dorrington et al. 2012). As  such,  the morbidity burden  in older adults  cannot be 
accurately inferred from mortality causes alone and the burden of morbidity and its impact on 
mortality  remains  under‐estimated. Directly measuring morbidity  is  even more  problematic 
due to  limitations  in diagnostics  in resource‐limited settings and the high costs of conducting 
longitudinal  studies.  Of  data  available  from  developed  countries,    studies  comparing 
prevalence or  incidence of single clinical events concur that there  is high morbidity risk from 





myocardial  infarction  in HIV positive  individuals  compared  to  that  in  the general population 
(Lang, Mary‐Krause et al. 2010). A  limitation of these studies  is that they have not examined 
the effect of multiple co‐morbidities on HIV prognosis during ART. A recent  large Swiss study 
with  8  444 participants,  2 233  (26%)  aged  50  to 64  years  and 450  (5%)  aged 65  years  and 
above,  that  estimated  the  prevalence  of multiple  co‐morbidity  of  diabetes,  cardio‐vascular 
disease, osteoporosis  and non‐AIDS defining malignancies  in a  cohort of HIV positive  adults 
aged  16  years  and  above,  also did  not  assess  the  extent  and  consequences of multiple  co‐








Similar  results were obtained  from a  study on 33 420 HIV positive and 66 840 HIV negative 
individuals  from The Veterans Ageing Cohort Study  (VACS)  in the USA where  levels of 11 co‐
morbid conditions were examined by HIV status and association with CD4 count and viral load 
(Goulet, Fultz et al. 2007).  In  the VACS, similar  to  the Swiss Study  (Hasse, Ledergerber et al. 




adults but again did not  relate  this morbidity  to ART outcomes  (Onen, Overton et al. 2010). 











at  national  and  local  levels    (Bailis,  Segall  et  al.  2003;  Bradshaw,  Groenewald  et  al.  2003; 
Lorant,  Deliege  et  al.  2003;  Ahmed,  Tomson  et  al.  2005;  Lopez  and Mathers  2006;  Lopez, 
Mathers et al. 2006; Goulet, Fultz et al. 2007; Mayosi, Flisher et al. 2009). A study based  in 
Abidjan, Cote d’Ivoire that compared HIV positive patients pre‐and post‐ART  initiation  in 608 
patients  with  a  median  age  of  31  years,  reported  a  decline  in  all‐cause  morbidity  with 
increased duration on ART. Additionally the authors note that morbidity on ART was affected 
by   morbidity prior  to  initiating ART and  recommended  that when comparing HIV‐morbidity 
and mortality  rates, morbidity  history  should  be  taken  into  account  (Seyler, Messou  et  al. 
2007). However, the majority of studies  looking at mortality on ART  in older adults have not 
considered morbidity prior to ART initiation. This finding of pre‐existing morbidity at the time 
of  initiating ART  influencing morbidity and mortality  rates during antiretroviral  therapy,  in a 




In South Africa  there are  limited data;  in one national study which assessed  the burden of a 
wide  range of non‐communicable diseases  in  the context of   HIV and ART across urban and 








HIV,  in older adults  the burden of TB  coupled with non‐communicable diseases of ageing  is 
likely high given that increasing age is a well‐recognised risk factor for TB (Narasimhan, Wood 
et al. 2013). Clearly there  is need  for more studies  identifying and quantifying the morbidity 
causes and burden in adults aged 50 years and above in sub‐Saharan Africa and its association 
with HIV and ART to not only inform which conditions to screen for, but also inform on health 




adult  population.  Quantifying  the  contribution  of  cause  specific  co‐morbidity  to mortality 
following  initiation  of  ART  will  underscore  co‐morbidities  of  importance  which  when 









renal and  liver  function combined with effects of other chronic  therapies  raises   concerns of 
potentially altered drug metabolism, drug‐drug  interactions and  increased toxicities  including 
diabetes,  hepatotoxicity,  renal  insufficiency,  dyslipidemia,  neuropathy  and  lactic  acidosis 
(Easterbrook and Meadway 2001; Justice, Landefeld et al. 2001; Gebo 2006; Grabar, Weiss et 





Tuberculosis  treatment  regimens  that  contain  Rifampicin  are  generally more  effective  than 
those  that  do  not  contain  this  drug.  However,  Rifampicin  induces  activity  of  the  CYP3A4 
enzyme,  resulting  in  significant  interactions  with  many  of  the  anti‐HIV  drugs.  These 
interactions mean that Rifampicin cannot be co‐administered with any of the other approved 
non‐nucleoside  reverse  transcriptase  inhibitors  (NNRTIs)  or  protease  inhibitors,  due  to 
alterations in levels of the drugs or side‐effects such as liver toxicity and kidney failure. In older 
adults  co‐infected with  TB,  these  drug‐drug  interactions may  be  profound. Nevirapine,  the 
most widely used non‐nucleoside reverse transcriptase in resource‐ limited countries when co‐
administered  with  Rifampicin  in  TB/HIV  co‐infected  patients,  significantly  increases  risk  of 










which other  co‐morbidities  and drugs  interact with ART  in  sub‐Saharan African populations 




may already have  reduced  liver and kidney  function.  Longitudinal  studies  in African  settings 









on ART may be more complicated  than  that of younger adults aged below 50 years.  In sub‐
Saharan African  treatment  guidelines  are  tailored  to  cater  for  all  adults  aged  16  years  and 
above without accounting for the special needs of older adults. Patient management is difficult 
in the absence of empirical data to guide clinicians on how to administer ART and monitor its 












Saharan Africa  (Dunbar‐Jacob and Mortimer‐Stephens 2001),  included 31 studies  from North 
America  and  27  studies  from  sub‐Saharan  Africa  (12  countries).  The  review  reported  ART 
adherence  levels were higher  in African countries with a pooled estimate of 77% adherence 
than  in  North  America  where  the  pooled  estimate  was  55%  (at  levels  greater  than  80%). 





were  not  stratified  by  age making  it  difficult  to  determine  adherence  rates  in  older  adults 
(Dunbar‐Jacob and Mortimer‐Stephens 2001). A limitation of this study is that fact that 71% of 
North American  studies  and  66% of  the  sub‐Saharan African  countries were  based on  self‐
reports of adherence. Closer to home using data from 4 674 adults aged 16 years and above 
initiating ART between August 2004  and March 2011 within our Hlabisa HIV  treatment  and 
care programme in rural KwaZulu‐Natal, retention in care improved with each 10 year increase 
in age (Mutevedzi, Lessells et al. 2013). Despite our finding of better adherence in older adults, 





above  compared  to  younger  adults  have  been well  described  by  studies  from  Europe  and 
North America and report poorer immunological response to ART in older adults than in those 
aged  less  than 50  years old  (Grabar, Kousignian  et  al.  2004;  Silverberg,  Leyden et  al. 2007; 
Greenbaum,  Wilson  et  al.  2008;  The  Collaboration  of  Observational  HIV  Epidemiological 
Research Europe (COHERE) study group 2008). Despite poor  immunological response  in older 
adults, these studies show better virological responses  in older than  in younger adults which 
have  been  attributed  to  possible  better  adherence  to  ART  in  older  adults.  Although  the 













involution  in older adults, especially  in  those aged 65 years and above would attenuate  the 
impact of ART‐induced CD4 count reconstitution (Grabar, Weiss et al. 2006). The attenuation is 
likely  to be more  in  the  initial  rapid phase,  likely  resulting  in  less ART efficacy  in older  than 
younger adults which may  increase risk of early mortality  in the older adult group during the 
initial phase of ART.   Mortality difference by age  is  likely to change as HIV  load  is suppressed 
and  CD4  cell  counts  in  older  adults  gradually  increase.  Longitudinal  studies  examining  the 
relationship  between  immunological  and  virological  response  in  older  adults  compared  to 
younger  adults  following  ART  initiation  and  how  these  changes  affect  mortality  in  those 
receiving ART will help to better understand the  impact of age on response  to ART and may 
begin to show whether older adults would benefit from earlier initiation of ART at higher CD4 

















the presence of HIV‐associated  conditions.  Interactions of  these  two  in  terms of  treatment 
efficacy,  side effects and ultimately morbidity and mortality  in older age groups need  to be 
investigated  and understood  as  these outcomes place  an  additional burden on provision of 
efficient  care  in  the both  the private and public health  sector especially  in  resource  limited 
settings and should to be taken into account in health planning and health systems integration. 
HIV  is  a  global  threat  (UNAIDS  2012),  but  aetiologies  of  patient  outcomes  are  likely  to  be 
multifaceted and  locally and  regionally variable, demanding a  tailored  response(Easterbrook 
and Meadway 2001; Grabar, Weiss et al. 2006; Nguyen and Holodniy 2008). There  is  limited 
understanding  of  the  relative  contributions  of  age‐associated  differences  in  immunology, 
virology, access  to  treatment and  susceptibility  to  co‐morbid diseases and how  these  shape 
mortality patterns for older adults receiving ART in resource limited settings. Much of what we 
know  from  developed  countries  is  likely  not  transferable  to  other  settings  with  different 




with  high  HIV  prevalence  and  incidence  and  a  large  public  sector  HIV  treatment  and  care 














enhanced  access  to  ART  and will  inform  on whether  older  adults  require  intensive  clinical 
management and  follow up  following commencement of ART,  to optimise health benefits of 
ART. Early mortality causes in older adults will also underscore morbidities of importance that 
would require pro‐active intensive screening, diagnosis, treatment and management. Data on 
associations between biomarkers  and  subsequent morbidity and mortality  risk are useful  in 
informing clinicians on high risk groups that may require close clinical monitoring to  improve 
disease  prognosis  on  ART.  Quantifying  the  contribution  of  pre‐existing  co‐morbidity  and 
multiple  co‐morbidities,  at  time  of  initiating ART,  on  early mortality  on ART will  determine 
morbidities of public health importance that can be targeted to reduce mortality. Results from 
this  PhD may  inform  on  how  health  systems  and  services  can  be  integrated  for  efficiency, 
accessibility and cost effectiveness to both the individual and for the government, to inform on 
resource  allocation,  demand  forecasts  and  specific  programme  needs,  especially  in  South 









years  and  above  and  investigate  associations  between  chronic morbidity  and HIV  and  ART 
status in a rural South African population characterised by high HIV prevalence and  incidence 




morbidity  and  HIV  and  ART  status.  Since  HIV  positive  older  adults  potentially  face  a  dual 
burden of disease owing to chronic morbidities of ageing coupled with HIV‐related morbidity, 
which may be  exacerbated by ART,  this  study has  a  focus on HIV positive older  adults  and 
details morbidity  in older HIV positive adults at the time of  initiating ART.   Finally this  thesis 















b.   To establish associations of  inflammatory  cytokine  levels of  Interleukin 1 and 6 
(IL1  and  IL6),    high  sensitivity  C‐reactive  protein  (hsCRP)  and  Tumor  Necrosis 
Factor‐ alpha (TNFα) with HIV, ART, obesity and morbidity 
 






a. To  determine  causes  and  rates  of  serious  morbidity  (resulting  in 
hospitalization) following initiation of ART and the effect of age on such 
morbidity and to  
b. To establish whether abnormal biomarker  [haemoglobin  (Hb), Alanine 
aminotransferase  (ALT)  and  creatinine]  levels  at  ART  initiation  are 
associated with subsequent increased morbidity risk. 
 

















For purposes of  this PhD,  the PhD candidate conducted  two studies namely  the ART Clinical 




The  second  cohort was  of HIV  positive  patients  receiving HIV  treatment  and  care within  a 
defined health sub‐district (Hlabisa HIV Treatment and Care Programme) whilst the third one 






Demographic  Surveillance  set  up  in  2000  to  describe  the  demographic,  social  and  health 
impact of the HIV epidemic  in a population going through health changes and to monitor the 
impact of  intervention strategies on the epidemic  (Tanser, Hosegood et al. 2008). The Africa 
Centre  Demographic  Surveillance  forms  a  longitudinal  prospective  population‐based 
surveillance within a defined geographic area in rural northern KwaZulu‐Natal (Figure 2.1). The 
Africa Centre surveillance area  is predominantly rural, albeit with a township and an  informal 





characterised by  large  variations  in population densities  ranging  from 20 people/km2  in  the 
deep  rural areas  to 3 000 people/km2  in an area near a major  tarred  road. Since  the Africa 
Centre Demographic  Surveillance  inception, demographic,  social  and health data have been 
collected which  in each surveillance round covers approximately 90 000  individuals  in 11,000 
households  in  an  area  of  about  438  km2  (Tanser,  Hosegood  et  al.  2008);  in  each  round 
approximately two‐thirds of household members are resident within the surveillance area.  In 
2010  (the  first  full  year  for  this  PhD),  there were  61  431  household members  resident  in 
approximately 11 500 households within  the  surveillance area; 13% of whom were aged 50 
years and above (Nyirenda, Chatterji et al. 2012). According to the national health barometer, 
the  surveillance  area  is  located  in one of  the most  economically‐deprived districts  in  South 
Africa, with  limited provision of health  care  services  and essential housing  amenities    (Day, 
Barron  et  al.  2011;  Tanser,  Barnighausen  et  al.  2013).  The  principal  sources  of  income  are 
waged employment and state pensions  (Tanser, Hosegood et al. 2008).  Individuals enter  the 
household surveillance cohort at birth or via migration into the area and exit through death. To 
account  for  complex  patterns  of  cyclical migration,  individuals  are  observed  regardless  of 


























































































At  time  of  this  study,  data within  the  household  surveillance were  collected  6‐monthly  on 
residency  status  of  household  members,  births,  marriages,  deaths  and  migrations.  Socio‐
economic status and employment were collected on an annual basis. Within  the annual HIV 
surveillance, health  information  including dried blood  spots  for HIV  testing  is  also  collected 
(Table  2.1).  Data  collection  is  carried  out  by  comprehensively  trained  fieldworkers  with 
refresher trainings twice each year. The Africa Centre fieldwork training manual is available on 
the  Africa  Centre  website  (www.africacentre.ac.za).  Data  collection  tools  include  validated 
questionnaires that are translated  from English to the  local  language (Zulu). All Africa Centre 




All  data  from  the  Africa  Centre  demographic  surveillance  are  entered  in  a  dedicated 
















  Owner  and  members  of  household, 
geographic  location  of  household, 
household expenditure, asset ownership 
Individual socio‐economic data Age,  sex,  household  membership, 
education,  employment,  receipt  of 
government grants 
HIV status    VCT  history,  dried  blood  spot  for  HIV 
testing, VCT offered 
Sexual behaviour  Pregnancy  history,  contraceptive  use, 
sexual activity 



















Surveillance  Area  and  about  40%  of  the  total  programme  cohort  resides  within  the 
Demographic Surveillance Area  (Houlihan, Bland et al. 2010; Mutevedzi, Lessells et al. 2010; 







37%  of  all  HIV  positive  adults  in  the  area  had  been  successfully  started  on  ART which  in 
number terms came to more than 20 000 patients by mid‐2012 (Houlihan, Bland et al. 2010; 
Tanser,  Barnighausen  et  al.  2013).  Since  inception  of  the  programme  in  August  2004  ART 
initiation  was  a  physician  task;  in  mid‐2012  this  task  was  shifted  to  ART‐trained  nurses 
(National  Department  of  Health  2010;  National  Department  of  Health  2013).  Patient 
monitoring was always nurse‐ and  counsellor‐led and occurs at  two and  four   weeks and at 
four‐weekly intervals thereafter until a patient has a suppressed viral load and is clinically well 
when follow‐up is every other month for life (Houlihan, Bland et al. 2010; Mutevedzi, Lessells 
et  al.  2010;  Tanser,  Barnighausen  et  al.  2013).  The  programme  adheres  to  South  African 
National ART guidelines on HIV diagnosis, ART eligibility,  screening,  treatment  regimens and 
follow‐up which have evolved as follows: 
 Between  2004  and  April  2010:  eligibility  for  adults  based  on  CD4+  cell  count  <200 
cells/µL (National Department of Health 2004) 






 August  2011:  eligibility  criteria  raised  to  350  cells/µL  for  all HIV  positive  individuals 
(SANAC. 2011; National Department of Health 2013) 
 In  addition,  irrespective  of  CD4  count  threshold,  ART  was  also  recommended 




























































































































Basic detail    Age,  sex,  address,  ID  number,  contact  details, 
treatment clinic 




ART record    WHO  clinical  staging,  previous  ART/PMTCT,  ART 
regimen  at  initiation,  changes  in  ART  regimen 
during treatment 
Laboratory data    Baseline  and  6‐monthly  CD4  cell  counts  and  HIV 
viral load, baseline haematology and biochemistry 
Clinic visits  Monthly  attendance  and  bi‐monthly  for  patients 
stable on therapy 

















drug  events,  frequency  and  causes  of  hospitalisation  and  changes  in  social 
circumstances 
•  Provide  additional  detailed  information  related  to  the  HIV  treatment  and  care 









clinics, one of which  is  the  largest  clinic  in  the programme  in  terms of both  resources  and 
patient numbers and the other is a middle‐sized clinic (marked with blue circles in Figure 2.2.). 








too  ill  by  the  nurse  to  undertake  the  consent  process were  ineligible  to  participate.  Ethics 
considerations  and  informed  consent  details  are  documented  under  Section  2.3.  From  the 
start of  the Clinical Cohort  (March 2010), 1545 patients had  initiated ART at  the  two clinics. 
Approximately  1%  (n=21)  of  patients  initiating  therapy  declined  participation  in  the  Clinical 
Cohort due  to work commitments and  lack of  time  for study procedures. Of  the 23 patients 
who were  too  ill  to  enrol,  17  patients went  on  to  initiate  ART  at  the  district  hospital  and 
















































































and  the  other  during  follow‐up  visits  (Appendix  2.2)  to  systematically  record  and  collate 
information  on morbidity, ART‐related  factors  including  side  effects,  hospitalizations  and  in 
addition  some  limited  data  on  demographics  and  social  circumstances.  These  data  are 
collected at ART  initiation, two weeks post‐ART  initiation and then monthly thereafter during 
routine treatment collection visits  (Table 2.3).  If the patient has an unscheduled visit  for any 
reason,  that  opportunity  is  taken  to  capture  any  morbidity  events.  Cause  of  death  is 
ascertained through review of patient clinical  files and through  linkage with the  local district 
hospital. ART outcomes of mortality,  loss  to  follow‐up  and  transfers out of  the Hlabisa HIV 
Treatment and Care Programme are captured on a structured outcomes form (Appendix 2.3). 























main Hlabisa HIV  Treatment  and  Care  Programme  at  ART  initiation  and  then  at  6‐monthly 
intervals  Standard  haematology  (haemoglobin,  platelets  and  white  blood  cells)  and 
biochemistry (creatinine, albumin, total bilirubin and alaninine transaminase) tests are done at 
ART  initiation  or when  clinically  indicated,  and  are  then merged  to  the ART  Clinical Cohort 
data.  These  tests  are  performed  at  a  laboratory  under  the  South  African  National  Health 
Laboratory Services  (NHLS),  located at Hlabisa hospital. Test  results are directly  transferred, 
weekly, from the NHLS database  into the Hlabisa HIV treatment and care ARTemis database. 
The ARTemis database was developed and is maintained by the Africa Centre, where it is also 
housed.  No  additional  bio‐specimens  to  those  already  collected  in  the  main  treatment 





















































Also as part of  this PhD,  the PhD  candidate  conducted a  cross‐sectional  study on 422 older 
individuals aged 50 years and above conducted between March 2010 and August 2010. This 
SAGE Well‐being of Older People Study  (WOPS) employed  survey  instruments adapted  from 
the World Health Organization  (WHO) Study on global AGEing and adult health  (SAGE)  (He, 
Muenchrath et al. 2012) and was carried out within  the Africa Centre surveillance area on a 
multi‐stage  random  sample of  individuals  aged  50  years  and  above  between March‐August 








422  individuals  in  total.  Geographical  typology  of  the  randomly  selected  individuals  as 
illustrated  by  the  black  dots  within  the  yellow  surveillance  area  in  Figure  2.2  showed  a 
distribution  similar  to  the  general  distribution  of  the  older  adult  population  within  the 
surveillance area  (high population density along the main tarred roads and sparse density as 









Using  the  sampsi and  the mvsampsi/mvsamp1i  command  in STATA  (http://www.stata.com), 
the  sample  size of  422 would have no power  limitations  to detect differences  in morbidity 
prevalence between HIV positive and HIV negative individuals. Stratifying HIV positives into on 
ART and ART‐naive, the sample size would have 78% power to detect differences in morbidity 
prevalence  between  the  HIV‐negative  and  the  HIV‐positive  population  on  ART  but  power 








alpha  0.05    0.05 
P1  0.565 0.565 
P2  0.389    0.505 
Sample size n1  161 161 





















• Group 3:  (i) an older person with an adult child who  is HIV positive and  is either 
waiting to receive ART or  is receiving ART and (ii) or older persons who have  lost 
an adult child due to HIV or other causes. Although in the main WOPS study group 
three was split  into  two groups,  for this PhD the group  is combined because  the 
PhD researcher was  interested  in the HIV status of the 422 WOPS  individuals. All 






















For  all  groups  the  primary  entry  point  for  selection  for  the  study  was  the  Hlabisa  HIV 
Treatment  and  Care  Programme  clinics  or  the  Africa  Centre  Demographic  Surveillance  and 
Hlabisa HIV Treatment and Care Programme databases.   All older adults  resident within  the 
Africa Centre surveillance area who fulfilled the aforementioned circumstances were identified 
from the Africa Centre Demographic Surveillance database and the Hlabisa HIV Treatment and 
Care  Programme  database  as  this  was  a  simpler  and  efficient  route  of  identifying  eligible 




at a visited household were  invited to participate  in the study. Enrolment  in each group was 
done until the required numbers (100 for each of the first two groups, 200 in the third group) 
consenting  to  the  questionnaire,  blood  draw  and  anthropometric  measurements  were 
reached.  Persons  too  sick  to  participate  (n=3);  non‐contacts  (n=2)  and  those who  refused 
participation  (n=4)  were  excluded;  in  these  cases  replacements  were  selected  from  the 
respective  eligible  population.  For  the  third  group  HIV  status  of  older  adults  remained 








Eligible participants were visited  in  their households  to seek consent  for participation. Study 
procedures were  administered  if  they provided  informed  consent.  In households where we 
found more than one older person present, both of them enrolled. For households that had 
two surviving parents, preference was given to the male parent as  the aim was  to  recruit at 
least 30% males and  it was more common  for households  to have a  female  resident parent 





















isiZulu  language and all  interviews were conducted  in  isiZulu; a pilot study  including 15 older 
adults  was  conducted  to  further  validate  the  data  collection  instruments.  A  structured 
interview  was  followed  for  all  participants  with  participants  only  answering  the  relevant 
questions as  indicated by  the skip patterns  in  the questionnaires. The  interview  time  ranged 

















Health  measurements  of  blood  pressure,  height  and  weight  were  taken  before  the 
questionnaire was administered.  Venous blood samples were collected into EDTA and a serum 
storage  (SST)  blood  tubes  and  used  to  determine  biomarkers  of  pro‐inflammatory  cytokine 





protein,  triglycerides  and  cholesterol).  The  specimens  were  stored  appropriately  and  then 
shipped daily to a laboratory in Amanzimtoti about 300km from the study site for processing. 
The  laboratory  that  processed  specimens  is  accredited  by  the  South  African  National 





To obtain hospitalisation data on patients  accessing  care within Hlabisa HIV  Treatment  and 
Care Programme, patient data are linked between Hlabisa HIV Treatment and Care Programme 
and an  information system that was developed by the Africa Centre  in mid‐2010, at the only 




Information  System  contains  data  on  patient  registration  (name,  date  of  birth,  identity 
number, sex, address and nearest clinic), hospital admission (admission date, admitting doctor, 
admission ward, admission diagnosis, HIV and ART status), ward  information (ward admission 
date,  ward  discharge  date,  responsible  doctor,  HIV  and  CD4  test  results  and  special 
investigations  and  procedures)  and  hospital  discharge  (discharge  date,  discharge  diagnosis, 
outcome, HIV status and ARV medication).  
 






comprised  of  communicable,  perinatal, maternal  and  nutritional  conditions  in  young  adults 
whilst  for  older  adults majority  of  hospitalisation  was  due  to  non‐communicable  diseases 
(Figure  2.5).  In  the  same  year  (2011)  the  overall  hospital mortality  rate was  10.9  per  100 




































































Patient data are collected by a professional nurse, with  ICD‐10 coding  training, who  reviews 
the  recorded  admission  and  discharge  diagnoses,  interacts  with  clinicians  if  needed,  and 
assigns  an  ICD‐10  code  to  each  diagnosis.  From  the  paper  based  system,  admissions  and 
discharge diagnoses are captured electronically on a daily basis by a dedicated clerk and  the 


















































burden  in HIV  positive  older  adults,  at  the  time  of 







Aug 2004 ‐ ongoing  1 409  4   
To  determine  cause‐specific  incidence  rates  of 
serious  morbidity  following  ART  initiation  and  the 
effect  of  age  on  such  morbidity  and  to  establish 



















initiation  in older adults  compared  to young adults; 
quantify  the  contribution  of  baseline morbidity  on 

















Both  the  ART  Clinical  Cohort  and WOPS  studies were  approved  and  approvals  continue  to  be 




Community  Advisory  Board  and  then  from  the  Biomedical  Research  Ethics  Committee  of  the 










All  potential  participants  were  provided  with  information  on  details  of  the  study  aims  and 
methodologies, what participation entailed, how privacy and confidentiality would be maintained 
and time requirements for their participation. A detailed description of potential benefits and risks 
for each study was also provided.  Informed consent was administered  in the  local Zulu  language 
and  at  a  level  that  the  participant  could  comprehend.  This  process  of  informed  consent  was 










individual  by  study  staff.  Individual  identifiers  were  excluded  from  all  analysis  datasets  and 
participants were only  identified  through  the  study numbers. All  interviews were  conducted  in 
areas that ensure privacy i.e. in a closed room at the clinics or an area identified by the participant 
in the participants’ households. For WOPS groups 3 details of the HIV positive adult child were not 




All  databases  for  the  above mentioned  surveys  and  studies  are  housed  and maintained  at  the 




Centre  surveillance  area  and  their  information  can  be  linked  between  the  two  databases.  All 
patients  within  Hlabisa  HIV  Treatment  and  Care  Programme  accessing  care  at  Hlabisa  district 







Surveillance  and  Hlabisa  Hospital  Information  System  via  Hlabisa  HIV  Treatment  and  Care 
Programme. All WOPS participants reside within the surveillance area and can be linked to Hlabisa 





































of  residency  and  mother’s/father’s    name  are  used  to  link  individuals  across  the  different 
databases, after which the  individual  is  identified as  ‘matched’ between the different databases. 




and  surname  are  different  the  individual  will  not  be  identified  as  being  the  same  individual 
participating  in the Africa Centre surveillance and also accessing HIV care within the Hlabisa HIV 
Treatment and Care Programme.  In such cases of  inconsistencies  (less than 5%) the case will be 
investigated by checking the full data spectrum of the two individuals across all four data sources 
until  it  is  clear  whether  or  not  it  is  one  or  two  individuals  with  that  particular  ID  number.  
Additionally the source hard copy document for the ID number for both studies in question i.e. the 




attempted  but  not matched.  The  reasons  for  failure  to match  are  also  documented  under  the 
comments section. Those that are not matched for example patients within Hlabisa HIV Treatment 





households  located outside  the Africa Centre  surveillance  area),  are  captured  as  ‘not matched’ 
under the “matched” variable within the respective parent database. 
 
Analyses  utilising  linked  Hlabisa  HIV  Treatment  and  Care  Programme  and  Africa  Centre 
Demographic Surveillance data have been successfully used before  to answer different  research 
questions pertaining but not limited to determining ART coverage within the surveillance area and 





For all  studies, Microsoft SQL Server  (MS SQL) databases are held and maintained by  the Africa 
Centre  according  to  already  established  and  set  data  management  guidelines 
(www.africacentre.ac.za).  Participant  confidentiality  is maintained  at  all  times  during  the  strict 
document chain of custody. All data forms are captured by Africa Centre data capturing staff and 
securely  filed.  All  databases  contain  appropriate  quality  control  constraints  to  minimise  data 















variables  and  proportions with  95%  Confidence  intervals  for  categorical  variables. Median  and 
proportions test inclusive of Kwallis2 test for equality of medians and χ2 for equality of proportions 




were  used  for  assessment  of  associations.  For  longitudinal  data  analyses  Kaplan‐Meir  time  to 
event  analysis  and  normal  and  time‐stratified  Cox  regression  techniques  were  employed  to 
estimate  event  rates  and  establish  rich  factors  respectively.  For  all  analyses  underlying 
assumptions were tested for and if found to be violated then the analysis method was substituted 
for a more fitting method. Comprehensive details of this are also documented  in chapters 3 to 7 
under  analytical methods  sub‐headings  and  immediately  before  presenting  the  results.  Unless 
otherwise stated all probability values were two‐tailed with a threshold significance set at 0.05. All 


















































Wealth  score  ‐  Household  socio‐economic  status  was  determined  using  a  wealth  index, 
constructed using a set of assets a household owns, with ownership of each asset represented by 
a binary indicator. The wealth index of each household was derived in STATA (StataCorp, 2012) by 
principal  component  analysis  (Colley  and  Lohnes 1971). Each household was  assigned  a wealth 
score, the distribution of these scores has mean zero and a standard deviation of one, which were 
then divided into quintiles. The first (lowest) quintile represents households with the least number 


















Laboratory marker      Abnormal levels      Units 
Haemoglobin (Hb)      <8           g/dL 
Alanine Aminotranferase (ALT)     >60 (2xupper limit of normal)    IU/ml  
Glomerular filtration rate (GFR)    <60          ml/min/1.73m2 
















and Care Programme. My  focus has been data  collection and analysis  relating  to adult patients 
aged 16 years and above whilst the other epidemiologist focuses on children aged below 16 years. 
I  have  been  responsible  for  the  scientific  component  of  the  programme  including  patient  data 
handling,  analysis  and publication. As  co‐investigator on use of  routinely  collected patient data 
within  Hlabisa  HIV  Treatment  and  Care  Programme  for  research  purposes,  my  specific  roles 
include  compiling annual ethics  recertification applications  to  the  local ethics  review board and 
regular monitoring of regulatory documents and  liaison with the ethics board for ethics updates. 
Additionally  I  serve  as  a member of  the Hlabisa HIV  Treatment  and Care Programme database 
management team, which regularly reviews data quality and assesses whether database structure 
and  performance  are  optimal  to meet  required  needs.  I  am  also  involved  in  the Africa  Centre 







regular  feedback  to  the monitoring  and  evaluation  team  on  data  quality  and  possible  areas  of 
improvement.  I also  regularly provide  the  local Department of Health with  research  findings on 




Treatment  and  Care  Programme.  I  am  responsible  for  extensive  and  in‐depth  data 





responsibility.  My  publications  relevant  to  the  background  [Chapter  1  (Appendix  1.1)], 



















































I was  responsible  for  seeking ethics approval  from both our  local  research ethics  committee as 
well as from the  local department of health authorities. Furthermore  I was  involved  in obtaining 




to ensure  specimen  integrity  is maintained  from  the  time of  specimen  collection  in  the  field  to 
when the specimens are processes in the laboratory and results received at Africa Centre. 
I was responsible for staff recruitment including developing job adverts, interviewing and selecting 








health  components,  health  and  anthropometric  measurements,  specimen  collection  and 
management  including all  laboratory components of the study. For validity and reliability checks 
on  all  study  tools,  systems  and  logistics  I  oversaw  a  pilot  study  including  15  participants.  All 
procedures  including  informed  consent  and  questionnaire  administration  and  anthropometric 
measurements were done except for collection of blood specimens. I was involved in checking the 
questionnaires  to  ensure  accuracy,  consistency  and  completion  and  feedback  of  pilot  findings 
including delivering an additional training as  informed by the pilot. Additionally I validated WOPS 
participants  morbidity  self‐reports  against  those  reported  within  Africa  Centre  Demographic 
Surveillance as a way of checking reliability of self‐reports by older adults and this work  is under 
peer review by the Journal of Clinical Epidemiology for publication (Appendix 2.7). 
During  the  course of  the  study  I was  solely  responsible  for  the management of  the  laboratory 
component  of  the  study,  quality  control  and  quality  assurance  of  laboratory  documents, 
specimens and  the  results  thereof  including daily checks on  laboratory  results and  referring any 
patients with  urgent  results  to  a  doctor within  the Africa  Centre. Additionally  I  participated  in 
checking all questionnaires completed  to ensure research quality and standards as stipulated by 
Good Clinical Practice (GCP) are met. 























Older people  aged  50  years  and  above  are  at  risk of  chronic morbidity  such  as heart diseases, 
arthritis, diabetes and hypertension, associated with physiological changes with age(Grabar, Weiss 
et al. 2006; Gebo 2008; Christensen, Doblhammer et al. 2009; Mayosi,  Flisher et al. 2009), but 
these  conditions  remain  often  undiagnosed  particular  in  resource  poor  settings.  The  disease 
burden may be exacerbated by both HIV and antiretroviral therapy (ART)(Andrew and David 2000; 
Gebo 2006; Grabar, Weiss et al. 2006; Nguyen and Holodniy 2008; Rhee and Greenblatt 2008), 




















Similar  to HIV  and  ageing,  obesity  is  linked  to  chronic  health  problems  such  as  cardiovascular 
diseases, diabetes and arthritis (Cheymol 2000; Bastard, Maachi et al. 2006; Population Reference 
Bureau 2008)  and  is  characterised by  chronic  low‐grade  inflammation  (Trayhurn 2005; Bastard, 
Maachi et al. 2006). Understanding the associations of obesity, morbidity and HIV and ART status  
























in  a  geographically  defined  rural  South  African  area  in  KwaZulu‐Natal.  Nested  within  this 
household  surveillance  is  an  annual  HIV  surveillance.  On  1  January  2010,  there  were  61  431 















Life‐style factors      smoking, alcohol 
Venous blood specimen     laboratory testing of lipid profiles, IL1, IL6, hsCRP, TNFα  
Anthropometric measures    weight and height 
Vital signs        blood pressure 
 





























BMI  (indicator of obesity): Calculated  from  the weight and height measurements ascertained  in 
















Penninx,  Kritchevsky  et  al.  2004;  Rodger,  Fox  et  al.  2009),  log‐transforming  continuous  levels 
(Penninx, Kritchevsky et  al. 2004),  taking  the median  (Harris,  Ferrucci et  al. 1999) or  the  lower 
cytokine detection  limit  (Puts, Visser et al. 2005) as cut‐off.   For CRP, values >3µg/ml have been 
used  to  indicate  increased  risk  of  heart  disease  whilst  values  >8.5  µg/ml  appears  to  indicate 
clinically relevant  inflammation (Puts, Visser et al. 2005). To ensure uniformity and comparability 








































Wealth  score:  stratified  into  five  hierarchical  quintiles were  the  first  quintile  represented  the 










o HIV  positive  ART  naive  older  adults  were  the  ones  who  were  recorded  in 
Hlabisa HIV Treatment and Care Programme as not having initiated ART when 
the  participants  eligible  for  the  Wellbeing  of  Older  People  Study  were 
sampled.  
o Those,  whose  date  of  ART  initiation  with  Hlabisa  HIV  Treatment  and  Care 
Programme was more than one year prior to Wellbeing of Older People Study 
sampling date, and had  continuously  received ART, were  categorised as HIV 
positive and on ART.  
To  ensure  that  there  was  no  contamination  of  the  group  comprising  HIV  positive  ART  naive 




All  laboratory  tests were  conducted  by  a  South African National Accreditation  System  (SANAS) 
certified  laboratory  (Global  Clinical  and  Viral  Laboratory).  Tests  were  conducted  using  kits  by 
BioVendor  Research  and  Diagnostic  Products,  Czech  Republic.  Lower  detection  concentrations 







Baseline  characteristics were described using medians and  IQRs  (equality of medians  tested  for 
using Kwallis2 test (Siegel and Castellan 1988)) for continuous variables and proportions with 95% 
CI for categorical variables. To assess the association of HIV and obesity with morbidity, ordinary 
logistic  regression was employed. Because  IL6 was categorized  into an ordinal variable, ordered 
logistic  regression  (STATA bulletin 2000; UCLA 2012) assessed  the association between  IL6  , HIV 
and obesity. Ordered logistic regression takes into account the hierarchy in the dependent variable 
categories  assuming  proportional  odds  (POR)  and  results  in  a  single  equation  estimating  the 
relationship between predictor variables and all levels of the dependent variable. Due to violation 
of proportional odds assumption, associations of HIV and obesity with CRP were examined using 
generalized  ordered  logistic  regression  which  estimates multiple  equations  over  the  different 
hsCRP  levels  without  assuming  proportional  odds,  producing  partial  proportional  odds  ratios 














(Tanser,  Hosegood  et  al.  2008;  Nyirenda,  Chatterji  et  al.  2012)  and  setting,  few  individuals 
reported current  (n=48, 11.4%) or ever smoking  (n=49, 11.6%) or current drinking  (n=58, 13.8%) 








health care utilisation  frequency  (p>0.001). Over a  third of  those HIV negative  (37.9%) had only 




Of  the  422 participants,  124  (29.4%,  95% CI:  25.0‐33.8)  reported never having been diagnosed 
with any chronic condition (Table 3.1) whilst 169 (40.1%, 95% CI: 35.4‐44.7) and 100 (23.7%, 95% 
CI:  19.6‐27.8)  reported  being  diagnosed with  one  and  two  conditions,  respectively;  29  (6.9%) 
individuals had more than two conditions. Significantly more HIV negative and HIV positive ART‐
naïve  participants  than  HIV  positive  participants  receiving  ART  reported  current morbidity  i.e. 






Correlation of  self‐reported chronic morbidity with  the WHO composite heath  score and with 
self‐rated health on day of interview 
Table 3.1 shows that similar to patterns of self‐reported chronic morbidity across HIV/ART status 
strata,  the WHO composite health score and self‐rated health were higher  in  those HIV positive 

































Sex  Male  30 18.6  (12.6‐24.7) 36 33.3  (24.4‐42.3) 30 27.5 (19.1‐36.0) 106 25.1  0.05 
Age at interview  68 61‐75  57 53‐62 53 51‐60 60 53‐69  <0.001 
Employment  No  158 98.8  (97.0‐1) 99 92.5  (87.5‐97.5) 96 88.9 (82.9‐94.9) 395 94.3  0.01 
Yes   2 1.3  (0‐3.0) 8 7.5  (2.5‐12.5) 12 11.1 (5.1‐17.1) 24 5.7  
Main source 
of income 
Grants  145 91.2  (86.8‐95.6) 81 75.0  (66.8‐83.2) 69 63.9 (54.8‐73.0) 332 79.4   
No source of income 7 4.4  (1.2‐7.6) 9 8.3  (3.1‐13.6) 18 16.7 (9.6‐23.8) 36 8.6 <0.001 
Other  7 4.4  (1.2‐7.6) 18 16.7  (9.6‐23.8) 21 19.4 (11.9‐27.0) 50 12.0   
BMI 
categories 
Underweight  4 2.6  (0.1‐5.1) 7 6.6  (1.8‐11.4) 12 11.2 (5.2‐17.2) 25 6.1  
Normal  46 29.9 (22.6‐37.1) 40 37.7  (28.4‐47.0) 30 28.0 (19.5‐36.6) 127 31.0   
Overweight  45 29.2  (22.0‐36.5) 37 34.9  (25.8‐44.1) 35 32.7 (23.8‐41. 7) 127 31.0  0.04 
Obese  48 31.2  (23.8‐38.5) 17 16.0  (9.0‐23.1) 24 22.4 (14.5‐30.4) 105 25.6   
Morbidly obese  11 7.1  (3.0‐11.2) 5 4.7  (0.7‐8. 8) 6 5.6 (1.2‐10.0) 26 6.3  
Smoking  Never smoked  117 73.1  (66.2‐80.0) 99 91.7  (86.4‐96.9) 74 67.9 (59.1‐76.7) 324 77.0   
Past smoker  24 15.0  (9.4‐20.6) 6 5.6  (1.2‐9.9) 16 14.7 (8.0‐21.4) 49 11.6  0.001 




Alcohol  Never drank  94 58.75  (51.1‐66.4) 82 75.9  (67.8‐84.1) 64 58.7 (49.4‐68.0) 269 63.9   
Past drinker  41 25.63  (18.8‐32.4) 14 13.0  (6.6‐19.4) 33 30.3 (21.6‐39.0) 94 22.3  0.01 




No  38 23.6  (17.0‐30.2) 39 36.1  (27.0‐45.2) 29 26.6 (18.3‐5.0) 121 28.7  0.12 
Yes  123 76.4  (69.8‐83.00) 69 63.9  (54.8‐73.0) 80 73.4 (65.0‐81.7) 301 71.3   
Current 
morbidity 
No  70 43.5  (35.8‐51.2) 66 61.1  (51.9‐70.4) 54 49.5 (40.1‐59.0) 215 51.0  0.03 




No  52 32.3  (25.0‐39.6) 52 48.2  (38.7‐57.6) 48 44.0 (34.6‐53.4) 173 41.0  0.04 
Yes  109 67.7 (60.4‐75.0) 56 51.9  (42.4‐61.4) 61 56.0 (46.6‐65.4) 249 59.0   
Composite 
health score 
Continuous  46.7 43.1‐53.1 52.3 47.9‐57.4 48.6 44.1‐54.1 49.22 44.6‐
55.1 
0.001 
Healthy  47 29.2 (22.1‐36.3) 59 54.6  (45.2‐64.1) 41 37.6 (28.5‐46.8) 159 37.7  <0.001 
Unhealthy  114 70.8 (63.7‐77.9) 49 45.4  (35.9‐54.3) 68 62.4 (53.2‐71.6) 263 62.3   
Self rated 
general health   
Good/very good  65 40.4 (32.7‐48.0) 64 59.3  (49.9‐68.6) 42 38.5 (29.3‐47.7) 193 45.7  0.006 





Not at all  6 3.7 0   0 9 2.1  
1 to 2 times  61 37.9 (30.3‐45.4) 4 3.7  (0.1‐7.3) 13 11.9 (5.8‐18.1) 98 23.2  <0.001 
3‐6 times  35 21.7 (15.3‐28.1) 6 5.6  (1.2‐9.9) 29 26.6 (18.2‐35.0) 83 19.7   
















The distribution of  laboratory measured  IL1,  IL6, hsCRP and TNFα  for both HIV positive and HIV 
negative older adults showed little variation in terms of the median.  HIV positive and HIV negative 
older adults had a similar median  IL1  level of 1.6 pg/mL (Table 3.2). Although the medians were 
the  same  across  groups,  significantly more HIV‐negative  people  had  IL1  levels  above  1.6µg/mL 
than  those HIV positive ART‐naive  (p=0.003). For TNFα, only 7  (1.8%) participants had elevated 
levels, with medians similar across all HIV status strata (p=0.231) therefore variations  in TNFα by 
















higher  IL6 median  levels  compared  to  HIV  negative  individuals  (Table  3.2).  There was  a  trend 
towards  highest  hsCRP  levels  (>8.5pg/ml)  in  those  HIV  positive,  with  a  statistically  significant 
difference in HIV positive ART‐naive compared to HIV negative.  
 
































IL1 (pg/mL)  1.6   (1.6‐1.6) 1.6  (1.6‐1.6)   1.6  (1.6‐1.6) 1.6  1.6‐1.6 
<=1.6        123   83.1  (77.0‐89.2) 100  92.6  (87.6‐97.6) 94  96.9  (93.4‐1.0) 353  (90.1) 
>1.6  25   16.89  (10.8‐23.0) 8  7.4  (2.4‐12.4) 3 3.1  (0‐6.6) 39  (10.0) 
IL6 (pg/mL)  1.94   (1.6‐2.6) 2.5  (2.0‐3.1)   2.6  (2.0‐3.2) 2.4  2.1‐2.6 
<=1.56  70  47.3  (39.2‐55.4) 38  35.2  (26.1‐44.3) 36  37.1  (27.4‐46.8) 157  (40.1) 
>1.56‐2.9  20   13.5  (8.0‐19.1) 24  22.2  (14.3‐30.1) 19  19.6  (11.6‐27.6) 68  (17.4) 
>2.9‐5  26  17.6  (11.4‐23.7) 21 19.4  (11.9‐27.0) 19 19.6  (11.6‐27.6) 73  (18.6) 
>5  32   21.6  (15.0‐28.3) 25 23.2  (15.1‐31.2) 23 23.7  (15.2‐32.3) 94  (24.0) 
CRP (µg/mL)  3.7  (2.5‐4.1) 4.2 (3.5‐5.8)   4.3 (2.6‐6.5) 3.9  3.2‐4.3 
<=1  31  21.2  (14.6‐27.9) 16  15.1  (8.2‐22.0) 21  21.7  (13.4‐29.9) 78  (20.1) 
>1‐3.9  52  35.6  (27.8‐43.4) 33  31.1  (22.3‐40.0) 25  25.8  (17.0‐34.6) 122  (31.4) 
>3.9‐8.5  39   26.7  (19.5‐33.9) 24  22.6  (14.6‐30.7) 19  19.6  (11.6‐27.6) 92  (23.7) 















IL1 (pg/mL)  1.6  (1.6‐1.6) 1.6  (1.6‐1.6)   1.6  (1.6‐1.6) 1.6  1.6‐1.6 
<=1.6  134   90.5  (85.8‐95.3) 107  93.0  (88.4‐97.7) 103  87.3  (81.2‐93.3) 353  (90.1) 
>1.6  14   9.5  (4.7‐14.2) 8 7.0  (2.3‐11.6) 15  12.7  (6.7‐18.8) 39  (10.0) 
IL6 (pg/mL)  2.5   (2.0‐3.2) 2.5  (1.7‐3.2)   2.08  (1.6‐2.6) 2.4  2.1‐2.6 
<=1.56  58  39.2  (31.3‐47.1) 47  40.9  (31.8‐49.9) 51  43.2  (34.2‐52.2) 157  (40.1) 
>1.56‐2.9  24   16.2  (10.2‐22.2) 17  14.8  (8.3‐21.3) 25  21.2  (13.8‐28.6) 68  (17.4) 
>2.9‐5  26   17.6  (11.4‐23.7) 28  24.4  (16.4‐32.3) 17  14.4  (8.0‐20.8) 73  (18.6) 
>5  40   27.0  (19.8‐34.2) 23  20.0  (12.6‐27.4) 25  21.1  (13.8‐28.6) 94  (24.0) 
hsCRP 
(µg/mL) 
2.5  (1.8‐4.0) 3.2  (2.5‐3.9 )   6.15 (4.8‐6.9) 3.9  3.2‐4.3 
<=1   46  31.3  (23.8‐38.8) 17  14.9  (8.3‐21.5) 13 11.2  (5.4‐17.0) 78  (20.1) 
>1‐3.9  39  26.5  (19.4‐33.7) 54  47.4  (38.1‐56.6) 27  23.3  (15.5‐31.0) 122  (31.4) 
>3.9‐8.5  27   18.4  (12.1‐24.67) 20  17.5  (10.5‐24.6) 43  37.1  (28.2‐45.9) 92  (23.7) 
























































































































































































HIV+ on ART  0.44  0.25‐0.79  0.49  0.26‐0.92 
HIV+ not on ART  0.98  0.55‐1.73  1.08  0.58‐2.01 







overweight  1.13  0.66‐1.93  1.15  0.67‐1.96 
obese/morbidly obese  1.60  0.90‐2.83  1.63  0.92‐2.89 
Government grant No  1  1 
Yes  2.17  1.23‐3.81  2.01  1.08‐3.76 
*Cholesterol:HDL Ratio 1  1  1 
Ratio 2  2.25  1.18‐4.27  2.23  1.17‐4.24 
Ratio 3  1.98  1.09‐3.62  1.98  1.08‐3.62 

















Current morbidity  50‐65 years old only (n=248)    50‐60 year old only (n=199) 
Adjusted OR  95% C.I  p‐value    Adjusted OR  95% C.I  p‐value 
HIV‐  1    1 
HIV+ on ART  0.37  0.18‐0.80  0.011    0.35  0.14‐0.87  0.024 
HIV+ not on ART  0.84  0.39‐1.82  0.662    0.87  0.35‐2.14  0.756 
HIV unknown  0.39  0.11‐1.38  0.143    0.42  0.09‐1.95  0.266 
Age ( 1 year increase)  1.02  0.96‐1.10  0.479    1.04  0.95‐1.15  0.398 
BMI normal  1    1 
Overweight  1.3  0.65‐2.60  0.459    1.09  0.50‐2.38  0.823 
Obese/morbidly obese  1.76  0.83‐3.75  0.141    1.76  0.75‐4.16  0.197 
Government grant No  1    1 
Yes  1.81  0.94‐3.49  0.078    1.77  0.90‐3.45  0.096 
*Cholesterol:HDL Ratio 1  1    1 
Ratio 2  2.01  0.92‐4.76  0.08    2.09  0.82‐5.34  0.124 
Ratio 3  2.39  1.10‐5.22  0.028    2.14  0.89‐5.19  0.091 






















































































































































































































the  partial  proportional  odds  (apPOR=2.30;  p=0.004)  of  having  slightly  raised  hsCRP  levels 
(>1ug/mL), a level that is unlikely to be of clinical significance.  
 
ART‐naïve  HIV  positive  individuals  had more  than  double  apPOR  of  having  hsCRP  levels  (>3.9 
ug/mL), a  level that  is  indicative of  increased cardiovascular disease risk  (p=0.008). Assessing  for 
factors associated with hsCRP  levels > 8.5 µg/mL, HIV  infection (both on and off ART) and having 
the  highest  ratio  of  cholesterol:HDL  (>7.1  for  females  and  >9.6  for  males)  were  the  only 
independent factors associated with these very high  levels of hsCRP (>8.5ug/mL), levels that may 
signify  clinically  relevant  inflammation with  the  likelihood  being  even  higher  in  ART‐naïve  HIV 
positive participants (Table 3.3).  
 
The  association of BMI  and hsCRP was  also examined  in  this  same  generalised ordered  logistic 
regression model whose results showed that although all BMI  levels above normal  increased the 
odds of having hsCRP  levels  likely to be of clinical significance  (>1ug/mL), being obese/morbidly‐
obese nearly tripled the likelihood of having hsCRP levels, associated with increased cardiovascular 
disease  risk, of >3.9ug/mL beyond which BMI was not associated with higher CRP  levels  (Table 
3.3). Compared to those aged below 60 years, those aged 60‐69years were twice as likely to have 
elevated hsCRP levels. Having cholesterol:HDL >7.1 for females and >9.6 for males was associated 





Table  3.5: Generalised  ordered  logistic  regression model  for  factors  associated with  elevated 
CRP levels in old adults n=422 
 
CRP levels  Odds Ratio  P‐value  95% Confidence interval 
<=1pg/mL   
HIV‐  1  
HIV+ on ART  2.30 0.004 1.31  4.06 
HIV+ ART naive   1.03 0.93 0.51   2.08 
HIV unknown  0.83 0.61 0.42  1.66 
BMI normal  1  
Overweight  2.54 0.005 1.33  4.85 
Obese/morbidly obese  3.72 <0.001 1.81   7.63 
Age 50‐59years  1  
60‐69 years  1.06 0.87 0.54   2.05
70+ years  1.27 0.41 0.73  2.21 
>1‐3_9pg/mL         
HIV‐  1  
HIV+ on ART  2.30 0.004 1.31  4.06 
HIV+ ART naive   2.30  0.008 1.25  4.24 
HIV unknown  0.83  0.61 0.42  1.66 
BMI normal  1  
Overweight  0.78  0.37 0.46  1.33 
Obese/morbidly obese  2.78  <0.001 1.58   4.89 
Age 50‐59years  1  
60‐69 years  2.09 0.009 1.21  3.61
70+ years  1.27 0.41 0.73  2.21 
>3_9‐8_5pg/mL   
HIV‐  1  
HIV+ on ART  2.30  0.004 1.31  4.06 
HIV+ ART naive   2.81  0.002 1.47   5.38 
HIV unknown  0.83  0.61 0.42  1.66 
BMI normal  1  
Overweight  0.80 0.48 0.43   1.48 
Obese/morbidly obese  1.41  0.27 0.77  2.61 
Age 50‐59years  1  
60‐69 years  1.43  0.23 0.80  2.57 
70+ years  1.27 0.41 0.73  2.21 
Across all levels of hsCRP 
aCholesterol:HDL ratio 1  1  
Ratio 2  1.12 0.70 0.64  1.96
Ratio 3  1.47  0.16 0.86  2.53










•  HIV‐infected older adults on ART were significantly  less  likely (OR=0.49, p=0.027) to report 
current morbidity than HIV‐uninfected adults 





elevated  inflammation markers  of  IL6  (>1.56pg/mL)  was  nearly  doubled  in  HIV‐infected 
individuals on (aPOR 1.84; 95%CI: 1.05‐3.21) and not on (aPOR 1.94; 95%CI: 1.11‐3.41) ART.  
•  Compared  to HIV‐uninfected, HIV‐infected  individuals on ART had more  than  twice partial 
proportional  odds  (apPOR=2.30;p=0.004)  of  having  non‐clinically  significant  raised  hsCRP 
levels(>1ug/mL) 
•  ART‐naïve  HIV‐infected  individuals  had more  than  double  apPOR  of  having  hsCRP  levels 
indicative of increased heart disease risk (>3.9ug/mL;p=0.008).  
•  Being obese/morbidly‐obese nearly tripled the  likelihood of having hsCRP  levels associated 
with increased cardiovascular disease risk (>3.9ug/mL) 
















of young HIV positive adults aged below 50 years. A  later objective of  this PhD  (Chapter 7) will 













































 Pre‐existing chronic morbidity  ‐ was defined as chronic morbidities  for which the patient 
















to  haemoglobin  levels,  patients  liver  and  kidney  function  are  evaluated  based  on  laboratory 
measured  levels  inclusive of Alanine Aminotranferase (ALT), Creatinine and Glomerular Filtration 
Rates  (National  Department  of  Health  2003;  National  Department  of  Health  2004;  National 
Department of Health 2010; National Department of Health 2013). These markers were assessed 




Laboratory marker      Abnormal        Units 
Hemoglobin (Hb)      <8           g/dL 
Alanine Aminotranferase (ALT)     >60 (2xupper limit of normal)    IU/ml  
Glomerular filtration rate (GFR)    <60          ml/min/1.73m2 




Analysis  included all adults  (≥16 years) who were enrolled  into  the ART Clinical Cohort between 
March 2010 and July 2012 (inclusive). This time cut‐off reflects the fact that the same dataset was 
used to assess the effect of baseline morbidity on very early mortality (occurring within the first 3 




observation  time  of  6  months;  3  months  in  which  very  early  mortality  could  occur  and  an 
additional 3 months to allow for reporting hence capturing the mortality events. Proportions and 
medians  of  categorical  and  continuous  baseline  characteristics  respectively  were  described 
stratified by age at ART initiation i.e. young (<50 years) or older (≥50 years) adults. Differences in 
baseline characteristics between the two groups were assessed using the non‐parametric equality‐
of‐median  test  for continuous variables and proportions  test  for categorical variables. Estimated 
glomerular filtration rate (eGFR) was calculated using the 4‐variable Modification of Diet in Renal 








and above  initiated  therapy within  the Hlabisa HIV Treatment and Care Programme at  the  two 
clinics where the ART Clinical Cohort was based. All patients were recruited  into the ART Clinical 
Cohort; 21 adults  (1%) declined participation. As such 1409 patients were enrolled  into  the ART 
Clinical Cohort, 425 (30.2%) male, median age 33 years and 193 (13.7%) aged 50 years and above 
at  time of  initiating ART. The proportion of males  initiating  therapy and  the median age at ART 








Health 2010; National Department of Health 2013)  (median 148;  IQR 82‐205) and  just over 40% 
classified as having WHO diseases stage 3 or 4,  the majority had a normal BMI; about 35.3% of  
ART  Clinical  Cohort  participants  were  overweight  or  obese  (Table  4.1).  Based  on  laboratory 






Based  on  report  of  currently  taking medication  for  pre‐existing  chronic medication  at  time  of 
initiating ART, 147 patients  (10.4%) had one  and 15  (1.1%) more  than one pre‐existing  chronic 
morbidity. Specifically, 100 (65.79%) were on anti‐hypertensive treatment, 14 (9.2%) had asthma, 
12  (7.9%)  epilepsy,  25  (16.5%)  arthritis,  18  (11.8%)  diabetes,  4  (2.6%) were  on medication  for 












Characteristic  n  %  95% C.I 
Sex (Male)  425  30.2  27.8‐32.6 
Age       
<50  1216  86.3  84.5‐88.1 
50+  193  13.7  11.9‐15.5 
BMI       
under weight  184  13.1  11.3‐14.8 
normal  703  49.9  47.3‐52.5 




Missing  24  1.7  1.0‐2.4 
Blood pressure       
Normal   1162  82.5  80.5‐84.5 
Abnormal (>90/>140)  237  16.8  14.9‐18.8 
Pre‐existing  chronic morbidity treatment (yes)       
Asthma   14  9.2   
Epilepsy  12  7.9   
Arthritis  25  16.5   
Diabetes  18  11.8   
Hypertension  100  65.8   
Psychiatric  4  2.6   
Other  7  4.6   
Number of pre‐existing  chronic morbidity therapy 
0  1247  88.5  86.8‐90.2 
1  147  10.4  8.8‐12.0 




WHO disease staging       
1&2  799  57.0  54.4‐59.6 
3&4  603  43.0  40.4‐45.6 
Concurrent TB therapy       
no  1117  79.8  77.7‐82.0 
Pulmonary  241  17.2  15.3‐19.2 
Extra‐pulmonary  41  2.9  2.1‐3.8 
Hb       
Abnormal (<7)  66  4.7  3.6‐5.8 
Missing  68  4.8  3.7‐6.0 
CD4 count       
<50  216  15.4  13.5‐17.3 
50‐200  821  58.4  55.9‐61.0 
>200  368  26.2  23.9‐28.5 
Glomerular filtration rate       
>=60  1222  86.7  85.0‐88.5 
<60  127  9.1  7.5‐10.5 
Missing  60  4.3  3.2‐5.3 
ALT       
<=60  1242  88.2  86.5‐89.8 
>60  62  4.4  3.3‐5.7 
Missing  105  7.5  6.1‐8.8 
ART regimen       
TDF+3TC+EFV  1,101  78.14  76.0‐80.3 
TDF+3TC+NVP  64  4.54  3.5‐5.6 
AZT+3TC+NVP  10  0.71  0.3‐1.2 
AZT+3TC+EFV  59  4.19  3.1‐5.2 
d4T+3TC+NVP  24  1.70  1.0‐2.4 






HIV‐associated  morbidity  took  into  consideration  all  serious  HIV  related  morbidity  and  thus 
included  all  patients  initiating ART with WHO HIV disease  stage  3 or  4. Although nearly  three‐
quarters of the cohort (n=1037, 73.8%) initiated therapy at CD4 cell counts below 200, 421 (30.0%) 
were asymptomatic (WHO stage 1) whilst 433 (30.7%) were classified as WHO disease stage 3 or 4. 
Of  the  433  patients with HIV‐associated morbidity  at  time  of  initiating ART,  about  half  (n=216 
49.9%)  reported  severe weight  loss whilst  50  (11.6%)  and  36  (8.3%)  had  oral  candidiasis  and 
chronic  diarrhoea  respectively.  Twenty  five  (5.6%)  had  oesophageal  candidiasis,  6  (1.4%) 
cryptococcal meningitis,  3  (0.7%)  PCP  and  3  (0.7 %)  renal  failure.  HIV‐associated morbidity  at 





Pre‐existing  chronic  morbidity  was  defined  as  chronic  morbidities  for  which  the  patient  was 
already receiving therapy at time of  initiating ART. HIV‐associated morbidity took into account all 
serious  morbidity  at  time  of  initiating  ART,  classified  according  to  WHO  HIV  disease  staging 
classification as stage 3 or 4. Assessing for pre‐existing chronic, HIV‐related and TB morbidity, 660 
(46.8%)  patients  had  no  morbidity;  228  (16.2%)  had  TB  only;  67  (4.8%)  pre‐existing  chronic 
morbidity  only;  337  (23.9%)  HIV‐associated  morbidity  only  (Table  4.3).  One  individual  had 







Table  4.2: Cause‐specific  prevalence  of WHO HIV‐disease  stage  III  or  IV morbidity  at ART 
initiation 
 
Morbidity cause  Number  Percentage  95 % Confidence Interval
Bacterial meningitis  1  0.07  0 0.21
HIV associated arthritis  1  0.07  0 0.21
Neurologic  1  0.07  0 0.21
Renal failure  3  0.21  0 0.45
PCP  3  0.21  0 0.45
Cryptococcal meningitis  6  0.43  0.09 0.77
Herpes  7  0.5  0.13 0.86
Anaemia  8  0.57  0.17 0.96
HIV associated malignancies  11  0.78  0.32 1.24
Oesophageal candida  25  1.77  1.08 2.46
HIV wasting  25  1.77  1.08 2.46
Chronic diarrhoea  36  2.56  1.73 3.38
Urino‐genital  40  2.84  1.97 3.71
Oral candidiasis  50  3.55  2.58 4.52
Severe weight loss  216  15.33  13.45 17.21
TB  249  17.67  15.68 19.67






























(≥50  years old)  and  young  (<50  years old)  adults majority of patients were  female,  there were 
significantly more males  among  the  older  (42.5%,  95%  CI  35.5‐49.5%)  than  the  young  adults 
(28.2%, 95% CI 25.7‐30.7). About a  third, 37.8%, of older adults and only 13.5% of young adults 




>140/diastolic pressure  >90 mmHg).  The proportion of older  adults who were  initiated on ART 
with  a CD4  count of  less  than  50  cells/µl was  significantly  smaller  for older  adults  (9.9%)  than 
among young adults  (16.2%; p=0.023), yet TB was more prevalent amongst younger adults: 220 
(18.1, 95% CI 15.9‐20.3) younger adults had pulmonary TB and 21 (10.9%, 95% CI 6.5‐15.3) older 











For  all  pre‐existing  chronic morbidity,  older  adults  had  higher  proportions  currently  receiving 
therapy  than  younger  adults,  reaching  statistical  significance  for  arthritis,  diabetes  and 
hypertension as shown in Table 4.4. As such, 77 (6.3%; 95% CI 5.0‐7.7%) of younger adults had one 
chronic condition whilst 70  (36.3%; 95% CI 29.5‐43.1%) of older adults were on  therapy  for one 
named chronic condition. Four times as many older adults as younger adults had more than one 







Characteristic  n % 95% C.I n % 95% C.I
  YOUNGER ADULTS (1216) OLDER ADULTS (193)
Sex (Male)  343 28.21 25.67‐30.74  82 42.49 35.49‐49.49
BMI 
under weight  165 13.57 11.64‐15.50  19 9.84 5.63‐14.06
normal  618 50.82 48.01‐53.64  85 44.04 37.01‐51.07
overweight  254 20.89 18.60‐23.18  49 25.39 19.23‐31.55
obese/morbidly obese   157 12.91 11.02‐14.80  38 19.69 14.06‐25.32
mis  22 1.81 1.06‐2.56  2 1.04 0‐2.47
Blood pressure 
Normal  
Abnormal (>140/>90mmHg)  164 13.49 11.56‐15.41  73 37.82 30.96‐44.69
Hb (g/dL) 
Abnormal (<8)  62 5.10 3.86‐6.34  4 2.07 0.06‐4.09
mis  64 5.26 4.01‐6.52  4 2.07 0.06‐4.09
CD4 count 
<50  197 16.24 14.16‐18.32  19 9.90 5.66‐14.13
50‐200  709 58.45 55.67‐61.23  112 58.33 51.33‐65.33
>200  307 25.31 22.86‐27.76  61 31.77 25.16‐38.38
Glomerular filtration rate (ml/min/1.73m2)
≥60  1077 88.57 86.78‐90.36  145 75.13 69.01‐81.25
<60  81 6.66 5.26‐8.06  46 23.83 17.80‐29.87
miss  58 4.77 3.57‐5.97  2 1.04 0‐2.47
ALT (IU/ml) 
≤60  1062 87.34 85.46‐89.21  180 93.26 89.72‐96.81
>60  56 4.61 3.43‐5.78  6 3.11 0.65‐5.57
miss  98 8.06 0.98‐6.27  7 3.63 0.98‐6.27
 
Concurrent TB therapy 
no  951 78.21 75.88‐80.53  166 86.01 81.10‐90.92
Pulmonary  220 18.09 15.93‐20.26  21 10.88 6.47‐15.29
Extra‐pulmonary  38 3.13 2.15‐4.10  3 1.55 0‐3.31









Characteristic  n  %  95% C.I  n  %  95% C.I 
  YOUNGER ADULTS  OLDER ADULTS 
Pre‐existing  chronic morbidity  
Asthma   10  0.82  0.31‐1.33  4  2.07  0.06‐4.09 
Epilepsy  9  0.74  0.26‐1.22  3  1.55  0‐3.31 
Arthritis  14  1.15  0.55‐1.75  11  5.70  2.42‐8.98 
Diabetes  4  0.33  0‐0.65  14  7.25  3.58‐10.93 
Hypertension  48  3.95  2.85‐5.04  52  26.94  20.66‐33.22 
Psychiatric  4  0.33  0‐0.65  0  0   
Other  6  0.49  0‐0.89  1  0.52  0‐1.53 
Number of pre‐existing  chronic conditions per patient 
0  1131  93.01  91.57‐94.44  116  60.10  53.17‐67.04 
1  77  6.33  4.96‐7.70  70  36.27  29.46‐43.08 






HIV‐associated morbidity at ART  initiation  included patients with WHO HIV disease  stage 3 or 4 
(433  (30.7%));  344  (28.3%;  95%  CI  25.8‐30.8%)  in  younger  adults  and  89  (46.1%;  95%  CI  39.1‐
53.1%)  in older  adults.  Figure  4.1  illustrates  that  younger  adults  initiated  therapy with  a wider 
spectrum of HIV‐related morbidity  than older  adults  albeit having a  significantly  smaller overall 
proportion of patients. In this cohort no older adults were diagnosed with bacterial or cryptococcal 
meningitis, herpes, renal failure, HIV‐associated arthritis or PCP; although the prevalence was also 







































existing  chronic morbidity  rather  than HIV‐associated morbidity  (Table  4.4). Older  adults  had  a 










Characteristic  n  %  95% C.I  n  %  95% C.I 
  YOUNGER ADULTS (1216)  OLDER ADULTS (193) 
None  606  49.8  47.0‐52.6  49  25.4  19.2‐31.6 
HIV‐associated only  282  23.2  20.8‐25.6  50  25.9  19.7‐32.1 
TB only  212  17.4  15.3‐19.6  16  8.3  4.4‐12.2 
Chronic only  40  3.3  2.3‐4.3  32  16.6  11.3‐21.9 
HIV‐associated & TB  31  2.6  1.7‐3.4  1  0.5  0‐1.53 
HIV‐associated & chronic  30  2.5  1.6‐3.3  38  19.7  14.1‐25.3 
TB and chronic  14  1.2  0.6‐1.8  7  3.6  1.0‐6.3 
HIV‐associated & chronic & TB  1  0.1  0‐0.24  ‐  ‐  ‐ 
Combined             
None  606  49.8  47.0‐52.7  49  25.4  19.2‐31.6 
Only 1  534  43.9  41.1‐46.7  98  50.8  43.7‐57.9 
Only 2  75  6.2  4.8‐7.5  46  23.8  17.8‐29.9 



















Table  4.7: Association  of  age with  pre‐existing  chronic/HIV‐associated/TB morbidity  at ART 
initiation.  
 
Morbidity type    aOR  95% C.I 
HIV‐associated   Young adults  1   
Older adults  2.30  1.67‐3.16 
TB   Young adults  1   
Older adults  0.50  0.31‐0.80 
Pre‐existing chronic   Young adults  1   
Older adults  9.91  6.77‐14.49 















only  1  patient  had  a  combination  of  non‐HIV  related  chronic morbidity, HIV‐associated 
morbidity and TB. 
 HIV‐related morbidity  at  baseline  included  severe  weight  loss,  oral    and  oesophageal 
candidiasis, chronic diarrhoea, cryptococcal meningitis, PCP and renal failure 
 Nearly  four  times  as  many  older  than  younger  adults  had  a  low  GFR  of  <60 
(ml/min/1.73m2) suggestive of poor kidney function. 
 Older adults had a higher proportion of patients  initiating ART with pre‐existing chronic 
morbidity  but  younger  adults  initiated  therapy  with  a  wider  spectrum  of  HIV‐related 
morbidity compared to older adults 
 Only 75  (6.2%; 95% CI 4.8‐7.5%) of younger adults compared  to 46  (23.8% 95% CI 17.8‐






















for  adults  receiving  ART  in  sub‐Saharan  Africa.  Previous  studies  are  based  in  resource‐  rich 
countries  whilst  the  few  that  are  from  developing  countries  are mainly  based  in  large  urban 
hospitals, where morbidity patterns and outcomes may differ  from those  in more deprived rural 




In all HIV positive patients  receiving ART,  the  risk and extent of  side effects and drug  toxicities, 
resulting  in morbidity, may depend on the patients’ kidney and  liver function which also reflects 
the ability to metabolise and excrete ART drugs (Chapter 1.7). For this reason and  in accordance 
with South Africa HIV  treatment guidelines, unless  the patient urgently requires  therapy, before 
ART initiation, kidney and liver function efficiency is evaluated through Creatinine and Glomerular 
filtration rate (GFR) and Alanine aminotransferase (ALT) respectively. Haemoglobin (Hb) levels are 
also  determined. However  few  studies  especially  in  resource  limited  settings  have  determined 





















Programme  was  linked  to  the  Hlabisa  hospital  information  system.  To  recap,  Hlabisa  hospital 
information  system  refers  to  an  electronic database  that  captures  information on  all overnight 













Since Hlabisa hospital  information  system was  initiated  around May  2010,  the  analysis  for  this 
study,  done  in  February  to March  2013,  included  all  patients  aged  16  years  and  above  who 
initiated ART at 17 primary health care clinics between 01 June 2010 and 31 July 2012. Data were 
censored  on  1  February  2013  to  allow  for  sufficient  time  to  capture  early  serious morbidity. 
Hospitalisation  details were  obtained  by  linking  adults within  Hlabisa  HIV  Treatment  and  Care 





All morbidity was  coded by a qualified nurse  registered with  the  South African Nursing Council 
who was also trained in WHO ICD10 coding. 
Serious morbidity was defined  as  any morbidity  resulting  in hospitalization  for greater  than 24 
hours (one or more overnight stays). 
Laboratory markers 
Within  the Hlabisa HIV  treatment  and  care  programme,  at  time  of  initiating ART  (baseline),  in 











described  stratified by age at ART  initiation  i.e. younger  (<50 years) or older  (≥50 years) adults. 
Differences  in  baseline  characteristics  between  the  two  groups were  assessed  using  the  non‐




Kaplan‐Meier analysis. All observations  started at  time of  initiating ART.  For  those hospitalised, 
observation ended at date of admission. Patients not seen for more than 180 days (nine months) 
from  the date of database  closure  (16  January 2013) were  classified as  loss  to  care. Data were 
censored  at  earliest  of  loss  to  care,  transferring  out  of  the  programme  or  last  clinic  visit.  To 
ascertain  the  independent  influence  of  age  on  risk  of  hospitalisation,  a  Cox  regression model 













age was 33  years  (IQR: 27‐41). Of  the 8 598 patients, 962  (11.2%) were older  adults  aged 50+ 
years. Median CD4 count was 165 (IQR: 89‐246) cells/µl and 1160 patients were on concurrent TB 






than  in  younger  adults  (28.9%,  95%  CI  27.9‐30.0%).  Interestingly,  a  lower  proportion  of  older 
adults  initiated ART with Hb  levels <8 g/dL  (1.6%, 95% CI 0.1‐2.3%), CD4 cell count <50 cells/µL 











A  total of 675 patients  (7.9%) were hospitalized over 8166 person years of  follow‐up, giving an 
estimated  incidence rate of 8.3 (95% CI 7.7‐8.9) per 100 person years. The rate of hospitalization 
was three‐fold higher  in the first 3 months subsequent to ART  initiation (incidence rate (IR) 17.6 
per 100 person years, 95% CI 15.8‐19.6 compared  to  later periods  (IR 5.4 per 100 person years, 
95% CI 4.9‐6.0). Additionally, patients initiating ART whilst concurrently taking TB medication were 
more  likely  to  experience  serious morbidity  leading  to  hospitalisation  than  patients  not  on  TB 
therapy: IR 13.0 95% CI 11.0‐15.5 per 100 person years and IR 6.1 95% CI 4.2‐8.9 for those on and 
not  on  TB  therapy  respectively.  Although  for  both  groups,  incidence  of  serious morbidity was 
higher  in  the  first 3 months  compared  to periods  thereafter,  for  those  initiating ART whilst on 
concurrent TB therapy, the IR was twice as high (IR 35.2; 95% CI 28.4‐43.6) per 100 person years 
compared to those without TB (IR 15.3; 95% CI 13.5‐17.4) per 100 person years. Post this period, 











(95%  CI  4.8‐7.9)  per  100  person  years  (Table  5.1).  Rates  of  serious  morbidity  resulting  in 
hospitalization were  non‐statistically  significantly  higher  in  younger  adults  than  in  older  adults, 
with slight overlap between the confidence intervals. 
 














0‐3 months  1686.9  Younger  309  18.32  16.38‐20.48  1   
  217.2  Older  26  11.97  8.15‐17.58  0.65  0.44‐0.97 
>3months  5507.4  Younger  306  5.56  4.97‐6.21  1   
  755.2  Older  34  4.50  3.22‐6.30  0.81  0.57‐1.15 
Overall  7194.3   Younger  615  8.55  7.90‐9.25  1   
  972.4   Older  60  6.17  4.79‐7.95  0.72  0.55‐0.94 
Age stratified into young adults aged 16‐49 years and older adults aged >50years 
 
Since a  considerable amount of hospitalisation  in younger adults was due  to pregnancy  related 
issues  such  as  infant  deliveries  and  spontaneous  abortions  (126/615,  20.5%) which would  not 
necessarily  apply  to  older  adults,  removing  pregnancy  related  conditions  resulted  in  similar 
hospitalization rates in both age groups [(6.8, 95% CI 6.2‐7.4 in younger adults and to 6.2, 95% CI 









Of  the  675  serious morbidities  that  led  to  hospitalization,  231  (34.2%) was  due  to  other  non‐
infectious conditions (Figure 5.1). The majority of conditions within this category were pregnancy 
related‐ (126 (54.6%) followed by injuries with 29 cases (12.6%). Diseases of the circulatory system 












occurred  in  younger  adults  (Figure  5.3).  It  is worth noting  that  although  a  lower proportion of 
older adults had TB at time of initiating therapy, they had a higher proportion of cases diagnosed 




commencement of ART  therapy. Fifty  two of  the 139 TB cases at admission  (37.4%)  in younger 
adults were on TB therapy whilst for older adults 4/16 (25%) were receiving TB therapy when they 
initiated  ART.  Older  adults  had  a  higher  proportion  of  respiratory  infections  requiring 
hospitalisation  than  younger  adults.  For  other  non‐infectious  conditions  (specific  diseases  prior 
listed)  younger  adults  had  a  higher  proportion  compared  to  older  adults  (Figure  5.3).  Small 
numbers  of  hospitalised  older  adults  likely  limited  statistical  power  to  detect  significant 
differences  in  categories,  except  for  non‐infectious  conditions, where  differences  by  age were 


























































































































































adults  (median 8 days,  IQR 4.5‐13 days) compared  to younger adults  (median 6 days,  IQR 3‐12) 
p=0.002. Duration  of  hospitalization  varied  by  cause  of  hospitalization with  patients  diagnosed 

















































































































causes  of  hospitalisation  such  as  genito‐urinary  diseases  and  other  non‐infectious  conditions 
mainly consisting of pregnancy related conditions and injuries had relatively low case‐fatality rates 
compared to rare conditions such as Kaposi sarcoma and advanced HIV/AIDS whose CFR were the 
highest at above 40%  (Figure 5.5). TB was a  common  cause  for hospitalisation and  its CFR was 





model  adjusted  for  baseline  laboratory  and  clinical  characteristics  and  gender was  employed. 
From  this analysis, compared  to younger adults  there was a  trend  towards  lower  risk of serious 






Adjusting  for  age  at  time  of  ART  initiation,  pregnant  females  were  at  higher  risk  of  being 
hospitalized  (aHR 1.34, 95% CI 1.05‐1.72)  than non‐pregnant  females. There were no  significant 





initiating  therapy  whilst  pregnant  were  about  half  less  likely  to  experience  serious morbidity 
leading to hospitalisation  (aHR 0.42 p<0.001) than non‐pregnant women even after adjusting for 
age.  In  the  same  adjusted  analysis,  patients  co‐infected  with  TB  at  ART  initiation  had  41% 
increased  risk  of  serious morbidity  leading  to  hospitalisation  (aHR  1.41  p=0.001)  whilst  those 
initiating therapy with advanced HIV as approximated by CD4 cell count  less than 50cells/µl also 
had 60% increased risk of hospitalization (p<0.001). Anaemic patients (Hb <8g/dL) and those with 
























Sex: Females not pregnant  ref       
Males  1.08  0.392  0.91  1.28 
Pregnant females  1.34  0.020  1.05  1.72 
Age: <50 years  ref       
≥50 years  0.78  0.073  0.60  1.02 
Concurrent TB therapy at ART initiation: No  ref       
Yes  1.41  0.001  1.15  1.72 
Unknown  0.60  0.015  0.40  0.90 
CD4 cell count (cells/µl): <50  1.59  0.000  1.30  1.94 
50‐200  ref       
>200  0.75  0.003  0.62  0.91 
Missing  1.36  0.218  0.84  2.21 
Hemoglobin (g/dL): ≥8  ref       
<8  2.80  0.000  2.09  3.76 
Missing  1.06  0.743  0.76  1.47 
Creatinine (µmol/L): ≤120  ref       
121‐240  1.46  0.053  1.00  2.14 
>240  3.97  0.000  2.15  7.34 
Missing   1.85  0.007  1.18  2.90 
Alanine transaminase (IU/L): ≤60  ref       
>60  0.99  0.973  0.70  1.41 

































































individuals  (Chapter 1, Section 1.7.1). Some African  studies have  reported a positive association 
between increasing age and rapid HIV progression and subsequent mortality (Toure, Kouadio et al. 
2008;  Lawn,  Little et al. 2009; Tuboi, Pacheco et al. 2010), while  in other African  studies  there 



















effect  of  age  on  response  to ART  in  terms  of  total mortality,  viral  suppression  and  CD4  count 
















Section  2.2.1  and  2.2.2.  The  programme  adheres  to  the  national  antiretroviral  treatment 






First‐line  ART  consisted  of  stavudine  (d4T),  lamivudine  (3TC),  and  either  efavirenz  (EFV)  or 





This  analysis  was  solely  based  on  data  obtained  within  the  Hlabisa  HIV  Treatment  and  Care 
programme and was not linked to any other data sources. Analysis included all adults (≥16 years) 
who  initiated ART between 1st August 2004 and 31st October 2009, excluding patients already on 
ART  who  transferred  into  the  programme  from  elsewhere.  Analysis  was  stratified  by  age  at 
initiation of ART (<50 years and ≥50 years). The <50 years age group was further stratified into 16‐
24  years  and  25‐49  years  to  assess  for  heterogeneity  in  overall  outcomes  and  baseline 
descriptions. We assessed differences between the three groups in baseline clinical characteristics 




for  categorical  variables.  To  evaluate  kidney  function  at  time  of  ART  initiation,  estimated 
glomerular filtration rate (eGFR) was calculated using the 4‐variable Modification of Diet in Renal 




out  of  programme,  or  22nd  April  2010.  Loss  to  follow‐up was  defined  as  having missed  three 
consecutive  monthly  pill  collection  visits  (three  months  (90  days)  without  a  clinic  visit).  To 
ascertain the independent influence of age on overall mortality, a Cox regression model adjusted 
for  all  significantly  different  baseline  factors  (P<0.05)  was  used  to  assess  mortality  hazard 
difference by age strata. The two bottom age strata (younger and mid‐age groups) were combined 
in  the  analysis  for  determination  of mortality  risk  factors  because  there  were  no  statistically 






2010),  consequently  stratified  Cox  regression  with  time  split  at  3  and  12  months  post‐ART 
initiation was used to determine risk  factors for   mortality  in the periods 0‐3 months (very early 
mortality), 3‐12 months (early mortality), and >12 months post‐ART initiation. For the two periods 
in  the  first  year,  analysis  was  further  stratified  by  age  to  establish  differences  in  mortality 
predictors between old and younger patients. For all Cox models, variables were included into the 




score  test based on  scaled  Schoenfeld  residuals  (Grambsch  and Therneau 1994). All  results  are 
reported at 5% significance level. 
 
Changes  in  CD4  cell  counts  in  the  24 months  following  ART  initiation were  quantified  using  a 
piecewise linear model based on follow‐up CD4 cell counts measured at six‐monthly time points ± 
three months.  For  909  and  504 patients with missing CD4  counts  at  6 months  and  12 months 











differences  in mortality  in  those  with missing  observations  compared  to  those  with  recorded 
observations.  Where  those  with  missing  data  had  significantly  different  mortality  rates,  we 
maintained a category of the missing group within the respective variable  in both the univariable 
and  multivariable  models  exploring  factors  associated  with  mortality.  This  adjusted  for  any 
overestimation of the effect of measured/recorded variables on mortality in the absence of those 










these, 808  (9.1%) were aged 16‐24 years, 7119  (80.5%) were aged 25‐49 years and 919  (10.4%) 
were  ≥50  years  at  time of ART  initiation  (range  16‐83  years). Overall median baseline CD4  cell 
count was 119 cells/μl (IQR 58‐174); slightly and non‐clinically significantly higher for older adults 








deaths  during  1  554.3  person  years  in  older  adults  ≥50  years  at  ART  initiation).  The  overall 
mortality  rate was 6.75 per 100 person‐years  (95% CI 6.34‐7.18). Table 6.2  shows  the mortality 
rate was  significantly higher  for  those  ≥ 50  years old  (8.69 per 100 person‐years, 95% CI 7.34‐
10.28) than for younger adults aged 25‐49 years old (6.55 per 100 person‐years, 95% CI 6.11‐7.02) 











45.0%).  Figure 6.1  (Kaplan‐Meier  curve)  illustrates mortality differences between  the  three  age 
groups. Mortality  rates were  significantly higher  for older  adults  (≥50  years)  in  the periods 0‐3 



































0 1 2 3 4
Time after ART initiation (years)

















Age  808  22 (21‐24)    7119  35 (30‐40)    919  54 (51‐58)   
Male sex  107  13.2  10.9‐15.6  2504  35.2  34.1‐36.3  400  43.5  40.3‐46.7 
WHO stage 3 or 4  328  40.6  37.2‐44.0  3435  48.3  47.1‐49.4  420  45.7  42.5‐48.9 
Missing   357  44.2  40.8‐47.6  2629  36.9  35.8‐38.1  348  37.9  34.7‐41.0 
CD4 cell count, cells/μl                   
Median (IQR)  777  133 (69‐182)  125.7‐144  6827  115 (55‐173)  113‐118  888  127 (71‐177)  122‐136 
>200  118  15.2  12.7‐17.7  764  11.2  10.4‐11.9  114  12.8  10.6‐15.0 
150‐200  220  28.3  25.1‐31.5  1643  24.1  23.1‐25.1  237  26.7  23.8‐29.6 
100‐149  162  20.9  18.0‐23.7  1449  21.2  20.3‐22.2  221  25.0  22.0‐27.7 
50‐99  139  17.9  15.2‐20.6  1431  21.0  20.0‐21.9  178  20.1  17.4‐22.7 
<50  138  17.8  15.1‐20.5  1540  22.6  21.6‐23.6  138  15.5  13.2‐17.9 
Viral load, log10 copies/ml   491  4.4  4.3‐4.6  4313  4.4  4.4‐4.4  542  4.5  4.4‐4.6 
Weight, kg (IQR)   704  56  54.7‐57.1  6262  59.3  59‐59.8  814  60  59.1‐61 
TB treatment   171  21.2  18.3‐24.0  1581  22.2  21.2‐23.2  175  19.0  16.5‐21.6 
Haemoglobin <8g/dL   76  9.4  7.4‐11.4  576  8.1  7.5‐8.7  44  4.8  3.4‐6.2 
Missing  110  13.6  11.3‐16.0  914  12.8  12.1‐13.6  101  11.0  9.0‐13.0 
*eGFR ≤60ml/min/1.73m2    30  3.7  2.4‐5.0  854  12.0  11.2‐12.8  311  33.8  30.8‐36.9 
Missing   93  11.5  9.3‐13.7  725  10.2  9.5‐10.9  86  9.4  7.5‐11.2 
Albumin <32 g/L   440  54.5  51.0‐57.9  3764  52.9  51.7‐54.0  474  51.6  48.3‐54.8 
















0 ‐ 3     186.3  32  17.2  12.1‐24.3 
>3‐12     447.8  18  4.0  2.5‐6.4 
>12‐24    340.9  13  3.8  2.2‐6.6 
>24       190.8  9  4.7  2.5‐9.1 
Total  1165.8  72  6.2  4.9‐7.8 
25‐49     years 
0 ‐ 3     1675.7  358  21.4  19.3‐23.7 
>3‐12     4166.9  251  6.0  5.3‐6.8 
>12‐24    3478.1  111  3.2  2.7‐3.8 
>24       2737.5  70  2.6  2.0‐3.2 
Total  12058.2  790  6.6  6.1‐7.0 
≥50       years 
0 ‐ 3     217.6  59  27.1  21.0‐35.0 
>3‐12     535.8  51  9.5  7.2‐12.5 
>12‐24    445.1  15  3.4  2.0‐5.6 
>24       355.7  10  2.8  1.5‐5.2 
Total  1554.3  135  8.7  7.3‐10.3 








initiation,  2  187  patients  (73.5%)  had  a  recorded  CD4  count.  Although  older  adults  initiated 
therapy with moderately higher median baseline CD4 cell count, their median CD4 cell count post‐
























































































































































































































































































































cells/μl,  higher  log10  viral  load,  lower  weight,  and  albumin  <32g/L)  and  increased  very  early 





between  3‐12 months  (early mortality), mortality  rates  remaining  higher  in  older  compared  to 
younger  adults  (9.5  vs  5.8  per  100  person  years  respectively;  rate  ratio  1.64,  p=0.001).  Low 
baseline CD4 cell count (<50 cells/μl) remained  independently associated with mortality  in those 
aged <50years, as did WHO  stage3/4 disease and  low albumin. For older adults  the only  factor 
independently associated with mortality in this period was haemoglobin <8g/dL.  There remained 
a trend towards increased mortality risk with CD4 cell count <50 cells/μl and albumin <32g/dL but 















Mortality  rates  did  not  differ  significantly  between  those with  complete  baseline  observations 
compared to those with missing observations. However, 116 (6.4%) of 1816 patients alive but with 














<50 years (n=7927) ≥50 years (n=919) <50 years (n=7154) ≥50 years (n=832)
Age (1yr increase)    0.9 (0.95‐1.04)    1.0 (0.99‐1.08) 
25‐49 years  1    1   
16‐24 years  0.8 (0.54‐1.34)    0.7 (0.45‐1.19)   
Sex Male  1.6 (1.32‐2.03)  1.8 (1.06‐3.17)  1.4 (1.09‐1.80)  1.3 (0.73 ‐ 2.41) 
WHO stage 3 or 4  1.8 (1.11‐2.81)  NS  2.1 (1.19‐3.57)  NS 
CD4 cell count (cells/μl)         
>200  1.6 (0.96‐2.52)  1.2 (0.35‐4.05)  1.5 (0.90‐2.51)  2.2 (0.83‐5.82) 
150‐200  1  1  1  1 
100‐149  1.2 (0.79‐1.88)  1.0 (0.37‐2.86)  1.0 (0.65‐1.68)  1.7 (0.70‐4.26) 
50‐99  1.6 (1.05‐2.33)  2.3 (0.97‐5.67)  1.5 (0.97‐2.31)  2.0 (0.79‐4.87) 
<50  2.4 (1.63‐3.46)  2.6 (1.07‐6.31)  2.8 (1.85‐4.10)  2.0 (0.80‐4.98) 
Missing  2.1 (1.16‐3.87)  4.0 (1.10‐14.4)  1.8 (0.92‐3.51)  0.3 (0.04‐2.63) 
Viral load (per log10 increase)  1.2 (1.03‐1.34)  2.3 (1.52‐3.43)  NS  NS 
Weight (1kg increase)  0.9 (0.93‐0.95)  0.9 (0.94‐0.99)  0.9 (0.97‐1.00)  NS 
TB treatment*  1.6 (0.84‐1.97)  0.9 (0.48‐1.69)  1.1 (0.79‐1.40)  1.4 (0.72‐2.63) 
Haemoglobin <8g/dL  2.1 (1.61‐2.64)  NS  NS  4.2 (1.79‐9.65) 
eGFR ≤60 ml/min/1.73m2†  1.7 (1.35‐2.23)  NS  1.4 (1.00‐1.98)   NS 
Albumin <32g/L  3.6 (2.44‐5.24)  2.6 (1.19‐5.58)  2.2 (1.56‐3.02)  1.5 (0.76‐3.02) 
























































•  Older  adults  had  the  lowest  proportion with  CD4  cell  count  <50  cells/μl  prior  to  ART 
initiation. 
•  The  overall mortality  rate was  6.75  per  100  person‐years,  significantly  higher  for  older 
adults  (8.69 per 100 person‐years)  than  younger  adults  (6.18  and 6.55 per 100 person‐
years in those age 16‐24 years and 25‐49 years old respectively). 







•  The  largest proportion of patients with poor  immunological response (failed to achieve a 
CD4 count  increase of ≥50 CD4 cells)  in the first 6 months of therapy was higher  in older 
adults 
•  Almost half of  all  those who  initiated with CD4  cell  count <50  cells/μl  (45.2%)  failed  to 
attain a CD4 cell count >200 cells/μl at 12 months post ART initiation 
•  Despite  having  poorer  immunologic  responses,  a  greater  proportion  of  older  adults 









•  Factors  associated  with  mortality  after  12  months  were  explored  in  a  single  model 
incorporating all ages because of the similar mortality rates in both age strata 
•  12  months  after  initiating  ART  there  was  no  longer  any  evidence  of  an  association 
between mortality and baseline CD4 cell count, but a lower absolute CD4 cell count and a 















or  the  influence of HIV‐related and HIV‐unrelated morbidities at  the  time of  initiating ART. This 





It quantifies  the effect of baseline morbidity  to very early mortality  risk  in both age groups and 
ascertains whether  levels of Hb, ALT  and GFR  at ART  initiation  are  indicators of  increased  very 
early mortality risk. These markers were of interest because treatment efficacy and mortality may 
depend  on  the  patients’  kidney  and  liver  ability  to metabolise  and  excrete ART  drugs.  For  this 
reason and in accordance with South Africa HIV treatment guidelines, unless the patients urgently 
















This  analysis  employed  data  collected within  the  ART  Clinical  Cohort which was  established  in 




from  those  initiating elsewhere within  the main Hlabisa HIV Treatment and Care Programme  in 
terms of their baseline characteristics as detailed under Chapter 4 in Section 4.3.1 which describes 
baseline demographic, clinical and laboratory characteristics of patients at ART initiation. Analysis 








Very  early mortality  was  defined  as mortality  within  the  first  91  days  (3 months)  of  ART.  In 
addition  to  specific  ICD10  coding  (Section 2.2.3.2),  causes of mortality were broadly  coded  into 
system‐specific  categories  such  as  genito‐urinary,  cardiovascular,  haematological  diseases, 





associated with  baseline morbidity  are  presented  in  Chapter  3.  In  this  chapter we  employ  the 
broad morbidity categories (none, HIV‐associated only, HIV‐associated and TB, HIV‐associated and 






















Laboratory marker      Abnormal        Units 
Hemoglobin (Hb)      <8           g/dL 
Alanine Aminotranferase (ALT)     >60 (2xupper limit of normal)    IU/ml  




described  stratified by age at ART  initiation  i.e. younger  (<50 years) or older  (≥50 years) adults. 
Differences  in  baseline  characteristics  between  the  two  groups were  assessed  using  the  non‐
parametric equality‐of‐median  test  for  continuous variables and proportions  test  for categorical 







were  estimated  by  Kaplan‐Meier  analysis.  Data  were  censored  at  earliest  of  loss  to  care, 
transferring out of the programme or  last clinic visit. Patients not seen  for  longer than 180 days 
(nine months) from the date of database closure (16 January 2013) were classified as loss to care. 
To ascertain the independent influence of existing baseline co‐morbidities on very early mortality, 






morbidities at baseline compared  to  those without. Attributable  fraction  (AFexposed)  refers  to  the 
proportion  of  cases  following  exposure whilst  the  etiologic  fraction,  also  known  as  population 
attributable  risk percentage  (PAR%),  is  the  reduction  in early mortality  incidence  that would be 
observed at population  level  if the population was entirely unexposed compared with  its current 
actual exposure levels. All definitions were in line with previously set definitions (Northridge 1995; 
Rothman  and  Greenland  1998).  Although  attributable  risk measures may  not  replace  relative 
measures of effect, they are essential in that, due to them being population based concepts,  they 






















(30.2%) male,  193  (13.7%)  aged  50  years  and  above  at  time  of  initiating  ART. Most  patients 
initiated therapy with a CD4 cell count <200 cells/µl (median 148; IQR 82‐205) and just over 40% 





ml/min/1.73m2 whilst 62  (4.4%) had ALT  levels greater  than  twice  the upper  limit of detection 
(>60 IU/ml). Baseline characteristics presented here mirror baseline characteristics within Hlabisa 
HIV Treatment and Care Programme as previously reported within this thesis (Chapter 7) and are 
also  similar  to  previously  published  data  from  Hlabisa  HIV  Treatment  and  Care  Programme 






(6.3%) had died, 100  (7.1%) were  lost to follow up  (LTFU) and a  further 129 (9.2%) had  formally 
transferred out of the programme. Truncating data at 3 months post‐ART initiation, 1316 patients 
(93.4%) were  actively  on  therapy,  59  (4.2%)  had  died,  24  (1.7%) were  LFU  and  10  (0.7%)  had 





















(n=6 deaths, 10.2%). Nine deaths  (15.3%) were  from unknown causes  (Table 7.1). Specific  ICD10 
mortality causes per category are listed in Table 7.1 and Figure 7.1.  
 


















































































due  to  non‐communicable  diseases  was  higher  for  older  than  younger  adults.  All  age‐







was  HIV/AIDS  were  already  severely  underweight  at  initiation  whilst  a  fifth  (3/15)  were 
asymptomatic  when  they  initiated  therapy.  None  of  the  72  patients  presenting  for  ART 
initiation with chronic morbidity only died within  the  first three months of ART. One patient 
who initiated ART whilst on TB and chronic (asthma) medication and presented with advanced 
HIV disease and wasting  (WHO stage 4), survived the  first  three months of ART. Mortality  in 




















HIV  Overall  15  4.44  2.67‐7.36 
  Young  14  4.80  2.84‐8.11 
  Old  1  2.15  0.30‐15.23 
TB  Overall 24 7.09  4.76‐10.59
  Young  23  7.89  5.24‐11.87 
  Old  1  2.15  0.30‐15.23 
Other Infectious and parasitic 
conditions 
Overall 5 1.48  0.71‐4.12
  Young  5  1.71  0.71‐4.12 
  Old  ‐  ‐  ‐ 
Non‐communicable conditions Overall 6 1.77  0.80‐3.95
  Young 5 1.71  0.71‐4.12
  Old  1  2.15  0.30‐15.23 
Unknown  Overall  9  2.7  1.4‐5.1 
  Young  6  2.06  0.92‐4.58 
  Old  3  6.44  2.08‐19.96 
All cause  Overall 59 17.45  13.52‐22.52
  Young 53 18.18  13.89‐23.80












coupled with  either  TB  (aHR  5.65  p<0.01)  or  any  chronic  pre‐existing morbidity  (aHR  6.44 
p<0.01) further increased the risk of mortality in the first three months of ART. Mortality risk in 













Overall,  assessing  for  exposure  to baseline HIV‐associate morbidity only  (337/1409  patients 





PAR% was  low at 8.3%. For  those  initiating with HIV‐associated morbidity  coupled with any 











Overall  assessing  for  early mortality  incidence  and  risk  attributable  to  combined  baseline 
morbidity (HIV‐associated, pre‐existing chronic and TB), in younger adults, the incidence early 
mortality  rate  ratio between  those with morbidity  and  those without was  still high  at 6.8% 
(95% CI 3.05‐17.83) with a PAR% of 74.0%. For older adults all 6 deaths that occurred within 
the first 3 months of ART were in patients with baseline morbidity and it was thus not possible 






HIV‐associated morbidity  coupled with  TB). However,  for HIV‐associated morbidity only  the 
attributable  fraction due  to  this morbidity was nearly double  in older  (93.4%; 95% CI  40.8‐
99.8%) than in younger adults (59.2%; 95% CI 26.0‐77.1%). The PAR% was also higher for older 
adults  (77.8%)  than  for  younger  adults  (24.6%)  and  so  were  the  rate  ratios.  However 
















with  a  BMI  in  the  underweight  category  were  at  increased  risk  of  very  early  mortality 
compared  to  patients  initiating  therapy with  normal  BMI  (aHR  2.6  p=0.002).  Haemoglobin 

























<50     ref          
≥50   0.64  0.386  0.24‐1.75
Sex Female  ref             
Male  0.84  0.87  0.646  0.49‐1.55
CD4 count at initiation (cells/µl) 
<50  1.28  1.26  0.434  0.71‐2.23 
50‐200  ref   ref          
>200  0.14   0.14  0.008  0.03‐0.61 
Hemoglobin (g/dl) 
>8  ref   ref          
≤8  1.18  1.16  0.731  0.50‐2.69 
missing  1.73  1.68  0.452  0.43‐6.50 
Estimated Glomerular Filtration Rate (ml/min/1.7m2) 
≥60  ref   ref          
<60  1.13  1.23  0.57  0.60‐2.50 
Missing   1.02  1.02  0.977  0.26‐4.03 
Alanine aminotransferase (IU/ml) 
≤60 (2xULN)  ref   ref          
>60  3.07  2.95  0.006  1.35‐6.43 
Missing   1.36  1.34  0.586  0.47‐3.82 
Body Mass Index 
Normal  ref   ref          
Underweight  2.63  2.58  0.002  1.40‐4.76 
Overweight/obese/morbidly obese  0.56  0.57  0.213  0.24‐1.38 
Missing  3.81 4.01  0.062  0.93‐17.25
Baseline morbidity 
none  ref   ref          
HIV‐associated only  5.36  5.52  <0.001  2.33‐13.06 
HIV‐associated and TB  5.80 5.65  0.005  1.68‐18.98
HIV‐associated and chronic 5.56 6.44  0.005  1.75‐23.62
TB only  3.36  3.35  0.012  1.30‐8.62 















(PAR)  29.75     
HIV‐associated and TB 
Exposed  Unexposed  Total 





(PAR)  8.33     
HIV‐associated and chronic 
Exposed  Unexposed  Total 





(PAR)  2.14     
TB only 
Exposed  Unexposed  Total 











 Similar  to previously  reported data within  this PhD, mortality on ART was highest  in 
the  first  3 months  of  initiating  therapy; most  of  which  was  in  the  first month  of 
initiating therapy. There was a decline in mortality in the first three months post ART‐
initiation from 2010 onwards   
 Using  broad  mortality  causes  categories,  there  were  44  infectious  and  parasitic 
mortality causes; mostly due to TB (n=24, 40.7%) 
 Mortality  from non‐communicable diseases was  low  (n=6, 10.2%) and was higher  for 
older than younger adults. 9 deaths (15.3%) were from unknown causes, also higher in 
older than younger adults 
 Just over half  (8/15) of patients dying due  to HIV/AIDS presented  for ART  initiation 



















to  the  contribution  of  HIV‐associated  morbidity  to  mortality.  Conversely,  the 
prevalence of patients  initiating  therapy with both TB  and HIV‐associated morbidity 
was  low  (n=32;  2.3%)  but  mortality  attributable  to  this  morbidity  is  high  at  a 
population level indicating need for public health intervention. 
 Although numbers are small, the effect of baseline morbidity on very early mortality in 
patients  initiating ART  is clear and points towards the need for early  identification of 
eligible HIV infected people and timely ART‐ initiation prior to diseases manifestation 
 Adjusting for possible confounders, patients  initiating therapy with ALT  levels greater 
than 60IU/ml a level twice the upper limit of normal (2xULN) had triple increased risk 
of very early mortality on ART;  those  classified as underweight by BMI were also at 
increased  risk  of mortality  in  the  first  three months  on  ART  compared  to  patients 
initiating therapy with normal BMI (aHR 2.6 p=0.002). 













Using  data  from  an  African  population  in  rural  Northern  KwaZulu‐Natal  in  South  Africa,  a 
setting with high HIV prevalence and  incidence with a  large public sector HIV treatment and 
care programme,  this PhD contributes  to knowledge on  the health complexities surrounding 
HIV  in  older  adults  aged  50  years  and  above,  an  area were  data  in  sub‐Saharan Africa  are 
critically lacking. This PhD fulfilled five aims specifically targeted at:  
 determining  older  adults’  health  in  terms  of  cause‐specific  morbidity  and 
mortality and associated risk factors, accounting for HIV and ART status,  
 assessing  how  biomarkers  in  older  adults  relate  to  their  current  or  future 
morbidity, and mortality, and  















and  HIV  and  ART  status  and  further  establish 







To  describe  and  quantify  the  cause‐specific 
morbidity burden in HIV positive older adults, at 










To  determine  cause‐specific  incidence  rates  of 
serious  morbidity  (resulting  in  hospitalization) 
following ART initiation and the effect of age on 































in  the  first  3  months  of  ART)  following  ART 
initiation  in  older  adults  compared  to  younger 
adults,  quantify  the  contribution  of  baseline 
morbidity  on  early mortality  risk  and  ascertain 
whether  levels  of  Hb,  ALT  and  Glomerular 






















The   HIV negative  comparison  group must be  socio‐demographically  similar  to  the HIV 
positive group, because co‐morbidity and mortality are age, race, ethnicity, sex and socio‐
economically  dependent  (Bailis,  Segall  et  al.  2003;  Bradshaw, Groenewald  et  al.  2003; 
Lorant, Deliege et al. 2003; Lopez, Mathers et al. 2006; Goulet, Fultz et al. 2007). This PhD 
started by comparing the chronic morbidity burden  in HIV positive adults aged 50 years 
and  above  to  that  in  HIV  negative  adults  also  aged  50  years  and  above.  To  ensure 
appropriateness  of  the  comparison  group,  both  the  HIV  positive  and  negative  groups 
comprised of older adults residing within the same defined geographic area with a largely 
homogenous rural community in terms of socio‐economic status, ethnicity and availability 





The  PhD  study  presented  here  contributes  to  knowledge  by  being  the  first  to 
demonstrate,  in a rural African setting where ART delivery  is devolved to primary health 








were  significantly  less  likely  (OR=0.49,  p=0.027)  to  report  current morbidity  than  HIV 
negative adults. A  study  from  this  setting previously  reported a higher WHO composite 
health score [a health measure collating an  individual’s  levels of difficulty  in eight health 
domains  (mobility,  self‐care,  affect,  vision, pain/discomfort,  sleep/energy,  interpersonal 
activities,  and  cognition)]  in  HIV  positive  than  in  HIV  negative  older  individuals,  not 
accounting  for ART  status  (Nyirenda,  Chatterji  et  al.  2012).  The  results presented here 
confirm  this  previous  finding  with  more  in‐depth  health  measures  and  highlight 








increases  the  risk of  age‐associated  chronic  conditions  such  as malignancies, metabolic 
disorders  inclusive of diabetes and cardiovascular conditions;  in a population of   77 025 
HIV‐positive adults  (median age 38 years)  included  in a prospective cohort,  involving 61 
French University hospitals, between 1992 and 1999, the risk of non‐AIDS defining cancers 
prior to ART (1992 to 1995) was twice as high in HIV‐positive men as in the general French 
male population  (Herida, Mary‐Krause et al. 2003).  Similarly,  in  a  study  that  linked  the 





pharynx,  lung  and  skin  cancer were  reported  in  HIV‐positive  people  compared  to  the 
general population. The Swiss study included 7304 HIV positive individuals aged 16 years 
and  above  contributing 28 836 person‐years  from 1985  to 2003  (Clifford, Polesel et al. 
2005).  
 
Similar  to cancer  risk  in HIV‐positive populations compared  to  the general HIV‐negative 
population, a study  in Italy involving 2854 HIV‐positive patients and 8562 controls with a 
mean  age  of  46  years  reported  higher  prevalence  of  diabetes mellitus,  cardiovascular 
disease,  bone  fracture  and  renal  failure  in  those  HIV‐positive  than  in  HIV‐negative 
controls,  with  these  conditions  occurring  at  younger  ages  in  the  HIV‐positive  group 
(Guaraldi, Orlando  et  al.  2011).  Rates  of  acute myocardial  infarction  between October 
1996 and  June 2004  in a  cohort  study  in Boston, USA with 3 851 HIV‐positive  (41% on 
ART) and   1 044 589 HIV‐negative  individuals showed  that  the  rate of acute myocardial 
infarction was  twice  as high  in  the HIV‐positive  group  than  in  those HIV‐negative. HIV‐
positive  individuals  also  had  higher  proportions  of  hypertension  (21.2%  versus  15.9%), 
diabetes  (11.5%  versus  6.6%)  and  dyslipidemia  (23.3%  versus  17.6%)  than  the  HIV‐
negative population (Triant, Lee et al. 2007). This Boston study included patients aged 18‐
84 years and the median age of participants was 38 years for those HIV‐positive and 39 
years  for  those  HIV‐negative.  Besides  these  studies  including  young  adults, morbidity 
differences by HIV status between these studies and this PhD may be largely driven by the 








92%  of whom were  receiving ART, with  high  rates  of  virological  suppression,  reported 
similar morbidity prevalence  in both HIV negative  and positive older  adults    and  lower 
than expected  cardiovascular  co‐morbidity  in  the HIV positive group which  the authors 
attributed to aggressive management of modifiable atherosclerotic risk factors within the 
US  (Onen, Overton  et  al.  2010).  In  another  study  (VACS)  recruiting  from  8  sites  in  the 
United States of America, data from 1525 HIV positive (75% on ART) and 843 HIV negative 
adults  showed  that    those  who  were  HIV  positive  had  less  prevalent  cardiovascular 
diseases,  hypertension,  diabetes  and  renal  disease  compared  to  HIV  negative  adults, 
although  the cohort was younger with a mean age of 53 years  (Armah, McGinnis et al. 
2012). In another VACS study, utilising data from  33 420 HIV positive adults of whom 31% 
were  aged  50  years  and  above, older HIV negative patients were more  likely  to  suffer 
from hypertension, diabetes and pulmonary disease  than HIV positive older adults. HIV 
positive  older  adults  were  not  stratified  by  ART  status  making  it  difficult  to  assess 
morbidity  differences  by  ART  status  (Goulet,  Fultz  et  al.  2007).  The  authors  further 
acknowledged  that  although  single morbidity  rates were  higher  in  HIV  negative  older 
adults, multi‐morbidity was more common in HIV positive older adults. 
 
In  line  with  finding  of  lower  morbidity  burden  in  HIV  positive  older  adults  on  ART, 





that  is  subjective  since  it measures  individual’s  self‐reported  levels of difficulty  in eight 






in older adults  receiving ART might have been masked by  the poor health  in  those HIV 
positive but waiting to receive ART.  
 




90%  of HIV  positive  older  adults  in  our WOPS  study  on ART  reported  to  have  utilised 
health care services for more than 6 times in the 12 months prior to the date of interview, 










et al. 2005) could possibly result  in  late diagnosis and poor prognosis  irrespective of HIV 
status  (WHO  1995;  Waweru,  Kabiru  et  al.  2003).  Despite  HIV  positive  older  adults 
potentially  facing  a  larger  morbidity  burden  than  HIV  negative  adults,  the  potential 
benefit  of  enhanced  access  to  care  for  HIV  positive  older  adults who  regularly  utilise 











Results  from previous  studies discussed above on morbidity and health  care utilisation, 
together with  results  from  this  PhD,  begin  to  point  towards  improved  health  and  less 
morbidity in HIV positive older adults receiving ART than in HIV negative individuals aged 
50 years and above. These results also provide evidence that comparison of co‐morbidity 
levels  between  younger  and  older  adults may  be misleading  as  younger  adults  nearly 
always  have  less morbidity  than  older  adults.  The  results  from  this  PhD  show  health 
benefits  of  enhanced  access  to  care  even  in  this  rural  African  area with mostly  lower 
socio‐economic status, poorer health care services,  limited and  lower cost ART regimens 
with more side effects and where access to ART was only substantially scaled‐up relatively 
recently.  These  results  underscore  the  need  of  extending  health  care  services  to  HIV 
negative older adults, which need  to go beyond mere provision at  fixed clinics. Bringing 
health  services  to  older  adults  through  regular  community  chronic  disease  screening 
would  ensure  health  care  reaches  all  older  adults  in  need,  and  could  translate  to 
considerable health benefits even for HIV negative older adults who might not be keen on 
utilising health care services based at fixed clinics. Indeed the South African government, 
in  response  to  continued  poor  health  outcomes  in  rural  areas  with  limited  health 
resources, is currently piloting the feasibility of district specialist health teams to facilitate 













IL6  levels  and more  than  twice  the  odds  of  elevated  hsCRP  levels,  indicating  immune 
inflammatory response. This PhD is to my knowledge the first to assess how in an African 
black population, controlling for age differences across HIV strata, cytokine levels differ by 












IL6  levels  increased  in  the  first month  of  interrupting  ART  (Kuller,  Tracy  et  al.  2008), 






group,  IL6 and hsCRP  levels were  lower  in those on ART for more than one year than  in 
ART‐naive older adults. Consistent with  these  findings  from  this PhD,  the VACS,    in  the 
United  States  including  1525 HIV  positive  adults  (75%  of whom were  on  ART), with  a 
median  age  of  52  years,  and  843 HIV  negative  adults, with  a median  age  of  54  years, 
reported higher levels of IL6 in the HIV positive than in the HIV negative group even when 
the HIV viral load was unsuppressed (≥ 500 copies/mL) or when CD4 cell counts were less 
than 200 cells/µL  (Armah, McGinnis et al. 2012). A  study utilising 494 participants  from 
the  SMART  study,  5386  participants  from  the  Multi‐Ethnic  Study  of  Atherosclerosis 
(MESA) study and 3231 participants in the Coronary Artery development in Young Adults 
(CARDIA) study, aged between 33 and 76 years, reported results similar to those of this 
PhD of elevated hsCRP  levels and  IL6  levels even after HIV RNA  levels were successfully 




unknown  HIV  status  from  the  MESA  and  CARDIA  studies  and  assumed  that  the 
participants from the two latter studies were likely to be HIV negative (Neuhaus, Jacobs et 
al. 2010). While these studies were not exclusively focused on older adults, these results 
together  with  this  PhD’s  results  begin  to  highlight  the  possibility  of  decrease  in 










the  association between  IL6  and HIV  is of  interest;  reported  findings were  in  line with 
those in this PhD, of high IL6 levels in those HIV positive (Cassol, Malfeld et al. 2010). The 




In  contrast  to what  is  found  in  this  PhD,  elevated  biomarkers  in  the VACS  study were 






effects. Another possible explanation of  the  lack of association between cytokine  levels 
and morbidity  in  this  PhD might be due  to  the  small  sample  size  (n=422) of my  PhD’s 
Wellbeing of Older People Study which provided data for this specific objective. Despite 
these  limitations  and  variations  between  studies  the  results  of  this  PhD  show  that 
cytokine  levels  in  the  presence  of  ART,  even  if  not  as  low  as  those  in  HIV  negative 
individuals, are not associated with chronic morbidity. 
 





2006),  it  remains  unknown  whether  elevated  cytokine  levels  result  in    morbidity  or 
whether  an  immune  inflammatory  response  due  to  morbidity  results  in  elevated 
cytokines. Results  from this PhD of  lower morbidity  in HIV positive older adults on ART, 
but  not  in  ART‐naïve  HIV  positive  older  adults,  than  in  HIV  negative  older  adults 
irrespective of high HIV‐associated cytokine  levels, together with those  from the SMART 
and VACS   studies  (Kuller, Tracy et al. 2008; Armah, McGinnis et al. 2012), suggest  that 
even  in the absence of co‐morbid conditions, cytokine  levels  in HIV positive older adults 
do not  return  to pre‐HIV  infection  levels despite ART. Cytokine  levels may  thus not be 
ideal markers  for chronic morbidity  in such populations.  In support of this suggestion, a 




previous  few  reports  of  elevated  cytokine  markers  in  HIV  positive  older  adults,  but 
additionally showing that these elevated levels in the presence of ART are not associated 
with  increased  chronic morbidity.  It would  be  beneficial  for  future  studies  to  quantify 





Obesity  is  linked  to  chronic  health  problems  such  as  cardiovascular  diseases,  diabetes, 
stroke  and  arthritis  (Cheymol  2000;  Bastard, Maachi  et  al.  2006;  2008)  and,  similar  to 
ageing,  is  characterised  by  chronic  low‐grade  inflammation  (Trayhurn  2005;  Bastard, 






high  obesity  levels,  it  is  the  ratio  of  total  cholesterol:HDL,  a marker  of  cardiovascular 
disease risk, that  is associated with high morbidity rather than BMI per se.  In an analysis 
adjusted  for  this  ratio, BMI ceased  to be an  independent  factor  for morbidity, with  the 
odds  of  morbidity  nearly  quadrupling  in  individuals  within  the  highest  ratio  quartile 
possibly  suggesting  that  total  cholesterol:HDL  ratio  may  be  a  stronger  indicator  of 
morbidity than BMI.   
 
Although  BMI  was  not  associated  with  morbidity  when  accounting  for  total 
cholesterol:HDL ratio, being obese/morbidly obese was associated with high hsCRP levels  
suggestive of  increased  inflammation  and  cardiovascular disease  risk,  similar  to  studies 
from developed countries  (Trayhurn 2005; Bastard, Maachi et al. 2006). Literature  from 
African  populations  is  scarce.  These  results  highlight  that  although  obesity  was  not 
directly associated with morbidity in this population, it was associated with elevated bio‐





Data  for  this  PhD  objective  here  discussed  (Section  8.1),  was  obtained  from  a  cross‐
sectional study that was nested within the Africa Centre Demographic Surveillance Area 
which  included  422  resident HIV  positive  and negative older  adults  aged  50  years  and 
above.  Eligible  participants  were  identified  through  linkage  of  the  Africa  Centre 
surveillance and the Hlabisa treatment and care programme database. A random sample 







observed  reduced  reported  morbidity  in  HIV  positive  older  adults  receiving  ART  was 
purely  due  to  survivor  bias  we  would  also  expect  an  even  larger morbidity  decrease 








adjusted.  Although  the  odds  ratio  for  the  association  between HIV  status  and  current 
chronic morbidity weakened when the analysis was adjusted for age, there still remained 
a statistically significant association between being HIV positive on ART and reduced odds 
of  morbidity.  To  rule  out  residual  confounding  due  to  age,  secondary  analyses  was 
restricted to those aged below 65 years old (50‐64 years) and further restricted to those 
aged 50‐60 years old.  In both analyses the finding of  less chronic morbidity  in those HIV 
positive on ART than in HIV negative individuals not only persisted but even strengthened 
suggesting  an  even  stronger  differential  in  current  chronic morbidity  by  HIV  and  ART 
status after reducing the age variations between the four HIV strata. 
 
Although  data were  self‐reported,  it was  assumed  that  any  unreliability  of  self‐reports 




validity of our  results. This assumption was based on  the  fact  that  there  is no evidence 
supporting the  likelihood of over‐reporting current morbidity amongst HIV negative, but 
not among  infected,  individuals. Studies that have examined health seeking behaviour  in 
older  adults  document  that  reports  of  being  unwell  and  seeking  health  care  are 
dependent  on  the  awareness,  interpretation  and  experience  of  symptoms  (Ahmed, 
Tomson et al. 2005) and it would thus be more likely to expect HIV positive individuals to 
over‐report  than HIV negative  individuals because of  their knowledge of  the underlying 
HIV  infection  and  considering  that  they  would  have  been  made  aware  of  existing 
morbidity during  their HIV clinic visits. Furthermore, both HIV positive and HIV negative 
participants  were  identified  from  the  community  via  the  longitudinal  demographic 
surveillance rather than from health care facilities and this would have reduced selection 
bias. Although  the WOPS  sample  size  of  422  adults  aged  50  years  and  above  is  small, 
limiting the extent to which the study could detect differences between groups, the fact 
that  despite  this  there  were  significant  differences  between  HIV  positive  participants 
receiving ART and  those HIV negative possibly points  towards an even  larger morbidity 
difference had  a  larger  sample  size been used. As  such  the  sample  size  issue does not 






determine whether  these  older  adults  have  special  HIV management  needs  over  and 





stage  III and  IV HIV‐associated morbidity burden at time of  initiating ART.   Knowledge of 
co‐morbidities  at  time  of  initiating  HIV  therapy  in  older  adults  is  useful  in  projecting 
subsequent clinical management needs. Moreover,  the management and determination 
of  good  clinical  outcomes  of  HIV  positive  older  adults  after  initiation  of  ART  is  likely 
dependent on prevalence of co‐existing morbidities at  time of  initiating  therapy.   These 
data  are  useful  in  developing  evidence  based  interventions  for  morbidity  and 
consequently mortality reduction.  
 
Objective  two of  this PhD aimed at quantifying cause‐specific morbidity burden  in older 
compared to younger adults aged 16 to 49 years used data from the ART Clinical Cohort. 
The  ART  Clinical  Cohort  was  nested  within  the main  Hlabisa  HIV  treatment  and  care 
programme, and  recruited adults aged 16 years and above  initiating ART at  two of  the 
largest primary health care clinics within the Hlabisa HIV treatment and care programme. 
In the ART Clinical Cohort similar to the Hlabisa HIV treatment and care programme, just 
over 10% of  adults who  initiated ART during  the  study period were aged 50  years  and 
above.  In  the Hlabisa HIV  treatment  and  care programme,  standard ART  regimens  are 
given according to the South African National HIV treatment guidelines and consist of two 
nucleoside  reverse  transcriptase  (NRTI)  and  one  non‐nucleoside  reverse  transcriptase 
(NNRTI). Up till 2010, the NRTIs consisted of Stavudine, Abacavir, Lamivudine, Zidovudine 
and Stavudine whilst the NNRTIs consisted of Efavirenz and Nevirapine. In 2010, Stavudine 
was  substituted with Tenofovir. As of April 2013, patients are  initiated on a  fixed dose 
combination  pill  consisting  of  Tenofovir,  Emtricitabine  and  Efavirenz  ,  unless 






Results of  this objective demonstrated  that,  compared  to younger  (16‐49 year old) HIV 
positive adults, both pre‐existing chronic morbidity burden at time of ART  initiation and 
HIV‐associated WHO stage  3 or 4 morbidity were higher in older adults, even though they 
presented  for ART  initiation with CD4  cell  counts higher  than  in younger adults. Whilst 






Weiss et al. 2006;  Iwuji, Churchill et al. 2013), the  findings  from this PhD  from both the 
main  treatment  programme  and  the  ART  Clinical  Cohort  suggest  the  opposite  with  a 
significantly  lower  proportion  of  older  adults  initiating  ART  with  CD4  cell  count  <50 





with  age  in  other  cohorts  (Hasse,  Ledergerber  et  al.  2011),  this  alerts  us  to  the  high 
frequency  of  renal  disease  in  this  setting  which  is  not  always  detected  with  serum 
creatinine measurements alone (Franey, Knott et al. 2009). However despite older adults 
having a lower proportion with CD4 cell count <50 cells/μl at time of initiating ART and a 









In Africa,  there  is  limited understanding of age‐related chronic morbidity burden  in HIV 
positive older adults requiring ART (Negin and Cumming 2010; Bendavid, Ford et al. 2012; 
Greig,  Carrillo  et  al.  2012;  Negin,  Barnighausen  et  al.  2012)  and  how  this  morbidity 
impacts on HIV prognosis on ART. Reports from the USA and Europe (Justice, Landefeld et 
al. 2001; Gebo 2008; Rhee and Greenblatt 2008)  indicate that use of ART  in older adults 
may  be  complicated  by  multiple  chronic  co‐morbidities  and  co‐administered  non‐HIV 
medicines.  This  PhD  study  using  data  from  the ART  Clinical  Cohort  including  1409 HIV 
positive  patients  aged  16  years  and  above  at  time  of  commencing  ART  shows  that, 
irrespective  of  age,  of  the  11.5% with  pre‐existing  non‐AIDS‐related  chronic morbidity, 
66% had  hypertension,  16% had  arthritis,  12%  had  diabetes,  8%  had  epilepsy,  9%  had 
asthma whilst  3% had  psychiatric  conditions.  Stratifying  by  age  at ART  initiation,  older 
adults had higher proportions of patients with pre‐existing non‐AIDS‐associated  chronic 
morbidity at time of initiating ART than younger adults: only 6 % (95% CI 5‐8%) of younger 
adults  had one  chronic  condition whilst  36%  (95%  CI  30‐43%)  of older  adults were  on 
therapy for one named chronic condition with four times as many older adults as younger 
adults  having more  than  one  chronic  condition.  Similar  to  findings  from  this  PhD,  in  a 
Swiss  HIV  cohort,  co‐morbidity  and  multi‐morbidity  of  non‐AIDS  diseases  especially 
diabetes mellitus,  cardiovascular  disease  and  osteoporosis  became more  important  in 
care of HIV  infected persons as  the age of  the patients  increased.    In  the Swiss  cohort 
diabetes was common in older adults but this was after a median of 6 years on ART rather 
than at ART  initiation  (Hasse, Ledergerber et al. 2011). Also comparable  to  results  from 





reported  the  majority  of  older  adults,  irrespective  of  HIV  status,  had  at  least  one 
morbidity; multiple morbidity was  common  in  those  HIV  positive  (Goulet,  Fultz  et  al. 
2007). Although  assessing  individuals  aged  65  years  and  above  and not  at  the  time of 
initiating  ART,  a  study  in  east  Africa  also  confirmed  high  prevalence  of    hypertension, 
diabetes  and  arthritis  in  older  adults  irrespective  of HIV  status  (Waweru,  Kabiru  et  al. 
2003).  Similar  to  this PhD,  a  study  from Botswana  reported  increased  risk of non‐AIDS 
defining morbidity amongst HIV older adults receiving antiretroviral therapy compared to 
younger HIV positive adults (Wester, Koethe et al. 2011). These studies including this PhD 
highlight  the  high  burden  of  non‐AIDS  associated  co‐morbidity  in  older  compared  to 
younger HIV positive individuals but comparability of the findings in this PhD of high pre‐




for  ART  initiation  with  more  pre‐existing  chronic  co‐morbidity  and  multiple  co‐
morbidities, 46% of older adults compared to 28% in younger adults had WHO HIV disease 
stage 3 or 4 morbidity. However, despite  younger adults having  less  co‐morbidity  than 
older adults, younger adults had a wider spectrum of HIV‐associated morbidity at time of 
initiating  therapy whilst  for older adults  severe weight  loss was  the most  frequent HIV‐










with  a  wide  spectrum  of  conditions  seen  in  younger  adults.  However  the  disease 
spectrum  in  older  adults  with  prolonged  exposure  to  ART  may  differ  from  baseline 
morbidity  and  community  based  care  health  workers  would  be  useful  monitoring 
morbidity changes in older adults on ART. 
 
TB prevalence  in older patients was half  that  in younger adults  (8% compared  to 17%). 
Whether  this  is due  to  a  true  low  TB  prevalence or under‐diagnosing due  to  clinicians 
alluding  TB  symptoms  to  other morbidities  of  ageing  remains  unknown  and  requires 
further  studies.  It  could  be  that  TB  presentation  is  different  in  older  adults  or  that 






of this thesis point towards this  low TB prevalence  in older adults at ART  initiation being 
more due to misdiagnosis than a true low prevalence. It is possible that TB presentation in 
older adults  is often alluded  to  respiratory problems often common  in older adults and 
this  finding  alerts  clinicians  of  the  need  for  more  vigorous  TB  screening  using  more 
sensitive TB screening methods  in this age group. By virtue of these older adults having 










VACS  and  SMART  studies,  show  a  similar  high  burden  of  co‐morbidity  and  multiple 
morbidity in older adults compared to younger adults. Over and above these studies, this 
PhD gives a clear presentation of the burden and causes of morbidity in older adults at the 
time  when  they  initiate  ART.  These  data  are  important  to  clinicians  by  highlighting 
conditions  that they should be aware of  that are  likely  to  interact or  interfere with ART 
and helps direct health services  integration by highlighting common morbidities  in older 
HIV positive adults who also require ART.   Unlike  in this PhD, the main  limitation of the 




for  pill  collection  visits  and morbidity was  coded  using  ICD10  coding  guidelines  (WHO 
2010). Medical  charts were  also  reviewed  for morbidity  and mortality  causes  ensuring 
that morbidity and mortality were comprehensively captured. In addition patients missing 
two  consecutive monthly  clinic visits were  tracked  to ascertain mortality and morbidity 
within that group. The morbidity results from this PhD study based on data from the ART 
Clinical Cohort are likely generalisable to other HIV positive older adults from comparable 
African  settings  as  their  characteristics were  similar  to  those  in  the main  Hlabisa  HIV 





















limited  settings  serious morbidities  leading  to  hospitalisation  place  a  huge  burden  on 
human  and  financial  resources  within  the  health  sector  and  appropriate  planning  is 
required, based morbidity frequency and severity, for adequate health service provision. 
To reduce the gap in knowledge, the third objective of this PhD used linked data from the 
Hlabisa HIV  treatment  and  care  programme  and  the Hlabisa  district  hospital,  the  only 
hospital  within  the  Hlabisa  health  sub‐district  within  which  the  treatment  and  care 
programme  in  located,  to  determine  differences  in  serious morbidity  rates  and  causes 
following ART initiation by age at ART initiation. 
 
Using    data  from  8  598  HIV  positive  patients  receiving  ART  in  the main  Hlabisa  HIV 
Treatment  and  Care  Programme,  contributing  675  patients  hospitalisations  over  8  166 
person years of follow‐up,  the estimated hospitalisation rate was 8.3 (95% CI 7.7‐8.9) per 









rate might be because  in  the Cote d’Ivoire  study  severe morbidity was  defined  as  any 
WHO  stage  3  or  4  disease  regardless  of  whether  or  not  the  morbidity  resulted  in 
hospitalisation and the cohort also included patients pre‐ART (Seyler, Messou et al. 2007). 
A  recent  study  from  an  urban  hospital  in  Gauteng  province  and  a  rural  hospital  in 
Mpumalanga province in South Africa, including 3 906 patients aged 18 years and above, 
pre‐ and post‐ART reported high rates (534/3 906, 14%) of hospitalisations over a median 
follow‐up  time of 13.1 months)  (Meyer‐Rath, Brennan  et  al. 2013). Comparison of  this 
estimate with  that  from  this  PhD  is  complicated  by  the  different measurement  scales 
employed by the two studies and by the fact that only 4% of the Meyer‐Rath et al. study 
group were  receiving ART. Similar hospitalisation  rates  to  those  reported  from  this PhD 




fold  higher)  in  the  first  three months  (17.6  per  100  person  years)  subsequent  to  ART 













associated  immune  reconstitution  inflammatory  syndrome  (TB  IRIS)  may  be  a  large 
contributor to early serious morbidity. The results obtained here are useful by highlighting 




a  large number hospitalisations was  actually due  to women under  the  age of 50  years 
being hospitalised for pregnancy related conditions inclusive of infant deliveries and a few 
miscarriages. This  finding  is as would be expected  in any population  irrespective of HIV 




odds  of  hospitalisation  (including  and  excluding  pregnancy  related  conditions)  in  older 
than younger adults on ART. The finding within this PhD of lower morbidity in older adults 
is  contrary  to  reports  in  the  Swiss  Cohort where  hospitalisations were  higher  in  older 
adults  than  younger  adults.  However  in  the  Swiss  cohort,    15%  of  patients were  not 
receiving ART and those on therapy had been on it for considerably longer periods than in 
our cohort, with a median time on ART of six years (Hasse, Ledergerber et al. 2011). This 














In  this  PhD,  excluding  pregnancy  related  conditions  ,  for  both  younger  and  older  HIV 
positive  adults  on  ART,  the  most  frequent  causes  of  serious  morbidity  resulting  in 
hospitalisation were non‐infectious conditions comprising of  injuries (12.6%), diseases of 


















periods  and  patients  initiated  therapy  at  much  higher  CD4  count  threshold  (Hasse, 





urban Cote d’Ivoire  (Seyler, Messou et al. 2007) and  from  rural and urban South Africa 
(Meyer‐Rath,  Brennan  et  al.  2013).  Further,  adults  with  TB  at  ART  initiation  had  an 
increased  risk  of  hospitalisation  and  so  did  patients  initiating  therapy  with  advanced 
disease  as  approximated  by  baseline  CD4  cell  counts<50cells/µl,  highlighting  the 
contribution  of  advanced  HIV  disease  and  co‐morbidity  to  poor  prognosis  even  after 
initiation of ART. Similar  to baseline morbidity, younger adults had a wider spectrum of 
hospitalisation  causes  than  older  adults  because  infectious  diseases  were  mainly 
concentrated in the younger age groups, whilst chronic morbidity mainly affects the older 
populations  (Murray  and  Lopez  1997;  Lopez  and Mathers  2006;  Lopez, Mathers  et  al. 
2006;  Mayosi,  Flisher  et  al.  2009).  A  similar  disease  spectrum,  mainly  consisting  of 
bacterial  and  parasitic  conditions  in  younger  adults was  reported  in  a  relatively  small 
study of 723 adults  in an urban African setting  (Seyler, Messou et al. 2007). Our  results 
shows considerable serious morbidity in older adults due to respiratory infections similar 





to  the  fact  that  the Meyer‐Rath  study  included  patients  pre‐ART.  Older  adults  had  a 










screening and  treatment  for TB and  cryptococcal  infection  should be  implemented and 
evaluated to  improve understanding of the epidemiology of these  infections particularly 
in  older  adults  (Lawn, Harries  et  al.  2010).  Considering  the  high  costs  associated with 
hospital admissions of  HIV positive patients (Meyer‐Rath, Brennan et al. 2013),   it would 
be beneficial to initiate ART in HIV positive individuals early, irrespective of age. In South 









in South Africa, with a comprehensive  tracking  system  for patients  lost  to  follow‐up,  to 
assess mortality  rates  and differences  in  two population groups defined by  age.  In  this 
analysis of 8846 adults with 997 deaths, overall mortality  risk was 32% higher  for  those 




years.  Although  consistent  with  previous  reports  from  non‐African  and  African  urban 
settings  (Fairall, Bachmann et al. 2008; Tuboi, Pacheco et al. 2010; Greig, Carrillo et al. 
2012;  Iwuji,  Churchill  et  al.  2013),  results  here  show  that  this mortality  difference  is 
restricted to the first year of ART, following which mortality rates  in older adults are no 
longer  statistically  significant  different  from  those  in  younger  adults  despite  an  only 
modest CD4 count reconstitution in the older age group.  Similar to findings from this PhD 
work, previous studies  from Europe and North America  (Grabar, Kousignian et al. 2004; 
Silverberg,  Leyden  et  al.  2007;  Greenbaum, Wilson  et  al.  2008;  The  Collaboration  of 
Observational HIV  Epidemiological  Research  Europe  (COHERE)  study  group  2008)  have 








achieving optimal viral suppression, might  imply  that  in older adults,  the degree of CD4 
count  reconstitution may matter  less once HIV has been  suppressed.   Previous  studies 
have postulated that excess mortality in older adults compared to younger adults may be 











in  both  age  groups  the  highest mortality  rates were  in  the  first  three months  of ART, 
which  is  in  line with data previously published  from  this and other programmes  (Lawn, 
Myer et al. 2005; Braitstein, Brinkhof et al. 2006; Lawn, Myer et al. 2006; Boulle, Bock et 
al.  2008; Mutevedzi,  Lessells  et  al.  2010). Very  early  (first  three months  following ART 
initiation)  and  early mortality  (between  three  and  six months  post‐ART  initiation) was 
higher  in  older  than  younger  adults,  although  older  adults  had  a  significantly  lower 
proportion of patients presenting for ART  initiation with CD4 counts  less than 50cells/µL. 
High early mortality mainly associated with advanced disease and a blunted immunologic 
response  in  older  adults  raises  an  important  question  of whether  older  adults  should 
initiate ART at higher CD4 count threshold than younger adults and calls for interventions 
to  encourage  early  presentation  for  ART.  The  benefits  of  initiating  ART  early  are well 
recognised  and  remain  the  reason  why  CD4  cell  count  thresholds  for  ART  eligibility 
continue to be reviewed and increased.  
 
In  South Africa,  since August  2011  the  CD4  cell  count  threshold  for ART  eligibility was 
increased from 200 to 350 cells/µl  for all HIV positive  individuals.  It  is worth noting that 
very early mortality rates within Hlabisa HIV Treatment and Care Programme between 1 
August  2004  to  31 October  2009 were  higher  (30.1  per  100  person  years)  than  rates 
obtained  in  the ART Clinical Cohort  from  1 March  2010  to  31  July  2012  (17.5 per  100 
person years). This difference may be attributed to earlier initiation of ART reducing very 
early mortality risk associated with advanced HIV. This finding  is not only peculiar to this 
study but  a  recent publication utilising data  from  the main Hlabisa HIV  Treatment  and 







In  HIV  positive  older  adults  compared  to  HIV  positive  younger  adults,  extremely  high 
mortality  rates  in  the  first  year  of  ART  suggests  that  strategies  to  reduce  this  early 
mortality need to be  implemented and evaluated with a degree of urgency and that the 
needs  of  older  adults,  over  and  above  those  of  younger  adults,  should  be  considered 
within these strategies (Lawn, Harries et al. 2010). It would be useful to understand better 
the  current  patterns  of  testing  and  health  care  usage  amongst  older  adults  so  that 
appropriate age‐specific  interventions  can be developed.  In HIV positive adults aged 16 
years and above during pre‐ART care, we have previously shown lower rates of retention 
in  older  adults  than  younger  adults  (Lessells, Mutevedzi  et  al.  2011). With  the  known 
association  between  older  age  and more  rapid  CD4  decline,  it  is  necessary  to  explore 
alternative care strategies such as community‐based follow‐up (May, Wood et al. 2009).  
 
Integrated  chronic  disease management  delivered  through  community‐based  follow‐up 
fits  in well with  the  proposed  re‐engineering  of  primary  health  care  systems  in  South 
Africa in an effort to manage the high burden of chronic conditions such as hypertension, 
diabetes  and  cardiovascular  diseases  coupled  with  HIV  and  TB  (Ministerial‐Task‐Team 
2011).  The  South  African  Minister  of  Health    in  his  parliamentary  speech  in  2011 
acknowledged that health systems  in South Africa were stretched and overburdened by 
HIV  and  TB  and  recognised  a  growing  epidemic  of  chronic  conditions,  he  therefore 
suggested  that  primary  health  care  systems  needed  to  be  re‐engineered  to  ensure 














50  years  and  above  at  time  of  ART  initiation,  and  showed  that  at  12  months, 
approximately one‐quarter of patients in the cohort had CD4 cell count ≤200 cells/μl with 
the  largest proportion and the  least  immunological response  in those aged 50 years and 
above  and  this was  associated with  increased  risk  of  death  subsequently.  Larger  CD4 
count  increases were  significantly associated with  reduced mortality  risk  irrespective of 
the time updated absolute CD4 count.  In addition, previous absolute CD4 cell thresholds 
(CD4  cell  count  at  six months  after  ART  initiation) were  not  associated with mortality 





Although  younger  adults demonstrated  superior  immunological  responses  compared  to 
older adults, virological suppression was achieved more frequently in older than younger 
adults.  This  finding  has  been  previously  reported  (Grabar,  Kousignian  et  al.  2004; 












ART.  Superior  virological  suppression  in  older  adults may  be  due  to  better  adherence 
within  this  group  as  previously  published    data  from Hlabisa  HIV  Treatment  and  Care 
Programme  has  shown  that  the  risk  of  disengaging  from  HIV  care  decreases  with 
increasing  age    (Mutevedzi,  Lessells et  al. 2013). Additionally,  the  fact  that  these older 








mortality  rates  have  enabled  this  analysis  (Mutevedzi,  Lessells  et  al.  2010).  A  major 
strength of the Hlabisa HIV Treatment and Care Programme is the comprehensive tracking 
system  for  patients  lost  to  follow‐up  which  ensures  that  deaths  are  ascertained 










missing  results  particularly  for  follow‐up  CD4  cell  counts  and  viral  loads  which  was 
addressed by  interpolation of missing CD4  cell  counts. The  immunological deficiency  in 











Programme;  only  42  of  997  deaths  (4.2%)  could  be  attributed  to  a  specific  cause. 
However,  the high number of deaths  immediately after ART  initiation suggests  that  this 
mortality  is still driven  largely by HIV disease.   Similar to our Hlabisa HIV Treatment and 
Care Programme, cause of mortality data are not systematically sought  in HIV treatment 
cohorts within Africa. A  large mortality  analysis  including  17  561 patients  from  17 HIV 







age,  a  quarter  of  all  deaths  in  the  very  early  phase  post‐ART  initiation  were  due  to 
advanced  HIV.  Just  over  half  of  HIV  positive  adults  on  ART  dying  due  to  HIV/AIDS 






shown  to be  the  leading  cause of death across all age groups  followed by  cryptococcal 
disease and other  infectious diseases (Lawn, Myer et al. 2005; Etard, Ndiaye et al. 2006; 
Castelnuovo, Manabe  et  al.  2009; MacPherson, Moshabela  et  al.  2009).  This  PhD  adds 
additional  information to existing knowledge by showing that although mortality due to 




A  recent  publication  from  the  same  setting  as  this  PhD  using  population  level  verbal 
autopsy  data  from  the  Africa  Centre  reported mortality  causes,  based  on  the  Global 
Burden of Diseases Classification,  in  the general population which were similar  to  those 
reported in this PhD study (Herbst, Mafojane et al. 2011). HIV and TB remained important 
mortality  contributors  followed  by  non‐communicable  diseases  (Figure  8.1  and  Figure 





contribution  to mortality, especially  in  younger men  (Herbst, Mafojane et al. 2011) but 
not in the PhD study, likely due to the fact that the PhD study focused on mortality in the 
first 3 months of  initiating ART and the age groups  included.   To highlight the difficulties 
and limitations in assigning causes of death in resource limited settings such as the Africa 






Unlike  in  European  cohorts  (Hasse,  Ledergerber  et  al.  2011) where  non‐communicable 
diseases were reported as the major cause of mortality, in our setting non‐communicable 
diseases were  a minor  cause of  very  early mortality  in both  younger  and older  adults. 
Mortality due to non‐communicable diseases, although not frequent, was non‐statistically 
significantly  higher  in  older  than  younger  adults,  similar  to  reports  elsewhere  (Hasse, 




adults  than  younger  adults,  possibly  due  to  the  fact  that  cause  of  death maybe more 
difficult to ascertain  in older adults who may have more co‐morbidities. Also, in diseases 
























































































In  addition  to prior mentioned  strengths  and  limitations of  the Clinical Cohort  (Section 
4.3.9),  the  reduction  in  very  early mortality  rates with  the  increase  in  CD4  cell  count 
threshold  for ART eligibility  resulted  in  fewer early deaths  (Lessells, Mutevedzi et al.  In 




treatment programme and  those enrolled  in  the Clinical Cohort showed no differences, 




The  extent  to which  co‐morbidities before or  at ART  initiation  and  drugs used  in  their 
treatment affect  the rate and  risk of death subsequent  to  initiating ART remains  largely 
undocumented,  especially  in  sub‐Saharan  Africa. Most  studies  discussed  above  report 
prevalence or incidence of morbidity after ART initiation, and fail to address the impact of 
co‐morbidity  at  start  of ART  on  efficacy  of ART,  information which would  be  useful  in 
providing estimates of how much benefit there is in initiating HIV positive individuals early 
on  ART,  both  at  patient  and  population  level.  Results  from  this  PhD  show  that  after 
adjustment  for differences  in age, sex, baseline  laboratory markers  (CD4 count, Hb, ALT 
and eGFR) and BMI, the risk of dying within the first three months of ART was five and half 
times higher  in older adults with HIV‐associated morbidity than  in older adults    initiating 
ART without HIV‐related symptoms,   Whilst  initiating ART with HIV‐associated morbidity 










be observed  if  the population was entirely unexposed compared with  its current actual 
exposure  levels,  the  ratio  of  early  mortality  incidence  in  those  presenting  for  ART 
initiation with  baseline morbidity  to  the  incidence  of  early mortality  in  those without 
morbidity was extremely high. For older and younger  individuals  initiating ART with any 
type  of morbidity,  very  early mortality  attributable  to  this morbidity was  85% with  an 
etiologic  fraction of  75%. Although  it  is  impossible  to  eliminate morbidity  in  any  given 






with  HIV  and  TB  co‐morbidity  compared  to  those  without)  of  5.5  and  with  82%  of 
mortality  in this group being due to the HIV and TB co‐morbidity. Although the mortality 
risk  in adults  initiating ART with WHO stage 3 or 4 disease was  lower than  in those with 
HIV and TB  co‐morbidity,  initiating ART  in adults before WHO  stage 3 or 4 HIV disease 
develops,  would  avoid  more  early  deaths  than  initiating  ART  before  TB  co‐infection 






their HIV disease progresses, at a population  level  it would be more beneficial to  initiate 
all  HIV  positive  adults  of  all  age  groups  onto  ART  early  whilst  still  asymptomatic 
irrespective of their TB status.  
 
The  first  study  for  this  PhD  (Mutevedzi,  Lessells  et  al.  2011)  provided  evidence  of 
extremely high mortality  rates  in  the  first  three months of  receiving ART, and  reported 
higher mortality rates than observed using later data from within the ART Clinical Cohort. 
The ART Clinical Cohort was implemented about six months (March 2010) after the South 
African  HIV  treatment  guidelines  were  expanded  with  higher  CD4  count  eligibility 
thresholds  for  those  pregnant  and with  TB  co‐infection.    About  five months  after  the 
implementation  of  the  ART  Clinical  Cohort  these  guidelines  were  again  updated  to  a 
higher  threshold  for  all  irrespective  of  TB  and  pregnancy  status,  following  which 
significant  very early mortality declines were observed not only within  the ART Clinical 
Cohort  but within  the whole  HIV  Treatment  programme  (Lessells, Mutevedzi  et  al.  In 
Press). Further  investigation of  this decline  showed  that mortality within  the  first  three 
months of ART started with the initial changes  in guidelines for adults aged 16 years and 
above  with  TB  and  those  pregnant  but  only  became  statistically  significant  after  the 
threshold was increased for all HIV infected adults (Lessells, Mutevedzi et al. In Press). The 
differences in population level benefits may partly be explained by the differences in total 
numbers  exposed  to  either HIV  associated morbidity  or both HIV  associated morbidity 
and  TB  as well  as  the differences  in  the mortality  rate  ratios  in  those  exposed  against 







Chronic morbidity  in  itself did not significantly  increase very early mortality, which  is not 
surprising considering  that, as discussed above,  infectious diseases are a more  frequent 
cause of mortality compared to chronic  illnesses. Low hospitalisation rates  from chronic 
morbidity have been  reported  in  this PhD study and  in another study on native African 
older  adult  population  (Waweru,  Kabiru  et  al.  2003),  suggesting      that  in HIV  positive 
adults,  infectious diseases are more  important  than chronic morbidities.   To date  there 
has been  little evidence  in this setting of drug toxicities as a cause of serious morbidity, 
but  this may  change with  increased  and prolonged exposure  to ART  and other  chronic 
morbidity treatments. For this reason it remains important to not only pro‐actively screen 
for  chronic morbidities  but  to  also monitor  liver  and  kidney  function  especially  for  all 
adults receiving lifelong ART with other co‐morbid chronic conditions. 
 
Worth noting  and  in  line with previous  studies  that have  called  for  earlier  initiation  in 
older  than  younger  adults  (Gebo  2006;  Patterson,  Napravnik  et  al.  2007;  Silverberg, 
Leyden  et  al.  2007;  Gebo  2008;  Rhee  and  Greenblatt  2008;  The  Collaboration  of 
Observational HIV Epidemiological Research Europe  (COHERE)  study group 2008; Onen, 




effects  of  HIV  compared  to  younger  adults.  Concurring with  this  finding,  as  discussed 







older, younger age was associated with higher TB  incidence  in the  first three months of 
ART (Houlihan, Mutevedzi et al. 2010), it could be that TB presentation is different in older 
adults  or  that  symptoms  are  less  frequently  attributed  to  TB  in  this  group  leading  to 
missed diagnoses and mortality  (Negin and Cumming 2010(van Duin 2012)).  In  line with 
this argument, results from this PhD work show that although older adults are  less  likely 
to be on TB therapy at time of  initiating ART, they are more likely to be hospitalised due 
to  TB  after  initiation  of  therapy.  Further,  irrespective  of  age  at  ART  initiation,  46%  of 
deaths within the first three months of ART were due to TB which was not diagnosed and 
treated at time of  initiating ART, whilst just under half of deaths due to unknown causes 
were  in  adults who were  receiving  TB  therapy when  they  initiated  therapy.  This was 
despite  all  TB  suspects,  identified  through  a  highly  sensitive  and  not  very  specific  TB 
screening algorithm, were tested for TB by X‐ray and culture before initiating therapy. The 
contribution of  immune  reconstitution  inflammatory  syndrome  (IRIS)  to  early mortality 
remains  unclear;  a  recent meta‐analysis,  using data  from  diverse  settings  across  high‐, 
middle‐ and  low‐income settings, suggested that IRIS might be responsible for 21% of all 
deaths after ART  initiation  (Muller, Wandel et al. 2010). Within this PhD work, those on 












to drug  side  effects  and  suboptimal drug  clearance  (Effros,  Fletcher  et  al.  2008).  Since 
kidney and liver function declines with age (Davies and Shock 1950; Effros, Fletcher et al. 
2008), the risk of drug toxicities and side effects is increased in older adults, necessitating 
vigilant monitoring of  liver  and  kidney  toxicities  through  laboratory markers of Alanine 
Transaminase (ALT)and creatinine and Glomerular Filtration Rates (GFR) correlates of liver 
and  kidney  function    respectively  (Davies  and  Shock  1950;  Effros,  Fletcher  et  al.  2008; 
Onen,  Overton  et  al.  2010;  Hasse,  Ledergerber  et  al.  2011).  However  studies  utilising 
these  bio‐markers  are  rare,  especially  in  populations  from  resource‐limited  countries 





cell  count  at  ART  initiation  and  TB  co‐infection,  adults with  poor  creatinine  clearance 
(creatinine levels >240 µmol/L) were at increased risk of hospitalisation as were anaemic 
adults (Hb <8g/dL). Elevated ALT levels did not significantly increase risk of hospitalisation. 













with  elevated  levels  of  creatinine,  GFR  and  ALT;  recent  results  from  the  D.A.D  study 
reported  increased mortality  risk  in adults with sub‐optimal  liver  function approximated 
through elevated ALT levels (Sabin, Ryom et al. 2013) as did  a smaller cohort of 885 HIV 
positive women and 425 HIV negative controls in four urban areas in the USA, where high 
creatinine  levels were  associated with  increased mortality  in  the  HIV  positive women 
(Gardner, Holberg et  al. 2003).  Further, a  study on 3 137 HIV positive Ghanaian  adults 




In  this PhD study, high morbidity and mortality  risk  in adults with sub‐optimal  liver and 
kidney  function  identified  a  group  of  individuals  requiring  enhanced  monitoring  and 
management of potential  side  effects  to  ensure  success of ART. Results  from  this  PhD 
confirms that diagnosis and management of sub‐optimal liver and kidney function should 
be  a  priority  in HIV  infected  adults,  especially  in  older  adults  and  illustrate  a  group  of 
adults  who  would  potentially  benefit  from  alternative  drug  regimens  that  have  low 
toxicities.  The  South African HIV  treatment  guidelines  introduced  Tenofivir  a  couple  of 
years  ago  instead  of  Stavudine  (National  Department  of  Health  2010;  National 


















exact  reason  for missing measurements  of  ALT,  creatinine  and  GFR  ,  it  is  likely  that 
missingness was at random given that the both explanatory and outcome variables were 
similar  in  those with missing    and with  complete  observations.  To  account  for missing 




The  results presented here  are  generalisable  to HIV positive populations  receiving ART 
from settings such as  this, as discussed above and previously  (Mutevedzi, Lessells et al. 








representative  of  the  treatment  programme  as  a whole.  The  ART  Clinical  Cohort  data 
were sufficient to describe and explore morbidity  issues surrounding HIV treatment and 
outcomes and provides a platform  for  future  larger cohort  studies with more statistical 
power. Also worth noting  is  that  the small sample size does not nullify our  findings but 




In  conclusion,  results  from  this PhD  study have  shown  that HIV positive  adults over 50 
years of age who were on ART for at  least a year have a  lower chronic (non‐HIV related) 
morbidity  burden  than  HIV  negative  adults  in  this  age  group,  despite  elevated 
inflammatory markers. This  reduction  in morbidity  is only evident  in HIV positive older 
adults  on  ART;  indeed  HIV  positive,  ART‐naive  older  adults  have  a  non‐statistically 
significant  higher morbidity  burden  than  in  HIV  negative  adults.  These  findings  could 
suggest benefit of enhanced access to health care in HIV positive older adults who utilise 
health  care  services  every  month  for  ART  pill  collection  visits.  It  also  suggests  that 











advanced HIV  disease,  older  adults  already  have  special  clinical  needs  over  and  above 
those  of  younger  adults.  Clinicians  need  to  be  cognisant  of  this  fact  and  both  health 
service  providers  and  older  adults  would  benefit  from  having  age‐  specific  HIV 
management guidelines.  Results here also show that although older adults have superior 
virological  suppression  following  ART  initiation  than  younger  adults,  they  have  only  a 
modest  increase  in  absolute  CD4  cell  counts  after  initiating  antiretroviral  therapy.  This 
finding  together  with  the  high  co‐morbidity  and  morbidity  at  higher  CD4  cell  counts 
compared to younger adults and the high early mortality in older adults largely driven by 
AIDS‐related morbidity at ART initiation highlights the need to consider timely initiation of 
ART  in older  adults;  the  recently  expanded  treatment  eligibility  criteria  in  South Africa 
may improve the health of older adults.  
 
This  PhD  study  finds  higher  rates  of multiple morbidity  in  older  than  younger  adults; 
health  care providers need  to vigilantly  screen  for  co‐morbidity  in older adults prior  to 
prescribing ART and take cognisance of possible drug interactions between ART and other 
prescribed  non‐AIDS  related medications  so  as  to minimise drug  interactions  that may 
increase liver and kidney toxicities, side effects or reduce efficacy of their co‐administered 
drugs. Considerable levels of reduced kidney function in older adults and of reduced liver 
function  (approximated  by  glomerual  filtration  rates/creatinine  levels  and  alanine 
transaminase  respectively)  associated  with  increased  risk  of  serious  morbidity  and 
mortality following ART initiation, in this PhD, indicates the need for frequent monitoring 
of  kidney  and  liver  function.  In  South  Africa  since  April  2013,  HIV  positive  adults  are 







This PhD  reports mortality attributable  to AIDS‐associated morbidity at ART  initiation  is 
high  for  both  younger  and  older  adults  and  highlights  the  need  for  enhanced  clinical 
monitoring of  individuals  initiating ART with advanced HIV disease  to  reduce high early 
mortality. Additionally,  in the absence of WHO stage 3 or 4 HIV disease, non‐HIV related 
chronic  morbidity  alone  does  not  significantly  increase  mortality  risk  compared  to 









For older adults, complexity  is added by  findings  from this PhD work showing that even 
though older adults are  less  likely to on TB treatment at ART  initiation and are less  likely 
to  be  hospitalised  due  to  TB,  their mortality  due  to  TB  is  significantly  high  indicating 




decreased  absorption  of  some  ART  drugs,  for HIV  positive  individuals  it  is  essential  to 
maintain  a  healthy  weight.  Community  based  interventions  on  lifestyle  modification 







would  benefit  from  integration  of  HIV  and  age‐related  chronic morbidity  services  and 
alludes  to  the  high  cost  of  maintaining  good  health  in  older  adults  due  to  multiple 




older  adults  into  responses  to  the  HIV  epidemic  as  we move  into  the  future  and  to 
specifically  address  the  needs  of  older  adults  in  HIV  treatment  delivery. Meeting  the 
complexities of geriatric care  for HIV  infected adults  in  the  future will  further challenge 




2011). The  results presented here  contribute  towards evidence  required  to understand 
issues surrounding  the health of older adults  in  the context of high HIV prevalence and 





firstly  understand mechanisms  and  processes  leading  to  increased morbidity  in  older 








in HIV negative older adults,  there  is need  for  studies evaluating whether at  these  low 
levels morbidity  risk  is  still  significant and  to assess which ART drugs  in  this  setting are 
most  effective  in  reducing  cytokine  levels. Within  the  current  South African  treatment 
guidelines it would be difficult to conduct such studies by collecting blood specimens for 
determining bio‐marker  levels using patients within existing  treatment  cohorts because 
since  April  2013  patients  are  initiated  on  a  fixed  dose  combination  pill  consisting  of 
Tenofovir,  Emtricitabine  and  Efavirenz,  making  it  difficult  to  tease  out  the  effects  of 
individual  drugs.  Differences  in  effectiveness  of  ART  in  reducing  inflammatory marker 
levels  are  best  explored  using  randomised multi‐arm  studies  and  such  studies  can  be 









To  elucidate  the  relationship  of  HIV,  co‐morbidity  and  cytokines  requires  longitudinal 








establish  the  temporal  relationship between morbidity or mortality and cytokine  levels. 
The  ART  Clinical  Cohort  set  up  for  purposes  of  this  PhD,  nested  within  a  large  HIV 
treatment  programme  will  continue  to  collect morbidity  events  that  will  be  useful  in 
understanding age‐driven long term HIV prognosis in the presence of ART. Moreover data 
















older adults  show  that health  services  integration makes delivery and  receipt of health 
care services easier and more efficient as consultation for multiple conditions can be done 
by  one  nurse/doctor  in  one  room.  Future  randomised  control  trials where  the  control 
group  receives  the  current  standard  of  care,  are  required  to  evaluate  different  health 





community  clinics  conducting  chronic  morbidity  and  TB  screening  and  the  use  of 






This  result  coupled with  the  recent  findings  of  the  benefits  of  ART  in  HIV  prevention 
highlights  the  need  for  early  therapy. However,  several  African  cohorts  have  reported 
increased  retention‐in‐HIV‐care  problems  as  HIV  treatment  cohorts  grow.  With  HIV 





Closer  to  home,  this  PhD  has  established  an  association  between  obesity  and  high 
inflammatory marker levels whose perpetually high presence may lead to disease. Future 
community  based  projects  that  provide  different  modes  of  weight  management  and 
healthy  life  style  techniques  such  as  providing  necessary  seeds  and  equipment  for 
gardening  and  funding  the  establishment  of  community  netball  or  soccer  teams,  are 
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Clinical ART Cohort           Adults (16 years and above)        Enrolment _v1 
BEFORE FILING TEAR OFF THIS PAGE AFTER FORM HAS BEEN DATA CAPTURED  
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All the questions on this form are about the patient named above. Try to obtain the relevant information as far as 
possible from the file or relevant clinic card(s) i.e. TB or PMTCT card. Where information from these sources is 






























Weight  . kg    Height  cm    Blood pressure /               
3a. Besides the HIV related drugs, are you on any other chronic/long term medication?
Yes    O→ Q3b     No    O→ Section 4    Don’t know  O→ Section 4 
3b. For which disease? (tick all that apply) 
Epilepsy         Diabetes         Hypertension   
Arthritis         Psychiatric      














1  2  DKN  Yes  No 
Y Y Y Y M M O  O  O  O  O  O  O 
Y Y Y Y M M O O O  O  O  O  O 
4c. Are you on TB treatment currently?  Yes O No O   Don’t know     O
2a. When did you have your first positive HIV test? Y Y Y Y M M 
      2b. When did you have your first CD4 count?  Y Y Y Y M M 
2c. What made you have an HIV test?                                                              
PMTCT    O      TB Clinic     O    Hospital     O 
   Private doctor  O       Main government clinic  O    Clinical trial/study  O     
Other    O  →     Specify      
  2d. Have you ever had a negative HIV test?   Yes     O →   2e    No     O → Section 3            Don’t know   O → Section 3 


















































1  2  MDR  XDR 
Y Y Y Y M M D D O  O  O  O  O  O 















        •  




        •  
        •  
Neurological 
  O  O 
        •  




        •  




        •  




        •  




        •  




        •  




        •  




        •  




        •  




        •  
        •  
Other 
 
O  O         
•  



























































Interviewer name and code      
 
6a. Are you employed? (tick one only)                                                                                                                                                                             
Yes, casual work    O      Yes, formal work O    Never employed    O 
  No, but was employed previously  O      
6b. Are you a recipient of a social security grant?                                                                                                                              
Yes     O      No    O→ Section 7     
Applied                 O      → Y Y Y Y M M D D  
 
6c. What type of social security grants do you receive? (tick all that apply)     
Care dependency    For how many children?       Old age       
Child support     For how many children?      Disability                   




7a. Have you disclosed your HIV status to anyone?                                   
Yes     O→Q7b      No   O→ section end    Refused to answer             O→ section end 
7b.To whom have you disclosed your HIV status? (tick all that apply)           
 Partner/Spouse        Parent        Church member     
 Child          Sibling        Neighbour     









  •     
  •     
  •     
5d. Are you being admitted to hospital for the current illness reported above?       Yes       O     No       O 
5e. What is the clinical staging of this patient?  I          O    ii          O   iii          O    iv         O 
Specify reason for staging     →   
5f. In the past 6 months have you been admitted to hospital?    Yes   O→5g      No   O→Section 6 





Clinical ART Cohort             Adults (16 years and above)        FollowUp_v3  
Clinical cohort number: 
 














All the questions on this form pertain to the patient named above. Try to obtain the relevant information as far as 
possible from the file or relevant clinic card(s) i.e. TB or PMTCT card. Where information from these sources is 



































Weight  . kg          Blood Pressure /                
2a. Have your ART drugs been changed since your last clinic visit?    Yes  O→Q2b    No  O →Section 3 
 






Drug 1  d4T  O  TDF O  AZT O  ABC O 
Drug 2  3tc  O  ddI O  FTC O 
Drug 3  NVP  O  EFV O  LPVr O  ATVr O 
     
2e. What were the reasons for changing the drug? (Tick all that apply) 
       
Treatment failure       TB      Pregnancy   
Psychiatric illness       Other    →  Specify   
  Adverse events      →  Specify   
 
3a. Have you suffered from any illness since your last clinic visit?  Yes  O→Q3b    No  O→Section 5 
3b. Which of the following did you consult for the illness mentioned above? (Tick all that apply)                    
  Clinic           Private doctor      Traditional healer     
       Hospital OPD         Did not consult  → Section 5  Health facility admission  →Section 4 
Other        →  Specify     
3c. What was the diagnosis given from the consultation above?      Code       
                    •  
3d. What was the diagnosis in Q3c. above based on? (tick all that apply)             




Clinical ART Cohort             Adults (16 years and above)        FollowUp_v3  
Clinical cohort number: 
 








































































Admission date  Y Y Y Y M M D D Discharge date Y Y Y Y M M D D 
4c. Which of the following was the main diagnosis most likely to be related to? (tick all that apply)          
New disease      ART Drug reactions       Worsening existing disease           












(B) CONDITION  (C)       SYMPTOMS                       (D)            SYMPTOM CODES 
New  Existing 
Musculoskeletal    O  O          •            •   
Ear/nose/throat    O  O          •            •   
Neurological    O  O          •            •   
Gastrointestinal    O  O          •            •   
Oral (teeth +mouth)    O  O          •            •   
Respiratory    O  O          •            •   
Cardiovascular    O  O          •            •   
Genitourinary       O  O          •            •   
Eyes    O  O          •            •   
Lymph nodes    O  O          •            •   
Systemic     O  O          •            •   
Skin    O  O          •            •   





















Clinical ART Cohort             Adults (16 years and above)        FollowUp_v3  
Clinical cohort number: 
 

















































     
 
6a. Have you had any of the following symptoms since your last clinic visit? (tick all that apply)        
Night sweats      Cough      Rapid weight loss       None   
Other        Specify   
 
6b. Have you been started on TB treatment since the last visit?                                                                                                           
Yes  O      No  O →section 7      Don’t know  O→ section 7   
6c. Complete the table below as fully as possible regarding the TB diagnosis reported above in 6b.  








1  2  MDR  XDR 





Yes     O    No    O→end   
Applied                 O      Y Y Y Y M M D D  
 
7b. What type of social security grants do you receive? (tick all that apply)     
Care dependency    For how many children?       Old age       
Child support     For how many children?      Disability                   






 Yes  O       No  O      Don’t know  O   


























Y Y  Y  Y  M  M D D  
2b. What was the reason for not attending clinic visits?
 




















       Immediate cause                     
 
   
       Underlying cause                     
 
   
       Associated cause (a)                      
      
   
                                      (b)                     
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Wellbeing of Older People Study (WOPS), 
Somkhele, South Africa 
in collaboration with the WHO 
Study on Global Ageing and Health (SAGE) 
 
WOPS ID   
 
Interviewer code                                         
 
Date of Interview    Y     Y     Y     Y    /     M     M      /     D     D     
 
Start time of interview      H       H     :    M  I  N  S 
Respondent’s DSID                                                                           Respondent’s BSID 
 
Respondent’s Name    Surname, First name(s)                                 BS Owner                                                               
 
Household Head                                                                                Location/Isigodi:                                                       
 
Date of Birth    Y     Y     Y     Y     /    M     M    /     D     D                 Age                             Sex:  Male      Female  
Section	1:	Respondent	and	household	characteristics	 	
101  What is your relationship to the head of this household?  
102  What is your current marital status? 
  _  
103  What is your highest level of education attained? 
 
(Tick only one) 
 
  Grade   or 
 
No formal education           Less than 1 year                   Adult education only               Certificate     
Diploma                             Bachelors degree                  Honours/Masters+                   Don’t know   
104  Are you currently in employment? Yes       No  
105  What is the main source of drinking water for members of this 
household?  
(Tick only one) 
Piped - inside house       Piped - public tap/kiosk             Borehole                       Well (non-borehole) 
Rainwater                       Protected spring                       Flowing river/stream      Dam/Stagnant water 
Other, specify  _________________ 
106  What type of toilet facilities do members of your household 
mainly use?  (Tick only one) 
Flush toilet                    VIP                                    Ordinary Latrine               Bucket/Chemical toilet 
No facilities (bush)             Neighbour’s latrine             Other, specify  _________________ 
107  What type of fuel does your household mainly use for cooking?      
(Tick all mentioned) 
Electricity from generator          Gas (LPG)                     Electricity from solar energy            Wood 
Electricity from grid                   Coal / charcoal               Kerosene/paraffin                 
Other, specify  __________________ 
108  Is your house connected to an electricity grid? Yes        No  
109  Does anyone in your household have any of the following in 
good working condition….?   (Tick all mentioned)  
Bicycle                                   Gas cooker                Radio                                           Fridge/freezer 
Mobile/cellular telephone                    TV             Video recorder/DVD player             Sofa/sofa set  
110  Does your household have any of the following domestic 
animals/fowl? 
(Tick all mentioned) 
Cows                         Goats                       Pigs                    Chickens/ducks                 Rabbits  
Other, specify____________________ 
111  [Please tell me] which of these sources is your main source of household income, by that I mean 
from which source does most of the money used in this household come from? 
 
(Tick only one) 
Earnings from selling or trading           Income from rental property       
Wages, salary from job                        Government grants                     
No source of income                            Other, specify _________________
112  Compared to 3 years ago would you say your financial situation is better or worse? Better                         About the same                            Much worse 
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Section	2:	Health	State	Description	
 
Interviewer to read: Now we will ask questions specifically about your health.  The first questions are about your overall health, including both your physical and your mental health. 
201 In general, how would you rate your health today? Very Good                     Good              Moderate                 Bad                 Very Bad  
202 Overall, in the last 30 days/month, how much difficulty did you have with 
work or household activities? None                             Mild                Moderate              Severe              Extreme/cannot do    
203 How was your health during the last two weeks? 
If ‘Very Good’ or ‘Good’ skip to Q205 Very Good                    Good             Moderate                Bad                  Very Bad  
204 What signs of illness did you experience in the last two weeks? 
 
Tick all that respondent mentions 
then read the others and tick all that apply 
 
Diarrhoea             Itchy skin                         Herpes zoster                       Night sweats              
Vomiting               Incontinence                   Feeling very weak                 Not able to sleep   
Confused              Painful wounds                Pain in the body                    Cough, chest pain        
Fever             Could not eat because of nausea      Could not eat because of pain when swallowing    
Others Specify _________________ 
 
Interviewer to read: I would like to review the different functions of your body. When answering these questions, I would like you to think about the last 30 days/ month, taking both good and bad 
days into account.  
When I ask about difficulty, I would like you to consider how much difficulty you have had, on an average, in the past one month, while doing the activity in the way that you usually do it. By 
difficulty, I mean requiring increased effort, discomfort or pain, slowness or changes in the way you do the activity. Please answer this question taking into account any assistance you have 
available (answer this question the difficulty you might have when you do it without assistance). 
Mobility 
 Overall in the last 30 days/month … 
Read and show scale to respondent 1. None        2. Mild       3. Moderate      4. Severe             5. Extreme/cannot do            6. N/A  
205 ….. how much difficulty did you have with moving around? 1.                 2.                  3.                        4.                     5.                       6.  
206 … how much difficulty did you have in vigorous activities (digging in the garden, lifting 
heavy objects such as a bag of potatoes)? (Vigorous activities require hard physical 
effort and cause large increases in breathing or heart rate) 
1.                 2.                  3.                        4.                     5.                       6.  
Self Care 
207  ….. how much difficulty did you have with self-care, such as bathing/washing or 
dressing yourself? 1.                 2.                  3.                        4.                     5.                                        
208  ….. how much difficulty did you have in taking care of and maintaining your general 
appearance (for example grooming, looking neat and tidy) 1.                 2.                  3.                        4.                     5.                                        
209  …..how much difficulty did you have in staying by yourself for a few days (3 to 7 days)? 
1.                 2.                  3.                        4.                     5.                                       
Pain and discomfort 
210  ….. how much of bodily aches or pains did you have? 1.                 2.                  3.                        4.                     5.                                       
211  ….. how much bodily discomfort did you have? 1.                 2.                  3.                        4.                     5.                                        
        If Q210 AND Q211 are ‘NONE’ skip to Q213 
212  …..how much difficulty did you have in your daily life because of your aches pain or 
discomfort? 1.                 2.                  3.                        4.                     5.                                        
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Cognition 
 Read responses 1. None           2. Mild              3. Moderate           4. Severe              5. Extreme/cannot do             
213  ….. how much difficulty did you have with concentrating or remembering things?(e.g. 
cooking, bathing). 1.                 2.                  3.                        4.                     5.                                        
214  …..how much difficulty did you have in learning a new task (for example, learning how 
to get to a new place)? 1.                 2.                  3.                        4.                     5.                                        
Interpersonal activities 
215  ….. how much difficulty did you have with personal relationships or participation in the 
community?(eg attending ceremonies, meetings) 1.                 2.                  3.                        4.                     5.                                        
216  …..how much difficulty did you have in dealing with conflicts and tensions with others 
(e.g. family/community matters)? 1.                 2.                  3.                        4.                     5.                                        
217  ….. how much difficulty did you have with making new friendships or maintaining 
current friendships? 1.                 2.                  3.                        4.                     5.                                        
218  …..how much difficulty did you have with dealing with strangers? 1.                 2.                  3.                        4.                     5.                                        
Sleep and energy 
219  ….. how much of a problem did you have with sleeping, such as falling asleep, waking 
up frequently during the night or waking up too early in the morning or sleeping too 
much? 
1.                 2.                  3.                        4.                     5.                                        
220  …..how much of a problem did you have due to not feeling rested and refreshed during 
the day? 1.                 2.                  3.                        4.                     5.                                        
Affect 
221  ... how much of a problem did you have with feeling sad, low or unhappy? 1.                 2.                  3.                        4.                     5.                                        
222  …..how much of a problem did you have with worry or anxiety (having the experience 
receiving bad news and having fast heart beating) 1.                 2.                  3.                        4.                     5.                                        
Vision  
(If respondent normally wears glasses or contact lenses, should ask the following Qs as “Since starting to wear glasses/contact lenses….”.) 
223  Have you ever had your eyes examined by a medical professional?  If yes, when was the last time? 
Interviewer: Enter years or months ago. Enter "00" if less than 1 year or 1 month ago. 
YES                    NEVER                               DON’T KNOW   
If Yes when,  years        months  
224  Do you use eyeglasses or contact lenses to see far away (for example across the street)? YES                      NO  
225  Do you use eyeglasses or contact lenses to see up close (for example at arms length, like when you are reading)?  YES                       NO   
 
226  …. how much difficulty did you have in seeing and recognizing an object or a person 
you know across the road (from a distance of about 20 metres)? 
 
INTERVIEWER: Indicate a spot that is similar distance for each respondent. 
1.                 2.                  3.                        4.                     5.                                        
227  …..how much difficulty did you have in seeing and recognizing an object at arm’s length 
(for example, sorting  beans, groundnuts or rice)? 
 
If Q226 & Q227are ‘None’ skip to Q229 
1.                 2.                  3.                        4.                     5.                                        
228  …..how much difficulty do you have fulfilling daily tasks because of not seeing properly? 
(e.g.  cooking, washing) 1.                 2.                  3.                        4.                     5.                                       
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Subjective wellbeing  
Interviewer to read: Now, we would like to ask for your thoughts about your life and life situation.  We want to know how you feel about your health and quality of life. 
 
229  Do you have enough energy for everyday life? 
Read and show scale to respondent 
Completely                     Mostly                     Moderate                   A little                       None at all   
  1. Very Satisfied         2. Satisfied        3. Neither satisfied nor dissatisfied        4. Dissatisfied       5. Very dissatisfied 
230  How satisfied you are with your health? 1.                            2.                    3.                                                        4.                      5.                            
231  How satisfied you are with your self? 1.                            2.                    3.                                                        4.                      5.                            
232  How satisfied you are with your ability to perform your daily living 
activities? 1.                            2.                    3.                                                        4.                      5.                            
233  How satisfied you are with your personal relationships? 1.                            2.                    3.                                                        4.                      5.                            
234  How satisfied you are with the conditions of your living place? 1.                            2.                    3.                                                        4.                      5.                            
235  Taking all things together, how satisfied are you with your life as a 
whole these days? 1.                            2.                    3.                                                        4.                      5.                            
236  How often have you felt that you were unable to control the 
important things in your life? Read responses 
Never                   Almost never                     Sometimes                 Fairly often               Very often    
237  How often have you found that you could not cope with all the 
things that you had to do? Read responses 
Never                   Almost never                     Sometimes                 Fairly often               Very often    
238  How would you rate your overall quality of life? Read responses Very Good                    Good             Moderate                Bad                 Very Bad  
Functioning assessment 
These next questions ask about difficulties due to health conditions. Health conditions include diseases or illnesses, other health problems that may be short or long lasting, injuries, mental or 
emotional problems, and problems with alcohol or drugs.  Think back over the last 30 days and answer these questions thinking about how much difficulty you had doing the following activities. 
 
INTERVIEWER: For each question, please tick only one response. 
 In the last 30 days/month, how much difficulty did you have …            
Read responses 1. None           2. Mild              3. Moderate            4. Severe             5. Extreme/cannot do           6. NAD 
239  … in sitting for long periods? 1.                 2.                  3.                        4.                     5.                                       6.  
240  … in walking 100 metres? 1.                 2.                  3.                        4.                     5.                                       6.  
241  … in standing up from sitting down? 1.                 2.                  3.                        4.                     5.                                       6.  
242  … in standing for long periods? 1.                 2.                  3.                        4.                     5.                                       6.  
243  ... with climbing one flight of stairs without resting? 1.                 2.                  3.                        4.                     5.                                       6.  
244  … with stooping, kneeling or crouching? 1.                 2.                  3.                        4.                     5.                                       6.  
245  …picking up things with your fingers (such as a coin from a table)? 1.                 2.                  3.                        4.                     5.                                       6.  
246  … in taking care of your household responsibilities? 1.                 2.                  3.                        4.                     5.                                       6.  
247  … in joining in community activities (for example, festivities, religious or other 
activities) in the same way as anyone else can? 1.                 2.                  3.                        4.                     5.                                       6.  
248  … concentrating on doing something for 10 minutes? 1.                 2.                  3.                        4.                     5.                                       6.  
249  … in walking a long distance such as a kilometre? 1.                 2.                  3.                        4.                     5.                                       6.  
250  … in bathing/washing your whole body? 1.                 2.                  3.                        4.                     5.                                       6.  
251  … in getting dressed? 1.                 2.                  3.                        4.                     5.                                       6.  
252  … in your day to day work? 1.                 2.                  3.                        4.                     5.                                       6.  
253  … with carrying things? 1.                 2.                  3.                        4.                     5.                                       6.  
254  … with moving around inside your home (such as walking across a room)? 1.                 2.                  3.                        4.                     5.                                       6.  
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  1. None           2. Mild              3. Moderate           4. Severe              5. Extreme/cannot do            6. NAD 
255  … with eating (including cutting up your food)? 1.                 2.                  3.                        4.                     5.                                       6.  
256  … with getting up from lying down? 1.                 2.                  3.                        4.                     5.                                       6.  
257  … with getting to and using the toilet? 1.                 2.                  3.                        4.                     5.                                       6.  
258  … with getting where you want to go, using private or public transport if 
needed? 1.                 2.                  3.                        4.                     5.                                       6.  
259  … getting out of your home? 1.                 2.                  3.                        4.                     5.                                       6.  
260  In the last 30 days/month, how much have you been emotionally affected by 
your health condition(s)? 1.                 2.                  3.                        4.                     5.                                       6.  
261  Overall, how much did these difficulties interfere with your life? 1.                 2.                  3.                        4.                     5.                                       6.  
262  Besides any vision (eyeglasses, contact lenses) or hearing aids, do you use any other devices (such as a cane, walker, or other) for any difficulties you experience? Yes         NO  
 
Depression 
Interviewer to read: Now I would like to ask you questions about your feelings of sadness or depression 
263 Have you ever been diagnosed with depression?      If ‘NO’ SKIP to Q266 Yes               NO  
264 During the last 2 weeks have you been taking any medications or other treatment for it? 
(Other treatment can include attending therapy or counselling sessions.) 
Yes               NO  
265 During the last 12 months have you been taking any medications or other treatment for it? Yes               NO  
266 During the last 12 months, have you had a period lasting several days when you felt sad, empty or depressed? Yes               NO  
267 During the last 12 months, have you had a period lasting several days when you lost interest in most things you usually enjoy such as personal relationships, 
work or hobbies/recreation? 
Yes               NO  
268 During the last 12 months, have you had a period lasting several days when you have been feeling your energy decreased or that you are tired all the time? Yes               NO  
                                          INTERVIEWER:   IF ANY ONE OF Q266, Q267 OR Q268 IS "YES”, CONTINUE TO Q269.  IF ALL 3  ARE "NO",  GO TO Q301 
269 Was this period [of sadness/loss of interest/low energy] for more than 2 weeks? Yes               NO  
270 Was this period [of sadness/loss of interest/low energy] most of the day, nearly every day? Yes               NO  
271 During this period, did you lose your appetite? Yes               NO  
272 Did you notice any slowing down in your thinking? Yes               NO  
273 Did you notice any problems falling asleep? Yes               NO  
274 Did you notice any problems waking up too early? Yes               NO  
275 During this period, did you have any difficulties concentrating; for example, listening to others, working, watching TV, listening to the radio? Yes               NO  
276 Did you notice any slowing down in your moving around? Yes               NO  
277 During this period, did you feel anxious and worried most days? Yes               NO  
278 During this period, were you so restless or jittery nearly every day that you paced up and down and couldn’t sit still? Yes               NO  
279 During this period, did you feel negative about yourself or like you had lost confidence? Yes               NO  
280 Did you frequently feel hopeless - that there was no way to improve things? Yes               NO  
281 During this period, did your interest in sex decrease? Yes               NO  
282 Did you think of death, or wish you were dead? Yes               NO  
283 During this period, did you ever try to end your life? Yes               NO  
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Section	3:	Chronic	conditions	and	health	service	coverage	
Interviewer: Now I would like to read you questions about some health problems or health care needs that you may have experienced, and the treatment or medical care received 
  HEART DISEASE 




LUNG DISEASE ASTHMA  DIABETES CANCER 
301 Have you ever been diagnosed with/told you have? Yes       NO  Yes     NO Yes     NO  Yes     NO Yes     NO  Yes     NO Yes     NO  Yes     NO
302 How long ago was the diagnosis? 0-6 months   
7-12 months  
>12 months  
0-6 months   
7-12 months  
>12 months  
0-6 months   
7-12 months  
>12 months  
0-6 months   
7-12 months  
>12 months  
0-6 months   
7-12 months  
>12 months  
0-6 months   
7-12 months  
>12 months  
0-6 months   
7-12 months  
>12 months  
0-6 months  
7-12 months
>12 months 
303 Have you been taking medications or other 
treatment for……. during the last 2 weeks? 
Yes       NO  Yes     NO Yes     NO  Yes     NO Yes     NO  Yes     NO Yes     NO  Yes     NO
304 ……. during the last 12 months? Yes       NO  Yes     NO Yes     NO  Yes     NO Yes     NO  Yes     NO Yes     NO  Yes     NO
 
Interviewer: Now I would like to ask you about some health symptoms you may have experienced, and the treatment or medical care received 
Heart Disease/Angina 
305  During the last 12 months have you experienced discomfort, pain, or heaviness in chest, arm, or breastbone when walk uphill or in a hurry? Yes   NO  
306  During the last 12 months/year have you experienced any pain or discomfort in your chest when you walk at ordinary pace on level ground? Yes   NO  If Q305 & 306 are ‘NO’      Q3
307  What do you do if you get the pain or discomfort when walking?  (Tick only one) Stop/slow down       Carry on walking   
Take pain relief medicine then carry on     
308  If you stand still, what happens to the pain or discomfort? Relieved            Not relieved             
309  Have you experienced these symptoms in the last 2 weeks? Yes   NO  
310  Have you been seeing a doctor or other health worker for these symptoms? Yes   NO  
311  During the last 12 months/year have you seen a traditional healer for these symptoms? Yes   NO  
312  Are you currently taking any herbal or traditional remedy for your symptoms? Yes   NO  
Arthritis 
313  During the last 12 months/year have you experienced pain, aching, stiffness or swelling in or around joints (arms, hands, feet) not related to 
injury & lasted for more than a month? 
Yes   NO  
314  During the last 12 months/year have you experienced any stiffness in the joint in the morning after getting up from bed or after a long rest? Yes   NO  If Q313 & 314 are ‘NO’      Q3
315  How long does this stiffness last? 30 mins or less      More than 30 mins   
316  Does this stiffness go away after exercise or movement in the joint? Yes   NO  
317  Have you experienced these symptoms in the last 2 weeks? Yes   NO  
318  Have you experienced back pain during the last month? On how many days if yes? Yes    Days________                 NO      
319  Have you been seeing a doctor or other health worker for these symptoms? Yes   NO  
320  During the last 12 months/year have you seen a traditional healer for these symptoms? Yes   NO  
321  Are you currently taking any herbal or traditional remedy for your symptoms? Yes   NO  
Stroke 
322  Have you ever suffered from sudden onset of paralysis or weakness in your arms or legs on one side of your body for more than 24 hours? Yes   NO  
323  Have you ever had, for more than 24 hours, sudden onset of loss of feeling in one side of your body, without anything having happened to 
you immediately before? 
Yes   NO  
Hypertension 
324  During the last 12 months have you seen a traditional healer for raised blood pressure (hypertension)? Yes    NO      If ‘NO’            Q327 
325  Are you currently taking any herbal or traditional remedy for your raised blood pressure (hypertension)? Yes                           NO  
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Chronic Lung Disease 
327  During the last 12 months/year have you experienced any shortness of breath while at rest or while awake? Yes   NO  
328  During the last 12 months/year have you experienced any coughing or wheezing for 10 minutes or more at a time? Yes   NO  
329  During the last 12 months/year have you experienced any coughing up sputum or phlegm for most days of the month for at least 3 months? Yes   NO  If 327 to 329 are ‘NO’        3
330  These symptoms that you say you experienced, have you experienced them in the last 2 weeks?  Yes   NO  
331  Have you been taking any medications or other treatment for your symptoms during the last 2 weeks?  Yes   NO  
332  Have you been taking any medications or other treatment for your symptoms during the last 12 months?  Yes   NO  
333  In the last 12 months/year have you had a tuberculosis (TB) test? Yes   NO  
334  Have you had blood in your phlegm or have you coughed blood? Yes   NO  
Asthma 
335  During the last 12 months/year have you experienced any attacks of wheezing or whistling breathing? Yes   NO  
336  During the last 12 months/year have you experienced any attacks of wheezing that came on after you stopped exercising or some physical activity? Yes   NO  
337  During the last 12 months/year have you experienced any feeling of tightness in your chest? Yes   NO  
338  Have you woken up with a feeling of tightness in your chest in the morning or any other time? Yes   NO  
339  Have you experienced shortness of breath that came on without obvious cause when you were not exercising or doing some physical activity? Yes   NO  
340           Go to Q344 if Q335, 336, 337, 338 & 339 are all ‘NO’               Have you experienced any of these symptoms you describe in the last 2 weeks?  Yes   NO  
341  Have you been seeing a doctor or other health worker for these symptoms? Yes   NO  
342  During the last 12 months/year have you seen a traditional healer for these symptoms? Yes   NO  
343  Are you currently taking any herbal or traditional remedy for your symptoms? Yes   NO  
Diabetes 
344  During the last 12 months/year have you been taking insulin or other blood sugar lowering medications? Yes   NO  
345  During the last 2 weeks have you been taking insulin or other blood sugar lowering medications? Yes   NO  
346  Have you been following a special diet, exercise regime or weight control program for diabetes during the last 2 weeks? Yes   NO  
Cataract/Eye problems 
347  In the last 5 years were you diagnosed with a cataract (cloudiness in the lens of the eye) in one or both of your eyes? Yes   NO  If ‘NO’            Q349 
348  In the last 5 years have you had eye surgery to remove this cataract(s)? Yes   NO   
349  In last 12 months have you experienced cloudy or blurry vision? Yes   NO  
350  In last 12 months have you experienced vision problems with light, such as glare from bright lights or rings around lights? Yes   NO  
351  Have you ever gone to the clinic because of eye problems? Yes   NO  
Oral Health 
352  Have you lost all your natural teeth? Yes   NO  
353  During the last 12 months have you had any troubles with your mouth and/or teeth (this includes problems with swallowing)? Yes   NO  If ‘NO’            Q357 
354  Have you received medication or treatment from a dentist during the last 12 months for mouth/teeth problems? Yes   NO  
355  In last 12 months have you seen a traditional healer for your mouth/teeth problems (including problems with swallowing? Yes   NO  
356  Are you currently taking any herbal or traditional remedy for your problems with mouth or teeth? Yes   NO  
Injuries 
357  During the last 12 months did you have an injury? Yes             NO       If ‘NO’           Q400 
358  How did the injury happen? Was it an accident? It was an accident                     Someone else caused it deliberately (intentional)               I did it to myself (self-inflicted)  
359  Did you receive medical treatment for the injury Yes             NO  
360  Did you suffer a physical disability as a result of being injured? Yes             NO  
361  In what way were you physically disabled? 
(Tick only one) 
Unable to use hand/arm           Difficulty using hand/arm       Walk with a limp       Loss of hearing     Loss of vision 
Weakness/shortness of breath      Inability to remember things   Inability to chew    OTHER _________________ 
362  What caused the injury? 
(Tick all mentioned) 
Fall                   Stabbed         Gun shot               Fire or burn              Near-drowning                 Poisoning         
struck/hit by person/object        Animal bite           Electric shock           OTHER, SPECIFY _________________ 
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Section	4:	Health	care	utilization	&	risk	factors	and	behaviours	
 
400  During the last 4 weeks, did you suffer from one of the following diseases or 
symptoms: 
 
Read the symptoms and record   
 
If no symptoms skip to 405 
 
Fever / malaria                                                     Yes                 NO  
Gastro-intestinal problems (e.g. diarrhoea)         Yes                 NO  
Coughing/ respiratory problems                           Yes                 NO  
Skin conditions such as (LOCAL NAMES)           Yes                 NO  
Trouble with mouth and/or teeth or swallowing    Yes                 NO  
Other  Specify _________________ 
401  For those symptoms, what did you do….? 
 
Tick all that apply 
Used own herbal medicine                                          Saw a traditional healer/ herbalist         
Took medicine (self treatment)                                   Visited the Pharmacy/chemist/shop     
Visited a government health centre /public clinic        Visited a private or missionary health clinic
Admitted to a government hospital                             Admitted to a private or missionary hospita
Did nothing about the symptoms                                Other Specify ___________________      
402  Where did you go first? 
 
Tick only one 
 
Traditional healer / herbalist /shrine                            Pharmacy/chemist/shop                               
Government health centre /public clinic                      Private or missionary health clinic   
Government hospital                                                   Private or missionary hospital                      
Others Specify _________________ 
403  Did you have to pay for consultation and/or drugs? Yes     NO       If ‘NO’           Q405 
404  Who paid for the consultation and/or drugs? Son/daughter                             Spouse                                   Self                                     
Other relative                             Insurance                               Was free                  
Other Specify __________________ 
405  During the last 12 months, how often have you visited a clinic or hospital? Not at all                     Once or twice                
Three to six times       More than six times        Don’t know  
406  When you visit the clinic or hospital how long, do you usually have to wait before it 
is your turn to be seen by a nurse or doctor?  
Not long                      Quite long                        Very long  
 
407  When you visit the clinic or hospital, do the health professionals usually give you 
enough time to explain to them what your health problem is? 
Always                        Sometimes                     Never   
 
408  When you visit the clinic or hospital, do the health professionals usually take the 
time to explain your health problem and treatment in a way that you understand? 
Always                        Sometimes                      Never   
 
409  Overall, are you satisfied with the services?  Satisfied                            Indifferent                            Dissatisfied  
410  Do you ever go to traditional healers for treatment? Yes                 Never goes to traditional healer          If ‘Never….’ skip to Q412 
411  What are the reason(s) that you go to the traditional healers for treatment? 
 
Tick all that apply 
Closer distance                                                   
Traditional healers are cheaper                          
Traditional healers allow you to  pay in goods    
Traditional healers will wait for your payment     
Traditional healers give better treatment            
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Health centre/clinic, hospital stays 
412  Were you ever hospitalized in the last year? If so, how many times? 
  
Yes       If ‘Yes’, Number of admissions _________ 
No         If ‘NO’ skip to Q450 
413  What type of hospital was it the last time you were hospitalized?  Public hospital                      Private hospital                        Charity or church run hospital   
Old people’s home or long term care facility                      Other Specify __________________ 
414  Which reason best describes why you were last hospitalized? Specify reason hospitalized _______________ 
1= communicable diseases, infections, malaria, infection TB, HIV; 2= nutritional deficiencies 3= acute conditions, (diarrhoea, flu, headaches, fever, cough and others); 4= injury; 5= surgery; 6= 
sleep problem; 7= occupational /work related condition/injury; 8= chronic pain in joints/arthritis (joints, back, neck); 9= diabetes or related complications; 10= problems with heart including 
unexplained pain in chest; 11= problems with mouth, teeth, swallowing; 12= problems with breathing; 13= high blood pressure, hypertension; 14= stroke/ sudden paralysis of one side of body; 15= 
generalized pain(stomach, muscle or other nonspecific pain); 16= depression, anxiety; 17= cancer; 87= other, specify 
415  Who paid for this hospitalization?  
 
Son/daughter        Spouse           Self           Other relative            Insurance           Was free   
Other, Specify __________________ 
Section	4.5:	Risk	factors	and	preventive	health	behaviours	
Tobacco use 
450  Have you ever smoked tobacco or used smokeless tobacco?   Yes                         No         If ‘NO’ skip to Q454 
451  Do you currently use (smoke, sniff or chew) any tobacco products such as cigarettes, cigars, pipes, chewing 
tobacco or snuff?     
Yes, daily            Yes, but not daily              No, not at all    
 
If ‘Yes, not daily’ OR ‘No, not at all’ SKIP TO Q454
452  For how long have you been smoking or using tobacco daily? Number of years ________ 
453  On average, how many cigarettes or pipes do you smoke or use each day? Number of cigarettes _____ 
Alcohol  
454  Have you ever consumed a drink that contains alcohol (such as beer, spirits, wine, etc.?)   
 
Yes      No      If ‘NO’ skip to Q458 
455  Have you consumed alcohol in the last 30 days/month?   Yes      No     If ‘NO’ skip to Q458 
456  During the past 7 days, how many standard drinks of any alcoholic beverage did you have each day? Number of drinks ______ 
457  In the last 12 months,/year how frequently [on how many days] on average have you had at least one alcoholic 
drink? 
Less than once a month       1 to 7 days per month        
1 to 4 days per week             5 or more days per week  
Nutrition 
458  In the last 12 months, were you ever hungry, but didn’t eat because you couldn’t afford enough food?   Yes      No        If ‘NO’ skip to next section 
459  In the last 12 months, how often did you eat less than you felt you should because there wasn’t enough food? Every week                           Every month        
Almost every month              Some months, but not every month  
Only in 1 or 2 months             Never              
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Section	5:	Anthropometric	measurements		
Interviewer to read: Now we would like to ask you to participate in a few tests to determine your health status. We would like to measure a few things, like your blood pressure, your weight an
height etc. We will start with taking your blood pressure. 
 
INTERVIEWER: Ask the respondent to release the arm and relax. 
501  
Time 1:  Systolic                Diastolic                 Pulse rate  
 INTERVIEWER: Ask the respondent to release the arm and relax. Wait for one minute before time 2. Do not ask the respondent questions. 
 
502  
Time 2:  Systolic                Diastolic                 Pulse rate  
 INTERVIEWER: Again, remind the respondent to relax and wait.  
 
503  
Time 3:  Systolic                Diastolic                 Pulse rate  
 
504  Interviewer: Can respondent stand up? Yes      No   
 
Interviewer to read: I would now like to measure how tall you are. To measure your height I need you to please take off your shoes. Put your feet and heels close together, stand straight and
forward standing with your back, head and heels touching the wall. Look straight ahead 
505  Measured height in centimetres                                                                  
 Height                          Not able to measure            refused  
 
Now we want to measure your weight – could you please keep your shoes off and step on the scale. 
506  Measured weight in kilograms  





Wellness of Older People Study                             Questionnaire                         English, Version 1 Page	11	
Section	6:	Care	giving	
Interviewer read: Now we would like to talk about people who live with you here in your household (resident); we mean those who share meals and usually stay here for at least four months a
year. Please include people who may presently be in an institution due to their health (for example, in hospital) for a short time. Lets start by talking about resident adults (18+ years) to whom 
may have provided care.  
6.1: Physical, nursing care and financial assistance to resident adults and children 
  Care giving to adults (18 years and above) Care giving to children (less than 18 years)
601  Are you providing any physical or nursing care to any adults/children 
resident in your household?    
 
Interviewer: First ask Q601 to Q613 for care giving to adults and then start again 
from Q601 to Q613 for care giving to children 
Yes       No       If ‘NO’ skip to Q604 
If Yes how many?                                      
Yes       No        If ‘NO’ skip to Q604 
If Yes how many?                                
602  Do you provide any care/ 




Bathing (washing one’s body)  
Eating (assistance with eating but not cooking) 
Dressing (putting on or taking off clothing) 
Toileting (getting to and using the toilet) 
Moving around (within or outside dwelling) 
Incontinence (help with hygiene problems) 
Preparing and giving medicines  
Taking care of wounds 
Yes        NO  
Yes        NO  
Yes        NO  
Yes        NO  
Yes        NO  
Yes        NO  
Yes        NO       Had no medicines  
Yes        NO       Had no wounds      
Yes        NO  
Yes        NO  
Yes        NO  
Yes        NO  
Yes        NO  
Yes        NO  
Yes        NO       Had no medicines  
Yes        NO       Had no wounds      
603  Do you provide any 








Taking to clinic or traditional healer 
Other 
Yes        NO  
Yes        NO  
Yes        NO  
Yes        NO  
Yes        NO  
Specify_____________ 
Yes        NO  
Yes        NO  
Yes        NO  
Yes        NO  
Yes        NO  
Specify_____________ 
604  Are there any adults/children often sick and need care and treatment? Yes        NO     If ‘NO’ skip to Q611 Yes        NO      If ‘NO’ skip to Q611 
605  Can you tell me for what the adults/children need care and treatment for? 
 
 
If not ‘HIV/AIDS RELATED’ skip to Q607 
HIV/AIDS related           
Health related reason,   Specify ____________ 
Other reason,                Specify ____________  
Don’t Know                   
HIV/AIDS related           
Health related reason,   Specify ____________
Other reason,                Specify ____________
Don’t Know                   
606  Interviewer: Ask only If HIV/AIDS is mentioned in Q605 
 
How many adults/children with HIV infection do you take care of?  
 
If more than one adult or child needs care and treatment, ask the next questions 
about the adult or child in most need of care and treatment 
 
       
 
       
607  Do you know the kind of treatment/medication (NAME) needs? 
  
DO NOT PROBE: Tick only one. 
 
ARV treatment                        
TB treatment    
Knows it is for AIDS, but not name  
Other, Specify  _________________________  
ARV treatment                        
TB treatment   
Knows it is for AIDS, but not name  
Other, Specify  _________________________  
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  Care giving to adults (18 years and above) Care giving to children (less than 18 years)
608  Does (NAME) need to take daily medication/ treatment from the clinic?  Yes    NO    If ‘NO’ skip to  Q611 Yes     NO    If ‘NO’ skip to  Q611 
609  Do you need to remind (NAME) to go for their medical appointments and/or 
to take their medicines/(ARV)?   
(Interviewer: only mention ARV if ARV was mentioned in Q607) 
Yes     NO  Yes     NO  
610  Do you accompany (NAME) going to the clinic/ hospital for follow up and /or 
ARV or TB treatment resupply? 
 
 (Interviewer: ask only if ARV or TB is mentioned in Q607) 
Yes     NO  Yes     NO  
611  Do you provide (NAME) with 
financial assistance such as……?  
 
Read and tick all that apply 
 
If all answers are NO skip TO Q613 
Paying for medicines  
Paying doctor or clinic or hospital fees 
Paying for food 
Paying for clothing 
Paying for transportation 
Paying for school expenses (of sick 
person’s children) 
Yes                            NO  
Yes                            NO  
Yes                            NO  
Yes                            NO  
Yes                            NO  
 
Yes                            NO  
Other SPECIFY ________________________ 
Yes                            NO  
Yes                            NO  
Yes                            NO  
Yes                            NO  
Yes                            NO  
 
Yes                            NO  
Other SPECIFY ________________________ 
612  Before (NAME) became ill, was s/he contributing to your household in cash 
or in kind or labour? 
Yes                  NO  Yes           NO  
613  Overall, how difficult would you say it is for you to provide care, physical 
assistance or financial assistance to adults/children? 
Very difficult    A little difficult    Not difficult  Very difficult   A little difficult  Not difficult  
 
6.2 Care-giving to adults (18 and above) who have died in the last 24 months (2 years) 
614  Has any adult resident member(s) of this household died in the last 24 months?   
 
Interviewer: If ‘NO’ deaths skip to Q701 
Yes        NO  
Number of deaths if Yes                 
615  Of the resident adults who died in the last 24 months, how many were contributing an income/in cash or in kind to the 
household? 
Number  of adults contributing   
616  Were any of the persons who died the main income earner for your household? Yes          NO               Don’t know  
617  Did you provide care to any of the adults who died in the last 24 months? 
 
Interviewer: if provided care to more than one adult member, ask the next questions about the most recent death.  
Yes           NO      If ‘NO’ go to Q701 
618  What is the NAME and SEX of the person who died? Name: ________________       Sex: Male        Female  
619  How old was (NAME) when they died?  
Age in years   
620  What was your relationship to (NAME)?  
Relationship type  
621  For how long was s/he sick before he/she died?   
If less than one month skip to Q625 Number of months  
622  Where was (NAME) living during the time s/he needed care?  Outside DSA          Inside the DSA    
623  Did you stay/live with (NAME) during his/her sickness?    Yes          NO       If ‘No’ skip to Q625 
624  How long did you stay/live with (NAME) during the time s/he needed care? 
Number of Months     Number of Days  
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6.3 Assessment of satisfaction with care-givers role 
  Interviewer read: Now I am going to ask whether you faced some problems related to your health and well-being the time you provided care and support to adult resident members who died 
in this household in the last 24 months 
625  During the time that you provided care how much difficulty did you have 
with…..? 
 
(Read responses and tick all that apply) 
Having enough energy to do extra work 
Taking care of your own ailments  (if exist) 
Knowing the correct care to give for health problems  
Visiting family and relatives and friends 
Sharing feelings about care giving responsibility 
Knowing how to protect yourself from getting the illness/ disease 
Stigma or problems as a result of or associated with illness or death  
Very much     some     None   
Very much     some     None  
Very much     some     None  
Very much     some     None   
Very much     some     None   
Very much     some     None  
Very much     some     None  
626  Did the care you gave to adult household members give you the following 
…?  
(Read and tick all that apply) 
A chance to keep busy and occupied 
A chance to do things that makes use of your abilities 
A chance to feel a sense of accomplishment despite the difficulties 
A chance to do something useful for your sick household member 
Yes      somewhat       No   
Yes      somewhat       No  
Yes      somewhat       No  
Yes      somewhat       No  
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Section	7:	Receiving	care	
Interviewer to read: Now we will continue asking questions about the assistance and care you might have needed and received. 
 
FINANCIAL ASSISTANCE 
701  Do you receive financial assistance for……? 
 
 
Read and record all that apply 
 




Paying for medicines                                      Yes     NO      
Paying doctor  or clinic or hospital fees          Yes     NO      
Paying for food                                                Yes     NO  
Paying for clothing                                           Yes     NO  
Paying for transportation                                 Yes     NO  
Paying school expenses (for offspring)       Yes     NO  
Other SPECIFY ______________ 
702  Who is/are the provider(s) of this financial assistance to you? 
 
Record all answers given 
Spouse        Son/daughter   Grandson/daughter    Sibling    
Other relative          Community           Neighbour/ Friend             Government        
Church     Insurance                        Other Specify __________________ 
703  For how long have you been receiving this assistance? Years      Months  
704  Overall, how difficult would you say it has/ had been to receive financial assistance? Very difficult                A little difficult             Not difficult  
705  In the past, before you became ill, were you contributing to the household in cash or in 
kind or labour? 
Yes         NO      If ‘No’ Skip to Q707 
706  Were you the main provider of cash or labour for the household? Yes        NO  
 
GOVERNMENT GRANTS 
707  Are you receiving any government grant meant for your use?  
Tick only one. If ‘No, none’ Skip to Q709.  
Yes, Care Dependency            Yes, Disability         Yes, Old Age Pension               No, none  
Other Specify _____________ 
708  On what do you mainly use this grant you receive? 
 
Tick only one 
Own upkeep                     Care and support another household  
Household expenses        Given to adult member of household      Other Specify _______________ 
709  Are you receiving any government grant on behalf of some other member of 
your household?  
 
Record all answers given 
Yes, Care Dependency                 Yes, Disability                          Yes, Old Age Pension        
Yes, Foster Care                           Yes, Child Support                    No, none                                 
 Other Specify _____________ 
 
PHYSICAL ASSISTANCE  
710  Do you receive physical assistance such as……?  
 
Read and tick all that apply 
 
If all answers to Q710 are ‘NO’ skip to Q713 
Buying food                                     Yes     NO                                                 
Agricultural work                              Yes     NO  
Fetching water                                 Yes     NO                                             
Cooking                                            Yes     NO  
Going to clinic or traditional healer   Yes     NO                 Other SPECIFY________________ 
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711  Who is/are the provider(s) of this assistance to you? 
 
TICK ALL THAT APPLY 
 
Parent                            Spouse      Son/daughter        Grandson 16+           Grand daughter 16+      
Grandson under 16        Granddaughter under 16              Community volunteer           Neighbour          
Government                   Church                                           Sibling                                 Friend                
Other Specify __________________ 
712  For how long have you been receiving this assistance? Years      Months  
 
NURSING CARE AND SUPPORT 
713  Do you know your HIV Status? Yes       NO      
714  Do you need care, support and/or treatment? Yes       NO      
715  Are you receiving any care, support and/or treatment? Yes       NO     If ‘No’ Skip to Q717 
716  Could you tell us why you need care, support and/or treatment? 
 
Do not read the response categories. Tick only one. 
 
Complete next section as well if ‘HIV/AIDS related’ is mentioned 
 
 
HIV/AIDS related                                                              
TB related                 
Health related reason, Specify ________________                 
Other reason, Specify _______________________ 
Don’t know                                                                       
Refused                       
717  Do you receive care/assistance with...? 
 
Read and record all that apply 
 
Bathing (washing one’s body)                                 Yes      NO  
Eating (assistance with eating but not cooking)      Yes      NO  
Dressing (putting on or taking off clothing)              Yes      NO  
Toileting (getting to and using the toilet)                  Yes     NO  
Moving around (within or outside dwelling)             Yes      NO  
Hygiene problems ( bowel and bladder control)      Yes      NO  
a. Do you receive care/assistance with...? Preparing and taking medicines                              Yes      NO     Had no medicines  
 
718  Overall how satisfied are you with the care/assistance you have 
received? 
Satisfied                Indifferent              Not satisfied  
719  Overall, how difficult would you say it has been for you to arrange 
this care/assistance? 
Very difficult           A little difficult        Not difficult  
720  Is there anything else you would like to tell us about the 
care/assistance you have received? 
Yes     NO       






Interviewer: If ‘HIV/AIDS related’ was mentioned in Q716 Go to Q801, otherwise thank the respondent and end interview.   	
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Section	8:	HIV	Experiences	
EXPERIENCES OF LIVING WITH HIV/AIDS (only for respondents who know they are HIV infected) 
Interviewer read: Now I would like to continue asking questions for this study about your health but the questions we will ask are now related to HIV and ARV treatment. We are asking the
questions to get a better understanding about how this HIV affects older people but also the experience older people have with the ARV treatment. 
801  How long ago did you learn that you have HIV? Years                           Months                         
802  How was your health at the time you tested HIV positive?  Good           Moderate          Bad     IF ‘Good’ Skip to Q804 
803  For how long had you been sick before you learnt that you have HIV?  Years                           Months                         
804  Since knowing that you have HIV, have you changed residence?  Yes     NO    If ‘NO’ SKIP TO 806 
805  Did you move dwellings because of ….?  
 
Read and record all that apply 
Needed care   Yes     NO          Fail to pay rent  Yes     NO               
Stigma            Yes     NO           Feeling better  Yes     NO          Other (specify)____________
806  During the last 3 months how would you say your health was?      Good                Moderate                Bad          IF ‘Good’ Skip to Q808 
807  What signs of illness did you experience during the last 3 months?  
 
Read responses and tick all that apply 
 
Diarrhoea        Itchy skin                         Herpes zoster                       Night sweats          
Vomiting          Incontinence                   Feeling very weak                 Not able to sleep   
Confused        Painful wounds                Pain in the body                    Cough, chest pain    
Fever        Could not eat because of nausea      Could not eat because of pain when swallowing
Others Specify _________________ 
808  Before taking ARVs did you need any personal / nursing care? Yes        NO            Not yet on ARVs               If ‘Not yet on ARVs’ End interview 
809  How long ago did you start ARVs treatment? Years                           Months                        Weeks                          
810  Do you experience any of these problems with taking the ARVs?  
Read and record all that apply 
Has side effects           Sometimes forgets                   Needs certain kinds of food                 
Other specify_______________ 
811  Did you experience any serious side effects after starting ARV such as..?   
 
Read and record all that apply  
 
If did not experience any side effects, Skip to Q815 
Skin conditions             Yes     NO                                          Yellow eyes                   Yes     NO    
Muscle weakness         Yes     NO                                          Pain in the muscle         Yes     NO     
Nausea/ vomiting          Yes     NO                                          Diarrhoea                      Yes     NO    
Hallucinations                Yes     NO                                         Bad dreams                  Yes     NO      
Self hate                        Yes     NO                                         Fears                             Yes     NO    
Sadness                        Yes     NO                                         Unreasonable/irritable   Yes     NO    
 Other specify_______________ 
812  How many weeks did these side effects last? Weeks   
813  Are you still experiencing these side effects? Yes     NO    
814  Have you changed ARVs because of side effects? Yes     NO    
815  Has your health improved since taking ARVs? Very much                               Same as before                     Is worse  
816  Does anyone living in the household ever remind you to take ARVs on time?  
Tick only one Daily or almost daily                Several times a week           Only once in a while  
Rarely or never                         At first but not now              Other Specify ________________ 
817  Does anyone accompany you when you go for follow up visits?  Yes, always       Yes, sometimes       Only when feeling sick        No     If ‘No’ End interview
818  Who usually accompanies you for follow up (and or resupply) visit? Family member                 Friend                            Community volunteer   
End of interview. Thank the respondent.                                                                                                                              









We are inviting you to participate in a clinical cohort of patients on antiretroviral treatment 
that is being conducted by the Africa Centre.  A cohort means a ‘group of individuals’. The 
‘cohort’ or group of individuals included in this study are patients who are on antiretroviral 
treatment (ART) in the Hlabisa HIV Treatment and Care Programme.  
This document gives you information about the study that will be discussed with you. Once 
you understand the study, and you agree to take part, you will be asked to sign a consent 
form, or make a mark on the form in front of a witness. 
 
Explanation of what we are trying to do. 
In the HIV Treatment and Care Programme we already collect some clinical data, for 
example information on when people start on their ART, when they were last seen at clinic, 
what their latest CD4 count is. This information helps us to ensure that we are looking after 
patients well in the programme. These data are stored in a database at the Africa Centre; only 
certain people in the programme have access to this information in order to protect patients’ 
details. We wish to extend our data collection to include additional information about 
patients’ health, including any illnesses, hospital admissions, and weights.  
 
Who will take part? 
All HIV-infected patients starting on ART in the Hlabisa HIV Treatment and Care 
Programme attending Kwamsane and Somkhele clinics will be invited to take part in this 
study. 
 
What does it mean to be involved in this study? 
If you agree to participate in this study, you will be interviewed by a research nurse whenever 
you are visiting the clinic for your routine treatment collection or for consultation due to ill 
health.  If you miss one ore more clinic visits you will be contacted by the research nurse to 
ask you about your health and why you have not been collecting your treatment. If you are 







about your admission and may ask you a few questions relating to your admission. This 
information will also be recorded on research questionnaires.  
 
Is there any risk of being in the study? 
There are no risks involved to your health in participating in this study.  The only foreseen 
discomfort is extra time spent at the clinic (approximately 20 minutes) whilst being 
interviewed by the research nurse. All possible steps will be taken to ensure the 
confidentiality of your medical records.  
 
Is there any benefit by being in the study? 
People being followed in this clinical cohort may experience better clinical care than those 
not in the cohort. With each clinic visit, you will have the opportunity to see the research 
nurse who will be able to assist with any queries you may have. We will also ensure that you 
have had all necessary tests carried out and that you understand the results of these (e.g. 
routine CD4 counts and viral loads). We will also refer you for additional help if you require 
it – for example, if you need help with a grant application an appointment will be made with 
the social worker.  
 
What if I do not want to take part? 
Taking part in this study is entirely voluntary. If you decide not to take part, or decide to take 
part and later withdraw from the study, you will not be penalised. You will continue to 
receive care in the ART programme and at the clinic. 
 
Who will have access to this information? 
The information that is collected will be kept confidential. Only the clinical cohort study 
researchers and staff will have access to this information and results. The name or identity of 
the study participants will not be revealed. The study results will be made known to the 
Hlabisa hospital management and clinic based staff without revealing the identity of the 
individuals who participated in the study. The results will also be made known to the 








Who can you contact for more information about this study? 
If you need more information or if there is something you do not understand concerning this 
study, you can contact the following people: 
 
Dr Ruth Bland, Project Principal Investigator 
Africa Centre for Health and Population Studies 
035 550 7500. 
 
Or  
Mr Mduduzi Mahlinza, Head of Community Liaison Office 
Africa Centre for Health and Population Studies  
 035 550 7500 
Or 
The Biomedical Ethics Committee 
Private Bag X54001, Durban, 4000 
Telephone:  +27 (0)31 – 260 4769 
Fax:  +27 (0)31 – 260 4609 









I...........................................................................  agree to be part of the Clinical ART Cohort. 
The study has been explained to me and I fully understand the information written in the study 
information sheet. I understand the implications of joining the study, and that I may be asked 
additional information regarding my health during each study visit.  
 
I understand that the study research nurse will contact me if I miss scheduled visits and, if I am 
admitted to hospital, may visit me to collect additional information about my illness and hospital 
stay. I also give permission for the research staff to look at my clinic file and clinic card. 
 
I understand that I may leave the study at any time and I will not be discriminated for doing so. I 
will continue to use the ART clinic and be given appropriate care as usual. 
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You  are  being  invited  to  take  part  in  the  research  study  named  “Wellbeing  of Older  Peoples  Study 
(WOPS)”, being conducted by the Africa Centre.  
 










The main aim of  this study  is  to describe  the household duties, mental and physical health and social 
circumstances of older people  aged 50  years and above.  In  this  study physical health  refers  to body 
illnesses such as arthritis, diabetes or hypertension; mental health refers to conditions like depression; 
social health  relates  to your ability  to having  friends,  church or  family members who you  can  talk  to 










brings money  into the home, who  looks after the small children  for example bathing the children and 
cooking for them. It will also ask questions on illnesses of the body and illnesses of the mind and who is 
available for you to talk to about your problems. For elderly people who have experienced death of an 
adult child  in  the  last 2 years  (24months),  they will be asked how  this has affected  the household  in 
terms of money, health or having more people to look after. 
 
The  results obtained here will be used  to  identify what problems  the elderly people  are  facing. This 




The  study will  recruit  people  who  are  aged  50  years  and  above  who  take  part  in  the  Africa  Centre 
Demographic Surveillance and  live  in  the Mpukunyoni area. The  study will have  in  total 400 male and 
female participants. The 400 will be chosen at random from the Africa Centre Surveillance and the Hlabisa 
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HIV Treatment  and Care programme  records  to make  sure  that everyone who  is eligible has an equal 
chance of participating in the study. 200 will be randomly selected from people aged 50 years and above 
who have been on ART for  less than three months or more than one year  in the Hlabisa HIV Treatment 
















If  you  agree  to  take  part  in  the  study,  you will  be  asked  a  set  of  questions  about  your mental  and 
physical health. You will be asked questions about whether or not you look after small children and who 
brings money  into your household. You will also be asked questions on how easy  it  is  for you  to get 
someone to talk to about your concerns and whether or not you have someone taking care of you.  If 
you fall into the group that has lost a child in the last 2 years then you will also be asked about the cause 





and  heart  diseases.  From  your  blood  only  these  tests will  be  done; we will NOT DO  any HIV  tests. 
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be  able  to  refer  you  for  counselling  and medical  advice.  In  cases  of  serious  distress  and with  your 
consent the nurse can either refer you to the clinic or offer you transport to get to the nearest clinic. In 







There  is also a minimal potential  risk of accidental  falls as during  the  interview you may be asked  to 








health  to  be  in  a  critical  condition  the  nurse will  transport  you  to  the  nearest  clinic where  you  can 







clinics.  Through ongoing  counselling we hope  to  contribute  to  the  reduction of  stigmatization  in  the 
community.   
 
Your participation  in this study will help us better understand the challenges older people  face  in this 
community.  With  this  information  we  can  advise  the  local,  provincial  and  national  authorities  to 
improve older people’s health  and wellbeing  in  your  community.  Since  this  is  a  study being done  in 




Taking part  in  the study  is voluntary. You are  free  to  refuse  to answer  the questionnaire and  to have 
your blood sample taken. You are free to refuse to answer any questions that you are not comfortable 
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to  check  that  procedures  are  being  correctly  and  safely  followed  but  they  will  maintain  absolute 
confidentiality. At the end of the study, we will inform the Africa Centre Community Advisory Board (CAB) 
about  the  general  results  of  the  study  but  not  results  for  any  individual. General  results will  also  be 
presented to you and the community at specially arranged meetings. Scientists from the Africa Centre will 





offered  for any additional costs  for clinic visits to take part  in a research study, we will NOT offer any 

































Wellbeing of Older People Study                    October2009          Consent form  
Informed Consent form                                                          English v1, October 2009	 Page	1	
 
Contact the Africa Centre community liaison office on 035-550-7686 if you have any question or concerns pertaining to the study. 
 
I...........................................................................  agree to be part of the Wellbeing of Older People 
Study (WOPS). The study has been orally explained to me and I fully understand the information 
written in the study information sheet. I understand the implications of joining the study and that I will 
be asked for a venous blood sample in addition to being interviewed. I also understand that my weight, 
height and blood pressure will be measured.   YES  NO     
         
  
In addition I do understand that if I am found to be ill at the time of the home visit, I may be referred 
for further health management.   YES  NO 
    
 
  
It has been explained to me and I fully understand that information relating to me previously collected 
in the Africa Centre Surveillance or in the Hlabisa HIV Treatment and Care programme may be used 
together with the information collected in this study. 
       YES  NO 
       
 
 
I also understand that all the information collected will be kept confidential and that all information 
will be anonymised and my name or any other personal identifier will not be used in any of the 
analyses.      YES   NO      
 
 
I understand that joining the study is completely voluntary and also understand that even if I join the 
study, I am free to withdraw from the study at any time and I will not be discriminated or penalized in 
any way for doing so.               YES   NO     
 
 
I consent to have my blood specimen stored for use by Africa Centre researchers for additional tests in 
the future provided that such tests are approved by the Ethics Committee.    
       YES   NO
      
 
 
______________________________  ____________________________ 
Signature of Participant    Signature of research nurse 
 
 
______________________________   




































































































































































































































































































































































































































































































































































































































































































  AC surveillance              WOPS                  




Hypertension ever diagnosed (Yes)  107   51.7  44.8‐58.6  112  54.1  47.3‐61.0 
Hypertension past diagnosis (Yes)  55   51.4  41.5‐61.2  106   94.6  88.7‐98.0 
Hypertension current diagnosis (Yes)  52    48.6  38.8‐58.5  6   5.4  2.0‐11.3 
Hypertension current treatment (Yes)  84     78.5  69.5‐85.9  100  89.3  82.0‐94.3 
Diabetes ever diagnosed (Yes)  27  13.0  8.4‐17.7  28  13.5  8.8‐18.2 
Diabetes past diagnosis (Yes)  14  51.9  31.9‐71.3  24  85.7  67.3‐96.0 
Diabetes current diagnosis (Yes)  13    48.2  28.7‐68.1  4  14.3  4.0‐32.7 





















































































































































































































Blant‐Altman mean difference  0.112  0.053  0.045  0.02 












































Average of self-reported ever diagnosed with hypertension (AC surveillance vs WOPS)
Mean difference -0.024










































0 1Average of self-reported ever diagnosed with diabetes (AC surveillance vs WOPS)
Mean difference -0.005















































Average of hypertension recent treatment (AC surveillance vs WOPS)
Mean difference -0.078







































0 1Average of self-reported diabetes recent treatment (AC surveillance vs WOPS)
Mean difference -0.005





























































































































































































































































































































































































































































































































































































Sex  Male  30  18.6  (12.6‐24.7) 36 33.3 (24.4‐42.3)  30 27.5 (19.1‐36.0) 106 25.1 0.05 
Age at interview  68  61‐75  57 53‐62  53 51‐60 60 53‐69 <0.001 
Marital status  Married  40  24.8  (18.1‐31.6) 36 33.3 (24.4‐42.3)  33 30.6 (21.8‐39.3) 120 28.5
Never been married  32  19.9  (13. 7‐26.1) 33 30.6 (21.8‐39.3)  43 39.8 (30.5‐49.1) 116 27.6 <0.001 
Divorced/widowed  89  55.3  (47. ‐63.0) 39 36.1 (27.0‐45.2)  32 29.6 (21.0‐38.3) 185 43.9
Employment  No  158  98.8  (97.0‐1) 99 92.5 (87.5‐97.5)  96 88.9 (82.9‐94.9) 395 94.3 0.01 
Yes   2  1.3  (0‐3.0) 8 7.5 (2.5‐12.5)  12 11.1 (5.1‐17.1) 24 5.7
Main source 
of income 
Grants  145  91.2  (86.8‐95.6) 81 75.0 (66.8‐83.2)  69 63.9 (54.8‐73.0) 332 79.4
No source of income  7  4.4  (1.2‐7.6) 9 8.3 (3.1‐13.6)  18 16.7 (9.6‐23.8) 36 8.6 <0.001 
Other  7  4.4  (1.2‐7.6) 18 16.7 (9.6‐23.8)  21 19.4 (11.9‐27.0) 50 12.0
BMI 
categories 
Underweight  4  2.6  (0.1‐5.1) 7 6.6 (1.8‐11.4)  12 11.2 (5.2‐17.2) 25 6.1
Normal  46  29.9 (22.6‐37.1) 40 37.7 (28.4‐47.0)  30 28.0 (19.5‐36.6) 127 31.0
Overweight  45  29.2  (22.0‐36.5) 37 34.9 (25.8‐44.1)  35 32.7 (23.8‐41. 7) 127 31.0 0.04 
Obese  48  31.2  (23.8‐38.5) 17 16.0 (9.0‐23.1)  24 22.4 (14.5‐30.4) 105 25.6
Morbidly obese  11  7.1  (3.0‐11.2) 5 4.7 (0.7‐8. 8)  6 5.6 (1.2‐10.0) 26 6.3
Smoking  Never smoked  117  73.1  (66.2‐80.0) 99 91.7 (86.4‐96.9)  74 67.9 (59.1‐76.7) 324 77.0
Past smoker  24  15.0  (9.4‐20.6) 6 5.6 (1.2‐9.9)  16 14.7 (8.0‐21.4) 49 11.6 0.001 
Current smoker  19  11.9  (6.83‐16.9) 3 2.8 (0‐5.9)  19 17.4 (10.3‐24.6) 48 11.4
Alcohol  Never drank  94  58.75  (51.1‐66.4) 82 75.9 (67.8‐84.1)  64 58.7 (49.4‐68.0) 269 63.9
Past drinker  41  25.63  (18.8‐32.4) 14 13.0 (6.6‐19.4)  33 30.3 (21.6‐39.0) 94 22.3 0.01 
Current drinker  25  15.6  (9.96‐21.3) 12 11.1 (5.1‐17.1)  12 11.0 (5.1‐16.9) 58 13.8
Composite 
health score 
continuous  46.7  (43.1‐53.1) 52.3 47.9‐57.4  48.6 (44.1‐54.1) 49.22 45‐55 0.001 
Healthy  47  29.2  (22.1‐36.3) 59 54.6 (45.2‐64.1)  41 37.6 (28.5‐46.8) 159 37.7 <0.001 




No  38  23.6  (17.0‐30.2) 39 36.1 (27.0‐45.2)  29 26.6 (18.3‐5.0) 121 28.7 0.12 
Yes  123  76.4  (69.8‐83.00) 69 63.9 (54.8‐73.0)  80 73.4 (65.0‐81.7) 301 71.3
Current 
morbidity 
No  70  43.5  (35.8‐51.2) 66 61.1 (51.9‐70.4)  54 49.5 (40.1‐59.0) 215 51.0 0.03 




No  52  32.3  (25.0‐39.6) 52 48.2 (38.7‐57.6)  48 44.0 (34.6‐53.4) 173 41.0 0.04 















IL1    1.6   (1.6‐1.6)  1.6  (1.6‐1.6) 1.6  (1.6‐1.6)  1.6 (1.6‐1.6)
  <=1.6        123   83.1 (77.0‐89.2)  100  92.6 (87.6‐97.6) 94  96.9 (93.4‐1.0) 353 (90.1)
  >1.6  25   16.89 (10.8‐23.0)  8  7.4 (2.4‐12.4) 3 3.1 (0‐6.6)  39 (10.0)
IL6    1.94   (1.6‐2.6)  2.5  (2.0‐3.1) 2.6  (2.0‐3.2)  2.4 (2.1‐2.6)
  <=1.56  70  47.3 (39.2‐55.4)  38  35.2 (26.1‐44.3) 36  37.1 (27.4‐46.8) 157 (40.1)
  >1.56‐2.9  20   13.5 (8.0‐19.1)  24  22.2 (14.3‐30.1) 19  19.6 (11.6‐27.6) 68 (17.4)
  >2.9‐5  26  17.6 (11.4‐23.7)  21 19.4 (11.9‐27.0) 19 19.6 (11.6‐27.6) 73 (18.6)
  >5  32   21.6 (15.0‐28.3)  25 23.2 (15.1‐31.2) 23 23.7 (15.2‐32.3) 94 (24.0)
CRP    3.7  (2.5‐4.1)  4.2 (3.5‐5.8) 4.3 (2.6‐6.5)  3.9 (3.2‐4.3)
  <=1  31  21.2 (14.6‐27.9)  16  15.1 (8.2‐22.0) 21  21.7 (13.4‐29.9) 78 (20.1)
  >1‐3.9  52  35.6 (27.8‐43.4)  33  31.1 (22.3‐40.0) 25  25.8 (17.0‐34.6) 122 (31.4)
  >3.9‐8.5  39   26.7 (19.5‐33.9)  24  22.6 (14.6‐30.7) 19  19.6 (11.6‐27.6) 92 (23.7)
  >8.5  24   16.4 (10.4‐22.5)  33 31.1 (22.3‐40.0) 32 33.0 (23.6‐42.4) 96 (24.7)









IL1    1.6  (1.6‐1.6)  1.6  (1.6‐1.6) 1.6  (1.6‐1.6)  1.6 (1.6‐1.6)
  <=1.6  134   90.5 (85.8‐95.3)  107  93.0 (88.4‐97.7) 103  87.3 (81.2‐93.3) 353 (90.1)
  >1.6  14   9.5 (4.7‐14.2)  8 7.0 (2.3‐11.6) 15  12.7 (6.7‐18.8) 39 (10.0)
IL6    2.5   (2.0‐3.2)  2.5  (1.7‐3.2) 2.08  (1.6‐2.6)  2.4 (2.1‐2.6)
  <=1.56  58  39.2 (31.3‐47.1)  47  40.9 (31.8‐49.9) 51  43.2 (34.2‐52.2) 157 (40.1)
  >1.56‐2.9  24   16.2 (10.2‐22.2)  17  14.8 (8.3‐21.3) 25  21.2 (13.8‐28.6) 68 (17.4)
  >2.9‐5  26   17.6 (11.4‐23.7)  28  24.4 (16.4‐32.3) 17  14.4 (8.0‐20.8) 73 (18.6)
  >5  40   27.0 (19.8‐34.2)  23  20.0 (12.6‐27.4) 25  21.1 (13.8‐28.6) 94 (24.0)
hsCRP    2.5  (1.8‐4.0)  3.2  (2.5‐3.9 ) 6.15 (4.8‐6.9)  3.9 (3.2‐4.3)
  <=1   46  31.3 (23.8‐38.8)  17  14.9 (8.3‐21.5) 13 11.2 (5.4‐17.0) 78 (20.1)
  >1‐3.9  39  26.5 (19.4‐33.7)  54  47.4 (38.1‐56.6) 27  23.3 (15.5‐31.0) 122 (31.4)
  >3.9‐8.5  27   18.4 (12.1‐24.67)  20  17.5 (10.5‐24.6) 43  37.1 (28.2‐45.9) 92 (23.7)







CRP levels  Odds Ratio  P‐value  95% Confidence interval 
<=1pg/mL     
HIV‐     
HIV+ on ART  2.30 0.004 1.31  4.06 
HIV+ ART naive   1.03 0.93 0.51   2.08 
HIV unknown  0.83 0.61 0.42  1.66 
BMI normal     
Overweight  2.54 0.005 1.33  4.85 
Obese/morbidly obese  3.72 <0.001 1.81   7.63 
Age 50‐59years     
60‐69 years  1.06 0.87 0.54   2.05
70+ years  1.27 0.41 0.73  2.21 
>1‐3_9pg/mL         
HIV‐     
HIV+ on ART  2.30 0.004 1.31  4.06 
HIV+ ART naive   2.30  0.008 1.25  4.24 
HIV unknown  0.83  0.61 0.42  1.66 
BMI normal     
Overweight  0.78  0.37 0.46  1.33 
Obese/morbidly obese  2.78  <0.001 1.58   4.89 
Age 50‐59years     
60‐69 years  2.09 0.009 1.21  3.61
70+ years  1.27 0.41 0.73  2.21 
>3_9‐8_5pg/mL     
HIV‐     
HIV+ on ART  2.30  0.004 1.31  4.06 
HIV+ ART naive   2.81  0.002 1.47   5.38 
HIV unknown  0.83  0.61 0.42  1.66 
BMI normal     
Overweight  0.80 0.48 0.43   1.48 
Obese/morbidly obese  1.41  0.27 0.77  2.61 
Age 50‐59years     
60‐69 years  1.43  0.23 0.80  2.57 
70+ years  1.27 0.41 0.73  2.21 
Across all levels of hsCRP 
aCholesterol:HDL ratio 1     
Ratio 2  1.12 0.70 0.64  1.96
Ratio 3  1.47  0.16 0.86  2.53
























































Association of Age with Mortality and Virological and
Immunological Response to Antiretroviral Therapy in
Rural South African Adults
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Abstract
Objective: To assess whether treatment outcomes vary with age for adults receiving antiretroviral therapy (ART) in a large
rural HIV treatment cohort.
Design: Retrospective cohort analysis using data from a public HIV Treatment & Care Programme.
Methods: Adults initiating ART 1st August 2004 - 31st October 2009 were stratified by age at initiation: young adults (16–24
years) mid-age adults (25–49 years) and older ($50 years) adults. Kaplan-Meier survival analysis was used to estimate
mortality rates and age and person-time stratified Cox regression to determine factors associated with mortality. Changes in
CD4 cell counts were quantified using a piecewise linear model based on follow-up CD4 cell counts measured at six-
monthly time points.
Results: 8846 adults were included, 808 (9.1%) young adults; 7119 (80.5%) mid-age adults and 919 (10.4%) older adults, with
997 deaths over 14,778 person-years of follow-up. Adjusting for baseline characteristics, older adults had 32% excess
mortality (p = 0.004) compared to those aged 25–49 years. Overall mortality rates (MR) per 100 person-years were 6.18 (95%
CI 4.90–7.78); 6.55 (95% CI 6.11–7.02) and 8.69 (95% CI 7.34–10.28) for young, mid-age and older adults respectively. In the
first year on ART, for older compared to both young and mid-aged adults, MR per 100 person-years were significantly
higher; 0–3 months (MR: 27.1 vs 17.17 and 21.36) and 3–12 months (MR: 9.5 vs 4.02 and 6.02) respectively. CD4 count
reconstitution was lower, despite better virological response in the older adults. There were no significant differences in MR
after 1year of ART. Baseline markers of advanced disease were independently associated with very early mortality (0–3
months) whilst immunological and virological responses were associated with mortality after 12months.
Conclusions: Early ART initiation and improving clinical care of older adults are required to reduce high early mortality and
enhance immunologic recovery, particularly in the initial phases of ART.
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Introduction
Older adults ($50 years old) comprise a significant proportion
of people enrolling in HIV treatment programmes in sub-Saharan
Africa yet outcomes after initiation of antiretroviral therapy (ART)
for this group have not been well described. Older adults have
generally been neglected in addressing the global HIV epidemic
[1]. Indeed, reporting mechanisms and estimates of epidemiolog-
ical trends usually only encompass adults aged 15–49 [2].
UNAIDS estimated that globally there were 2.8 million adults
aged 50 years and older living with HIV in 2005 [3]. Data from
our surveillance programme in rural KwaZulu-Natal estimates
overall HIV prevalence rate at 9.5% and incidence of 1% in adults
aged 50 years and older [4]. In a verbal autopsy study in rural
Kenya, HIV was the cause of death in 27% of people aged 50
years and older and was the leading cause of death up to the age of
70 years [5].
Age is a major determinant of mortality for many diseases in the
absence of HIV and ART [6]. In the pre-antiretroviral therapy
(ART) era, data from sub-Saharan Africa showed that older age at
seroconversion was associated with more rapid progression to
death [7,8,9,10]. Since the introduction of ART, there have been
conflicting data on outcomes for older individuals. Assessing age as
a continuous variable, two studies have suggested an association
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21795
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between increasing age and higher mortality on ART [11,12].
Two studies analysing age as a categorical variable have reported
significantly higher mortality for individuals aged .50 years: the
ART-LINC cohort in an analysis of 7160 patients from 10 sites
reported a two-fold increased risk in overall mortality for those
$50 years compared to 16–29 year olds [13]; while in the South
African Free State programme there was 58% increased risk of
mortality for adults .50 years compared to 20–29 year olds,
although the mortality also included people dying before ART
initiation [14]. Other studies including a 7 year cohort in Senegal
have reported no clear association between age and mortality on
ART [15,16,17,18,19]. Comparison across studies is complicated
by the use of different age categories. Moreover these studies have
included age as an explanatory variable rather than explicitly
assessing mortality within and between younger and older ages.
ART outcomes including mortality, immunological and virological
response may potentially be influenced by age [20,21] hence it is
important to understand treatment outcomes to inform on
appropriate HIV management in older adults. We aim to
explicitly assess how mortality rates following ART initiation
compare between older and younger adults and the factors
associated with mortality in each age category using data from a
large rural HIV Treatment and Care cohort and to quantify
immunological and virological responses in different age groups.
Methods
Ethics statement
Written informed consent was obtained from all participants in
the programme to allow use of anonymised routine clinical data in
research. Ethical approval for retrospective analysis of these data
was obtained from the Biomedical Research Ethics Committee of
the University of KwaZulu-Natal (BE066/07) and the Research
Office of the KwaZulu-Natal Department of Health.
Hlabisa HIV Treatment and Care Programme. The
Hlabisa HIV Treatment & Care Programme is a partnership
between the local Department of Health (DoH) and the Africa
Centre for Health and Population Studies (www.africacentre.ac.
za). The details of the programme have been previously described
[22,23].
The programme adheres to the national antiretroviral treatment
guidelines which at the time of study recommended initiation of
ART for adults with WHO stage IV disease or CD4 cell count
#200 cells/mm3 [24]. Co-trimoxazole was indicated for all
individuals with CD4 count #200 cells/mm3 or WHO stage 3/4.
First-line ART consisted of stavudine (d4T), lamivudine (3TC), and
either efavirenz (EFV) or nevirapine (NVP). ART was initiated at
primary health care (PHC) clinics (or at Hlabisa district hospital) by
a physician; monitoring and ART dispensing was subsequently
performed by nurses and counsellors. CD4 cell count and HIV viral
load were measured every 6 months on ART.
Data acquisition. Clinical information at baseline and at
monthly clinic visits after initiation of ART is transferred from
standardised clinic records to a centralised MicrosoftH Access
database. A comprehensive tracking service operates whereby
patients who are more than one week late for their clinic visit are
contacted by telephone and, if necessary, visited at home by a
tracker nurse. Information pertaining to death after initiation of
ART is therefore obtained either by the clinic staff or tracker team
through communication with family members, other clinic staff, or
hospital staff. Cause of death is recorded if known but not
systematically sought within the routine programme. Laboratory
results (CD4 cell count and HIV viral load) are regularly updated
from the National Health Laboratory Service (NHLS) laboratory
at a district hospital (Hlabisa Hospital). CD4 counts were analysed
using the Beckman Coulter EPICSH XL flow cytometer (Beckman
Coulter, Inc.). Viral load was measured at a provincial laboratory
using the NucliSens EasyQH HIV-1 assay (bioMe´rieux), with a
lower detection limit of 25copies/ml.
Data analysis. Analysis included all adults ($16 years) who
initiated ART between 1st August 2004 and 31st October 2009,
excluding patients on ART who transferred into the programme
from elsewhere. Analysis was stratified by age at initiation (,50
years and $50 years), a classification which ensured consistency
with previous reports [21]. The ,50 years age group was further
stratified into 16–24 years and 25–49 years to assess for
heterogeneity in overall outcomes and baseline descriptions. We
assessed differences between the three groups in baseline clinical
characteristics using the non-parametric equality-of-medians test
for continuous variables and proportions test for categorical
variables. Estimated glomerular filtration rate (eGFR) was
calculated using the 4-variable Modification of Diet in Renal
Disease (4-v MDRD) equation, without the ethnicity correction
factor, as validated in a South African population [25,26].
Kaplan-Meier survival analysis was used to assess and compare
mortality between and within age strata. Data was censored at earliest
of date of death, date of loss to follow-up, date of transfer out of
programme, or 22nd April 2010. Loss to follow-up was defined as
three consecutive months without a clinic visit. To ascertain the
independent influence of age on overall mortality, a Cox regression
model adjusted for all significantly different baseline factors (P,0.05)
was used to assess mortality hazard difference by age strata. The two
bottom age strata (young and mid-age groups) were combined in the
analysis for determination of mortality risk factors because there were
no statistically significant mortality outcome differences between the
two groups. This is also consistent with previous analysis that have
assessed those aged below 50 years as one group in comparison to
those aged 50 years and above [27,28,29,30]. Stratified Cox
regression with time split at 3 and 12 months post-ART initiation
was used to determine risk factors for mortality in the periods 0–3
months (very early mortality), 3–12 months (early mortality), and
.12 months post-ART initiation. For the two periods in the first
year, analysis was further stratified by age to establish differences in
mortality predictors between old and young patients. For all Cox
models, variables that were associated with mortality at 15%
significance level were individually included into the model and
model goodness-of fit assessed. Validity of the proportional hazards
assumption was tested using the score test based on scaled Schoenfeld
residuals [31]. All results are reported at 5% significance level.
Changes in CD4 cell counts in the 24 months following ART
initiation were quantified using a piecewise linear model based on
follow-up CD4 cell counts measured at six-monthly time points 6
three months. For 909 and 504 patients with missing CD4 counts
at 6 months and 12 months respectively the value was interpolated
from their CD4 cell counts immediately before and after that time
point. Of the 2977 patients alive and active 12 months post ART
initiation, 2187 patients (73.5%) had a recorded CD4 count.
Virological response at one year was based on viral load
measured between 6 and 15 months after ART initiation. The
effect of suboptimal virological response (defined as viral load
$400 copies/ml) on mortality after the first year of ART was
quantified in a Cox regression model adjusted for baseline
variables and follow-up CD4 cell counts. For both viral loads
and CD4 counts, where more than one measurement was
available within the specified time period, the one closest to that
time point was used.
Sensitivity analysis. To account for the effect of missing
baseline and follow-up explanatory data, we assessed for any
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differences in mortality in those with missing observations
compared to those with recorded observations. Where those
with missing data had significantly different mortality rates, we
maintained a category of the missing group within the respective
variable in both the univariable and multivariable models
exploring factors associated with mortality. This adjusted for any
overestimation of the effect of measured/recorded variables on
mortality in the absence of those with unmeasured/missing
variables. To assess for the extent of loss to follow up bias, we
conducted sensitivity analyses where patients lost were considered
dead. All analyses were performed with STATA version 11.0
(College Station, Texas, USA).
Results
Patient characteristics
Between 1st August 2004 and 31st October 2009, 8846 adults
initiated ART in the programme. Of these, 808 (9.1%) were aged
16–24 years, 7119 (80.5%) were aged 25–49 years and 919
(10.4%) were $50 years at time of ART initiation (range 16–83
years). Overall median baseline CD4 cell count was 119cells/ml
(IQR 58–174). Older adults had the lowest proportion with CD4
cell count ,50cells/ml prior to ART initiation and the highest
median CD4 count was amongst those aged 16–24 years (Table 1).
Mortality
There were 997 deaths in 14,778 person-years of follow-up (72 in
adults aged 16–24 years; 790 in adults 25–49 years and 135 in adults
$50 years at ART initiation). The overall mortality rate was 6.75 per
100 person-years (95% confidence interval [CI] 6.34–7.18),
significantly higher for $50 year old adults (8.69 per 100 person-
years, 95% CI 7.34–10.28) than younger adults (6.18 per 100
person-years, 95% CI 4.90–7.78 and 6.55 per 100 person-years,
95% CI 6.11–7.02 in those age 16–24 years and 25–49 years old
respectively). Overall, controlling for baseline differences (sex, WHO
disease stage, baseline CD4 cell count, haemoglobin, weight, eGFR,
education and employment) there was 32% excess mortality risk in
patients aged $50 years (aHR 1.32, 95% CI 1.09–1.60, P=0.004)
compared to those aged 25–49. There were no significant differences
in either overall mortality or time stratified mortality rates between
those initiating aged 16–24 and those aged 25–49 (Table 2).
In all age groups, the majority of deaths (769 deaths, 77.1%)
occurred in the first year after ART initiation, with mortality
particularly high in the first three months after ART initiation (449
deaths, 45.0%). Figure 1A (Kaplan-Meier curve) illustrates
mortality differences between the two age groups. Early mortality
rates were significantly higher for older adults ($50 years) but there
was no significant mortality difference after 12 months (Table 2).
Immunological response
Despite baseline CD4 cell count being higher for older adults;
their median CD4 cell count post-ART initiation was lower than
for both groups of younger adults at each time point (Figure 2A).
Overall 16.6% had a poor immunological response (failed to
achieve a CD4 count increase of $50 CD4 cells) in the first 6
months of therapy with the largest proportion being in those aged
Table 1. Baseline characteristics for individuals initiated on ART August 2004 - October 2009 (n = 8846), stratified by age at ART
initiation.
Variable 16–24 years 25–49 years 50+years
N
% or
median (IQR) (95% CI) N
% or
median (IQR) (95% CI) N
% or
median (IQR) (95% CI)
Age 808 22 (21–24) 7119 35 (30–40) 919 54 (51–58)
Male sex 107 13.24 10.90–15.58 2504 35.17 34.06–36.28 400 43.5 40.32–46.73
WHO stage 3 or 4 328 40.59 37.21–43.98 3435 48.25 47.09–49.41 420 45.70 42.48–48.92
Missing 357 44.18 40.76–47.61 2629 36.93 35.81–38.05 348 37.87 34.73–41.00
CD4 cell count, cells/ml
Median (IQR) 777 133 (69–182) 125.7–144 6827 115 (55–173) 113–118 888 127 (71–177) 122–136
150–200 220 28.31 25.14–31.48 1643 24.07 23.05–25.08 237 26.69 23.78–29.60
100–149 162 20.85 17.99–23.71 1449 21.22 20.25–22.19 221 24.89 22.04–27.73
50–99 139 17.89 15.19–20.59 1431 20.96 20.00–21.93 178 20.05 17.41–22.68
,50 138 17.76 15.07–20.45 1540 22.56 21.57–23.55 138 15.54 13.16–17.93
.200 118 15.19 12.66–17.71 764 11.19 10.44–11.94 114 12.84 10.64–15.04
Viral load, log10 copies/ml 491 4.38 4.26–4.56 4313 4.40 4.36–4.43 542 4.53 4.43–4.63
Weight, kg (IQR) 704 56 54.7–57.1 6262 59.3 59–59.8 814 60 59.1–61
TB treatment 171 21.16 18.34–23.98 1581 22.21 21.24–23.17 175 19.04 16.50–21.58
Haemoglobin ,8 g/dL 76 9.41 7.39–11.42 576 8.09 7.46–8.72 44 4.79 3.41–6.17
Missing 110 13.61 11.25–15.98 914 12.84 12.06–13.62 101 10.99 8.97–13.01
*eGFR #60 ml/min/1.73 m2 30 3.71 2.41–5.02 854 12.00 11.24–12.75 311 33.84 30.78–36.90
Missing 93 11.5 9.3–13.7 725 10.2 9.5–10.9 86 9.4 7.5–11.2
Albumin ,32 g/L 440 54.46 51.02–57.89 3764 52.87 51.71–54.03 474 51.58 48.34–54.81
Missing 98 12.13 9.88–14.38 767 10.7 10.05–11.49 93 10.12 8.17–12.07
CI, confidence interval; IQR, interquartile range.
*eGFR, estimated glomerular filtration rate: calculated using 4-variable MDRD equation (without ethnicity correction).
doi:10.1371/journal.pone.0021795.t001
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50 years and above (19.6% vs 11.1 and 16.9 in 16–24 year olds
and 25–49 years olds respectively). Almost half of all those who
initiated with CD4 cell count ,50 cells/ml (45.2%) failed to attain
a CD4 cell count .200 cells/ml at 12 months. Proportions with
CD4 cell counts below 200 cells/ml at specified time points post
ART initiation are displayed in Figure 2B.
Virological suppression
From the 5625 patients recorded as active at 12 months post-
ART initiation, 3809 (67.8%) viral loads were available for
analysis. Overall 86.3% had a good virological response (,400
copies/ml). A greater proportion of older adults (90.1%, 95% CI
84.7–87.0) had a good response compared to younger adults
(81.7%, 95% CI 77.4–86.1 and 86.2%, 95%CI 85.0–87.5 in 16–
24 year olds and 25–49 year olds respectively).
Factors associated with mortality
0–3 months. Using age stratified and time split analysis, from
the total 997 deaths, 449 occurred in the first three months after
ART initiation (very early mortality) giving the highest period
mortality rates of 20.9 and 27.1 per 100 person years in younger
and older adults respectively (P = 0.037). However, although
mortality risk was significantly higher in the older age group,
within each age group, age did not have an independent
association with mortality. There was strong evidence of an
association between male sex, markers of advanced disease at
initiation (CD4 cell count ,50 cells/ml, higher log10 viral load,
lower weight, and albumin ,32 g/L) and increased very early
mortality in both age groups. In younger adults, but not in older
adults, there were additional associations with WHO stage 3/4,
low haemoglobin, and renal impairment (Table 3).
3–12 months. Three hundred and twenty deaths; 269 (12.8%)
in younger and 51 (20%) in older adults occurred between 3–12
months (early mortality), mortality rates remaining higher in older
compared to younger adults (9.5 vs 5.8 per 100 person years
respectively; p=0.001). Low baseline CD4 cell count (,50 cells/ml)
remained independently associated with mortality in those aged
,50years, as did WHO stage3/4 disease and low albumin. For older
adults the only factor independently associated with mortality in this
period was haemoglobin,8 g/dL. There remained a trend towards
increased mortality risk with CD4 cell count ,50 cells/ml and
albumin ,32 g/dL but the low numbers of deaths in this period for
older adults (n= 51) likely limited statistical power (Table 3).
After 12 months. Factors associated with mortality after 12
months were explored in a single model incorporating all ages because
of the similar mortality rates in both age strata. As such in the adjusted
model (Table 4) mortality risk was not significantly different for older
adults compared to younger adults (adjusted hazard ratio [aHR] 1.01,
95% CI 0.66–1.55). There was no longer any evidence of an
association with baseline CD4 cell count, but a lower absolute CD4 cell
count and a reduced increment at 12 months post ART initiation were
both associated with higher mortality.
In all models there was no statistically significant association
between mortality and either education or employment.
Table 2. Mortality rates following ART initiation stratified by age at initiation and cohort period time (N = 8846).
Cohort period (years) Person-time (years) Failures Mortality rate 95% CI
16–24 years
0–0.25 186.34 32 17.17 12.14–24.28
.0.25–1 447.76 18 4.02 2.53–6.38
.1–2 340.94 13 3.81 2.21–6.57
.2 190.76 9 4.72 2.45–9.07
25–49 years
0–0.25 1675.67 358 21.36 19.26–23.70
.0.25–1 4166.90 251 6.02 5.32–6.82
.1–2 3478.11 111 3.19 2.65–3.84
.2 2737.47 70 2.56 2.02–3.23
$50 years
0–0.25 217.64 59 27.11 21.00–35.00
0.25–1 535.77 51 9.52 7.23–12.53
.1–2 445.10 15 3.37 2.03–5.59
.2 355.74 10 2.81 1.51–5.22
TOTAL 14778.19 997 6.75 6.34–7.18
doi:10.1371/journal.pone.0021795.t002
Figure 1. Age and mortality risk post ART initiation. Kaplan-
Meier plot of cumulative mortality probability after initiation of ART,
stratified by age group at time of ART initiation.
doi:10.1371/journal.pone.0021795.g001
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Figure 2. Age and immune response to ART. A. Median CD4 cell count (cells/ml) over time since ART initiation, stratified by age at ART initiation.
B. Proportion of patients failing to achieve a CD4 count .200 cells/ul at pre-defined time points post ART initiation, stratified by age at initiation.
doi:10.1371/journal.pone.0021795.g002
Table 3. Independent risk factors for very early (0–3 months after ART initiation) and early (3–12 months) mortality stratified by
age.
Variable Very early mortality (0–3 months) Early mortality (3–12 months)
,50 years (n=7927) $50 years (n =919) ,50 years (n =7154) $50 years (n=832)
Age (1yr increase) 0.99 (0.95–1.04) 1.03 (0.99–1.08)
25–49 years 1 1
16–24 years 0.79 (0.54–1.34) 0.73 (0.45–1.19)
Male sex 1.64 (1.32–2.03) 1.84 (1.06–3.17) 1.40 (1.09–1.80) 1.33 (0.73–2.41)
WHO stage 3 or 4 1.77 (1.11–2.81) NS 2.06 (1.19–3.57) NS
CD4 cell count (cells/ml)
150–200 1 1 1 1
100–149 1.22 (0.79–1.88) 1.03 (0.37–2.86) 1.04 (0.65–1.68) 1.73 (0.70–4.26)
50–99 1.57 (1.05–2.33) 2.34 (0.97–5.67) 1.50 (0.97–2.31) 1.97 (0.79–4.87)
,50 2.38 (1.63–3.46) 2.60 (1.07–6.31) 2.76 (1.85–4.10) 2.00 (0.80–4.98)
.200 1.56 (0.96–2.52) 1.19 (0.35–4.05) 1.50 (0.90–2.51) 2.19 (0.83–5.82)
Missing 2.12 (1.16–3.87) 3.97 (1.10–14.4) 1.80 (0.92–3.51) 0.30 (0.04–2.63)
Viral load (per log10 increase) 1.16 (1.03–1.34) 2.28 (1.52–3.43) NS NS
Weight (1kg increase) 0.94 (0.93–0.95) 0.96 (0.94–0.99) 0.99 (0.97–1.00) NS
TB treatment* 1.59 (0.84–1.97) 0.90 (0.48–1.69) 1.05 (0.79–1.40) 1.38 (0.72–2.63)
Haemoglobin ,8g/dL 2.06 (1.61–2.64) NS NS 4.15 (1.79–9.65)
eGFR #60 ml/min/1.73m2{ 1.73 (1.35–2.23) NS 1.41 (1.00–1.98) NS
Albumin ,32g/L 3.58 (2.44–5.24) 2.56 (1.19–5.58) 2.17 (1.56–3.02) 1.52 (0.76–3.02)
missing 4.38 (1.88–10.19) 0.67 (0.42–10.58) NS NS
Cox regression models split by time under observation (person years) into very early mortality (0–3 months) and early mortality (3–12 months). Risk factors determined
separately for age groups ,50 years and $50 years.
All values are adjusted hazard ratios with 95% confidence interval.
NS, not significant in univariable model.
*Concurrent TB treatment at time of ART initiation.
{eGFR, estimated glomerular filtration rate: calculated using 4-variable MDRD equation (without ethnicity correction).
doi:10.1371/journal.pone.0021795.t003
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Sensitivity analysis
Mortality rates did not differ significantly between those with
complete baseline observations compared to those with missing
observations. However 116 (6.4%) of 1816 patients alive but with a
missing viral load at 12 months subsequently died compared to
112 (2.9%) of 3809 with a recorded viral load (P,0.001), whilst
103 (7.1%) of those alive but with a missing CD4 cell count at 12
months post ART initiation died compared to 125 (3.0%) of those
with a recorded CD4 count (P,0.001), resulting in higher
mortality risk in some of these missing categories (Table 4).
Overall loss to follow-up was 12.9%; 11.6% and 6.5% in the
16–24 yrs, 25–49 yrs, and $50 yrs age groups respectively
(p,0.01). Despite these differences, the sensitivity Kaplan Meier
and Cox regression analysis results did not differ significantly from
those obtained using completely observed data.
Discussion
We used a large rural HIV treatment programme in South
Africa, with a comprehensive tracking system for patients lost to
follow-up, to assess mortality rates and differences in three
population groups defined by age. In this analysis of 8846 adults
with 997 deaths, overall mortality risk was 32% higher for those
who initiated ART at age $50 years compared to those initiating
at age 25–49. Although consistent with previous reports from
urban African settings [13,14] we show that this mortality
difference is only evident in the first year of ART, following
which mortality rates in older adults are no longer different from
that in younger adults despite only modest CD4 count
reconstitution in the older age group. Previous studies from
Europe and North America [32,33,34,35] have also reported
poorer immunological but better virological responses in older
compared to younger adults but have not explored how these may
relate to mortality rates in older age groups receiving ART. Our
study shows that despite older adults having a lower proportion of
individuals achieving good immunological response in the first
year on ART, their mortality rate as a group, after 12 months on
ART, was similar to that observed in the younger adult group.
This finding coupled with the fact that older adults had a higher
proportion of individuals achieving optimal viral suppression,
might imply that in older adults, the degree of CD4 count
reconstitution may matter less once HIV has been suppressed.
Mortality was not significantly associated to either education or
employment probably because in this population there is not much
heterogeneity in socio-economic variables and everyone is poor
[22].
The majority of people enrolled in HIV care and treatment
programmes in sub-Saharan Africa are younger adults, consistent
with prevalence patterns [37]. In this programme, just over 10% of
adults who initiated ART during the study period were $50 years
old. The higher proportion of males is contrary to the treatment
programme in general but is consistent with local prevalence data
that shows more males being infected later in life hence expected
to access care much later than females [4,23]. Whilst evidence
from high-resource settings has suggested that older adults present
with more advanced disease [33,38,39], our data suggest the
opposite with a higher median CD4 cell count and lower
proportion with CD4 cell count ,50 cells/ml in older adults.
The most striking clinical difference between the groups at
baseline was the higher proportion of renal dysfunction at baseline,
with 37% of older adults having an estimated glomerular filtration
rate (eGFR) of #60 ml/min/1.73 m2. Consistent with the
observed decline in GFR with age, this alerts us to the high
frequency of renal disease in this setting which is not always
detected with serum creatinine measurements alone [40].
In all age groups, the highest mortality rates were in the first
three months of ART in line with data previously published from
this and other programmes [23,41,42,43,44]. Very early and early
mortality was higher in older adults, although older adults
presented for ART initiation with higher CD4 counts than
younger adults. High early mortality mainly associated with
Table 4. Independent predictors of mortality after the first 12
months of ART (N = 5625).
Variable aHR 95% CI
Age 25–49 years 1
$50 years 1.01 0.66–1.55
16–24 years 1.35 0.86–2.14
Male sex 1.95 1.46–2.57
Baseline WHO stage 3/4 2.72 1.49–4.97
Missing 2.62 1.43–4.83







Weight (1 kg increase) 0.98 0.96–0.99
Albumin ,32 g/L 1.77 1.27–2.47
























aHR, adjusted hazard ratio; CI, confidence interval.
Risk factors determined through Cox proportional hazards regression
techniques, assessing mortality after 12 months post ART initiation, conditional
on being active on the treatment programme at 12 months.
doi:10.1371/journal.pone.0021795.t004
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advanced disease coupled with blunted immunologic response in
older adults raises an important question of whether older adults
should initiate ART at higher CD4 count threshold compared to
younger adults and calls for interventions to encourage early
presentation for ART. Older adults may also potentially benefit
from enhanced clinical care during initial phases of ART.
The high number of deaths immediately after ART initiation
suggests that this mortality is still driven largely by HIV disease itself.
However, for older adults, the higher mortality may be explained by
higher prevalence of non-HIV conditions such as cardiovascular
diseases and diabetes. Unfortunately we were unable to ascertain
the cause of death since this information within the programme was
extremely limited, with only 42 of 997 deaths (4.2%) attributed to a
specific cause. However, research in similar settings has shown
mortality in the first year of ART to be caused predominantly by
infectious diseases related to immunosuppression with tuberculosis
consistently shown to be the leading cause of death across all age
groups followed by cryptococcal disease and other infectious
diseases [18,19,44,45]. Although in previous analyses we showed
that younger age was associated with higher TB incidence in the
first three months of ART [36], it could be that TB presentation is
different in older adults or that symptoms are less frequently
attributed to TB in this group leading to missed diagnoses and
mortality [46]. The contribution of immune reconstitution
inflammatory syndrome (IRIS) to early mortality remains unclear;
a recent meta-analysis, using data from diverse settings across high-,
middle- and low-income settings, suggested that IRIS might be
responsible for 21% of all deaths after ART initiation [47]. Whether
the incidence, presentation or mortality attributable to IRIS is
higher in older adults requires further study.
Our study demonstrates that at 12 months, approximately one-
quarter of our cohort had CD4 cell count #200 cells/ml with the
largest proportion and the poorest immunological response in those
aged $50 years and this was associated with increased risk of
subsequent death. Larger CD4 count increases were significantly
associated with reduced mortality risk irrespective of recent absolute
CD4 count. In addition previous absolute CD4 cell thresholds (CD4
cell count at 6 months after ART initiation) were not associated with
mortality although CD4 count increments of greater than 100 cells/
ml at this stage decreased mortality risk beyond a year on therapy.
This may possibly imply that as long as there is an immune response
greater than a certain threshold, the influence of the absolute CD4
cells count on mortality becomes minimal and non-significant.
Despite younger adults demonstrating superior immunological
responses, they had inferior virological suppression, a finding that
supports previous observations [32,33,34,35], and was associated
with a nearly threefold increased risk of mortality after the first year
on therapy. Hence the increased risk in older adults associated with
poorer immunologic response may have been counteracted by the
reduced risk associated with superior virological response resulting
in equal mortality risk in both age groups after one year of ART.
Although it is possible that this lack of mortality difference may be
due to limited statistical power, there are also possible reasons why
this may be; the fact that these older adults are seen every 30 days by
health care personnel when they come to collect ART may mean
that they have a better chance of early diagnosis of age driven
morbidities and better clinical management of new and existing
morbidities hence limiting the effect of age on mortality. Babiker et
al previously suggested that the effect of age on mortality could be
attenuated in the HAART era if there was proportionately a
reduction in mortality in older age groups. As older adults are at
higher risk of HIVmortality primarily due to a faster decline in CD4
cell counts, HAART associated increases in CD4 could have a
larger impact in reducing mortality in an older population [6].
Our study population is similar to that from many rural public
health HIV treatment programmes and therefore our results are
likely generalisable to similar settings in sub-Saharan Africa. The
large cohort size and high mortality rates have enabled this analysis
[23]. A major strength of our programme is the comprehensive
tracking system for patients lost to follow-up which ensures that
deaths are ascertained contemporaneously, unlike in many other
programmes [48], giving us confidence that our mortality rates are
representative of the true population mortality rates.
Our study has certain limitations as a retrospective analysis of
routine programmatic data; we were hampered by missing results
particularly for follow-up CD4 cell counts and viral loads which
we attempted to address by interpolation of missing CD4 cell
counts. The blunted immunological response in older adults
compared to younger adults might have been underestimated
because CD4 cell count changes are influenced by survival bias,
i.e. individuals with the worst immunological response are more
likely to have died. Although we controlled for multiple biological
variables in determining factors associated with mortality, there
might still be residual confounding by adherence levels or other
unmeasured variables.
Extremely high mortality rates in the first year of ART, more so
for older adults suggests that strategies to reduce this early
mortality need to be implemented and evaluated with a degree of
urgency and that the needs of older adults should be considered
within these strategies. Medical interventions, particularly inten-
sive screening and treatment for TB and cryptococcal infection
should be implemented and evaluated to improve understanding
of the epidemiology of these infections in older adults [49]. Better
understanding of the current patterns of testing and health care
usage amongst older adults will inform on appropriate age-specific
interventions. Making HIV services more acceptable for this age
group might get them into HIV care at an earlier stage. We have
previously shown lower rates of retention in pre-ART care for
older adults [50]; with the known association between older age
and more rapid CD4 decline, it is necessary to explore alternative
care strategies, which might include integration with other chronic
disease management or community-based follow-up [51]. Further
work is ongoing within our programme to determine the causes of
death and the burden of co-morbidities in the older population.
Future work is required to evaluate whether more intensive follow-
up impacts on mortality for individuals at high-risk of death in the
first few months of ART.
Discussion around older adults and the HIV epidemic in sub-
Saharan Africa often only focus on the indirect impact of the
epidemic. Our finding of higher mortality on ART for older adults
compared to younger adults adds to the evidence base pointing to
a substantial direct effect of HIV on older adults’ health. As we
move into the next phase of ART scale-up the challenges of HIV
in older people will need to be addressed with more purpose.
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